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CHAPTER 1 
GENERAL INTRODUCTION 
L1 ANTECEDENTS 
Serotonin, chemically known as 5-hydroxytryptamine (5-HT), is a biogenic monoamine 
with a molecular weight of 176 dalton. In mammals, 5-HT is mainly found in the 
platelets, enterochromaffin cells and in the central nervous system (CNS), where it plays 
an important role as a nenrotransmitter (Page, 1958). 
Thanks to the seminal discovery of selective 5-HT receptor agonists and 
antagonists, many unsuspected functions of 5-HT in the CNS and the periphery have 
been elucidated. Accordingly, these findings originated a new era in the development 
of drugs with therapeutic usefulness in the treatment of pathologies such as anxiety, 
schizophrenia, hypertension, migraine, peripheral vascular diseases, etc. 
1.1.1 Serotonin in the 19"' century 
Long before the identification of serotonin as 5-hydroxytryptamine (5-HT), 
pharmacologists and physiologists already knew that a substance active on blood vessels 
and heart appears in sernrn when blood is allowed to clot. The first set of publications 
describing objectively that blood sernrn is by no means an innocuous substance dates 
back to the 19th centnry, when researchers such as Creite (1869), Rnrnmo and Bordoni 
(1889) and Weiss (1896) reported that a diminution in the amount ofnrine, albuntinnria, 
an increase in both respiratory frequency and heart rate, and an increase in blood 
pressnre followed by a sudden decrease (and eventually death) were induced when 
serum was injected subcutaneously or intravenously into an animal 
Of particular interest are the cardiovascular effects observed by Weiss (1896), 
namely that "if serum was continuously but slowly injected into a rabbit, cat or dog until 
it caused death, the heart rate was increased aod at first the beat was stronger but 
gradually failed, though it persisted until the respiration had ceased; in addition, an 
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increase in the peristalsis of the small intestines and death due to paralysis of the 
respiratory and vasomotor centres was noticed" (Weiss, 1896). 
1.12 Serotonin (5-hydroxytryptamine; 5-HT) in the 20"' century 
Subsequently, Brodie (1900) described in an extensive study that the intravenous 
injection of blood serum from any source into the cat produced a vagally-mediated 
reflex resulting in a reversible bradycardia, hypotension and arrest of the respiration, 
whereas injection of either blood plasma or boiled serum did not show this effect. 
Simultaneously, the vasoconstrictor properties of blood serum on perfused organs 
and excised arterial strips were being described and investigated as to its nature and 
origin. With respect to the latter, Janeway et a!. (1918) reported some findings of 
particular relevance, namely: i) that either the ox nncoagulated blood or the citrated 
plasma has no constrictor action on the excised strip of the ox carotid, in contrast to the 
marked constrictor action exerted by serum to which citrate had been subsequently 
added; ii) that the extract of platelets from either dog, ox or pig shows marked 
vasoconstrictor properties, but not that of erythrocytes or leucocytes; and iii) that either 
the "platelet substance(s)" or the blood serum causes a constriction of the ox coronary 
artery, whereas adrenaline causes relaxation. Therefore, Janeway et al (1918) 
concluded that the vasoconstrictor substance of clotted blood is derived from the 
disintegration of platelets, and that it is not adrenaline. Based on this conclusion, Hirose 
(1918) confirmed and extended these findings by establishing for the first time a direct 
correlation between the platelet count of human blood and its vasoconstrictor action 
after clotting in the ox carotid artery. From all the above findings it is quite clear that 
the basic cardiovascular effects of blood serum could be characterized before the 
chemical nature of the substance involved could have been elucidated; there was no 
further substantial advance in connection with the latter nntil the late 1940s, when Page, 
who was searching for humoral pressor agents that might explain arterial hypertension, 
in collaboration with Green and Rapport could isolate this vasoconstrictor substance as 
a crystalline complex and named it serotonin, as it could indeed increase the vascular 
tone (Rapport eta!., 1948a,b ): shortly thereafter, Rapport (1949) deduced that the active 
moiety of this complex (for which he retained the name serotonin) was 
5-hydroxytryptamine (5-HT). This compound, when prepared synthetically by Hantlin 
and Fischer (1951) and others, proved to have all the properties of natural serotonin. 
including those in the gastrointestinal system (Erspamer and Asero, 1952). It is 
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therefore not surprising that the introduction of synthetic 5-Hf in 1951 (see Hamlin and 
Fischer, 1951) touched off an explosion of research. 
12 DISTRIBUTION AND METABOLIC PATHWAYS OF 5-HT 
When serotonin was identified as 5-hydroxytryptantine (5-Hf), an extensive mass of 
evidence showed that it is widely distributed in natu.re as it had been found not only in 
the animal kingdom (vertebrates and invertebrates), but also in the vegetable kingdom 
(plants, fruits, nuts, etc.; see Erspamer, 1966). 
1.2.1 Localization 
In mammals 5-Hf can be found in the central nervous system, where it plays an 
important role as a neurotransmitter (Page, 1958) and in several peripheral structu.res 
such as the enterochromaffin cells of the gastrointestinal mucosa, platelets, certain 
nerves of the blood vessels, the blood vessels wall, lungs, and heart (amongst others). 
1.2.2 Biosynthesis 
Perhaps with the exception of platelets, 5-Hf is synthesized in most tissues in which it 
is stored. Over 90% of the 5-Hf content in the peripheral structu.res of the body is 
found in the enterochromaffin cells. From these cells 5-Hf enters the circulation. 5-Hf 
is synthesized de novo from the essential antino acid L-tryptophan by two enzymatic 
reactious: in the first reaction 5-hydroxytryptophan is formed, catalyzed by the 
cytoplasmic enzyme tryptophan 5-hydroxylase, the activity of which is rate limiting 
(Gershon et a!., 1977). Subsequently, 5-hydroxytryptophan is converted into 
5-hydroxytryptantine (5-Hf; serotonin) catalyzed by the enzyme aromatic L-antino acid 
decarboxylase, which is also involved in the biosynthesis of catecholamines (Douglas, 
1985). 
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123 Biodegradation 
The predominant metabolic pathway of 5-HT is oxidative deamination by MAO-A, to 
yield the unstable intermediate 5-hydroxyindole-acetaldehyde, which is subsequently 
oxidized to 5-hydroxyindole acetic acid (5-HIAA) by the enzyme aldehyde-
dehydroxygenase. 5-HIAA is finally excreted in the urine. 
12.4 Fate 
The bulk of 5-HT is synthesized in the enterochromaffin cells of the gastrointestinal tract 
(Douglas, 1985). 5-HT released from these cells into the portal venous circulation is 
rapidly removed by hepatic metabolism, and by uptake in platelets and pulmonary 
endothelial cells (Vane, 1969). It must be highlighted that the uptake process in the 
endothelial cells of the pulmonary circulation is a very rapid and effective mechanism, 
susceptible to inhibition by either imipramine or cocaine (Catravas and Gillis, 1983). 
After endothelial uptake, 5-HT is metabolized by the isoenzyme A of the monoamine 
oxidase system (MAO-A; Roth and Gillis, 1975); however, it has been shown that 
inhibition of MAO-A does not influence the clearance of 5-HT by the lungs, suggesting 
that not the metabolism of 3-HT but rather its uptake by the endothelial cells is the rate 
limiting step in the inactivation of 5-HT (Vane, 1969; Wiersma and Roth, 1980). 
Conversely, in the liver the rate-limiting is not the endothelial uptake but the 
deamination of 5-HT by MAO-A, which can be explained by the hepatic architecture, 
since the endothelial lining of the liver sinusoids is discontinuous (Ham. 1974 ). 
Compared with the pulmonary endothelial cells, the uptake of 5-HT by platelets 
is a relatively slow process, which does not contribute to a major degree to the rapid 
removal of 5-HT from the portal venous plasma (Vane, 1969). However, since platelets 
take up 5-HT during their entire life time, they do play an important role in the overall 
removal of 5-HT from the circulation (Vane, 1969). 
Because of the effective clearance of 5-HT from the portal plasma, the plasma 
level of 5-HT in the systemic circulation remains extremely low (about 2 nM), and it is 
therefore highly improbable that circulating 5-HT influences the cardiovascular system 
under physiological conditions (Houston and Vanhoutte. 1986). 
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1.3 FUNCTION OF 5-IIT 
The precise physiological role of 5-Hf, other than as a neurotransmitter in the centtal 
and, perhaps, the enteric nervous system (Gershon et al, 1990), is, at best, debatable, 
although some progress has been made in the understanding of the role of 5-Hf in 
certain pathophysiological mechanisms. 5-Hf exerts a complex variety of effects in the 
body. Since the substance is unable to cross the blood-brain barrier (Lexchin et al, 
1977), there is an apparent discrimination between its peripheral and its centtal function. 
In the periphery 5-Hf is involved in the contraction of smooth muscle cells, aggregation 
of blood platelets and presynaptic modulation (stimulation or inhibition) of transmission 
in the autonomic neurons. In the central nervous system S·Hf serves as a 
neurotransmitter and seems to play an important role in the regulation of -amongst 
others- memory, appetite, anxiety, sleep, depression, body temperature, sexual behaviour 
and the cardiovascular system. 
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CHAPTER2 
CLASSIFICATION OF 5-HT RECEPTORS 
2.1 INTRODUCTION 
At present, it seems to be a general rule that there exist multiple types and subtypes of 
a receptor for each of the several neurotransmitters, neuromodulators and autocoids 
occurring in both the central nervous system and the periphery. As far as 5-HT is 
concerned, this is parricnlarly complex, as 5-HT is considered to act on four different 
receptor populations designated the 5-HT,-like, 5-HT,, 5-HT, and the recently discovered 
5-HT, receptor (for references, see G6thert and Schlicker, 1990; Saxena and Villalon, 
1990a, 1991). It is notewor-JJy that the distinction made between the 5-HT, and the 
5-HT2 receptor was purely based on radioligand binding studies using rather unselective 
drugs (see below). Not until more selective agonists and antagonists became available, 
could these 5-HT receptor types be better characterized. In contrast with the 5-HT, and 
5-HT, receptor types, the revelation of the 5-HT, and 5-HT, receptor types was at first 
based on functional receptor correlates (see Saxena and Villalon, 1990a). However, this 
current knowledge did not originate overnight. 
2. L 1 Historical remarks 
As far back as 1957, Gaddum and Picarelli (1957) suggested the existence of two types 
of 5-HT receptors based on the studies of 5-HT -induced contractions of the isolated 
guinea-pig ileum. These contractions could be partially blocked by morphine (M) or 
dibenzyline (D), but were completely antagonized by the combined use of both 
compounds. In the dibenzyline-pretreated ileunt, atropine and cocaine were also able 
to block the effect of 5-HT. whereas in the morphine-pretreated ileunt, lysergic acid 
diethylamide (LSD), 2-bromolysergic acid diethylamide and dihydroergotantine 
antagonized the effect to 5-HT. They concluded that 5-HT must act by two different 
mechanisms and receptors: aM-receptor located on the parasympathetic nerve endings 
mediating the release of acetylcholine. and aD-receptor, located on the smooth muscles. 
Nevertheless, neither morphine nor dibenzyline are specific 5-HT receptor antagonists. 
but the distinction made between these two types of receptors is still valid. 
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In the following two decades, progress in the classification of 5-HT receptors was 
rather limited though, from time to time, it was pointed out that the 'M' and 'D' receptor 
classification of Gaddum and Picarelli (1957) did not always hold true (for example, see 
Saxena et a!., 1971; Saxena and De Vlaam-Schluter, 1974). In 1974, Bennett and 
Aghajanian reported the first successful radioligand binding study of 5-HT receptors 
using d-fHJ-LSD. ['H]-5-HT also showed a high affinity, but because of discrepancies 
between the binding of ['H)-LSD and ['H]-5-HT, a recognition site with two different 
states was suggested (Bennett and Snyder, 1976; Fillion et al., 1978). Nonetheless, 
studies with fHJ-spiperone and fHJ-5-HT revealed that at least two distinct 5-HT 
recognition sites exist in the cerebral membranes: a 5-HT1 recognition site with high 
affinity for ['H]-5-HT and low affinity for spiperone; and a 5-HT, recognition site with 
high affinity for ['H]-spiperone (Peroutka and Snyder, 1979). 
2.12 Discovery of "selective" 5-HT receptor antagonists 
The development of ketanserin, a quinazoiindione derivative with high affinity for 5-HT, 
recognition sites (Leysen et al, 1981), made it possible to correlate 5-HT, recognition 
sites with functional D-receptors, which were renamed as 5-HT, receptors. Shortly 
afterwards, ritanserin was shown to have higher affinity and selectivity for 5-HT, 
receptors (Leysen, 1985). The availability of these and other antagonists (see Saxena 
and Villalon, 1990a) made it possible to clearly characterize the 5-HT, binding site, and 
correlate it with the Gaddum and Picarelli's D-receptor. It is of interest to note that 
many compounds which are thought to be selective antagonists of the 5-HT2 receptor 
show a similar degree of affinity for 5-HT1c receptors, such as cyproheptadine, ritanserin 
and LY 53857 (Hoyer, 1988a). However, the main difference between 5-HT, and 
5-HT1c receptor appears to be the affinity of both ketanserin and spiperone for these 
receptors: both compounds have appreciable higher affinity for 5-HT2 receptors (Hoyer, 
1988a,b). Also, in general. the affinity constants of the drugs for the 5-HT1c "receptor" 
is apparently closer to those for the 5-HT, receptor than for the other 5-HT, binding site 
subtypes (Hoyer, 1988a,b ). 
On the other hand, the M-receptor described by Gaddum and Picarelli (1957) 
does not fall into either the 5-HT, or the 5-HT, category as this site cannot be blocked 
by classical 5-HT receptor antagonists (methiothepin_ mianserin, cyproheptadine; see 
below), but can be blocked by selective antagonists, like MDL 72222 (Fozard, 1984a,b) 
and ICS 205-930 (Richardson et al., 1985). Since both compounds did not label 5-HT 
recognition sites in the brain, these receptors were called 5-HT3 receptors. 
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Notwithstanding, shortly afterwards, 5-IIT, recognition sites were described in the brain 
by Kilpatrick et a!. (1987). Therefore, it is not surprising that by the use of selective 
antagonists, the 5-IIT, and 5-IIT3 receptors have been well characterized. 
22 PROPOSALS FOR THE CLASSIFICATION OF FUNCTIONAL 5-IIT 
RECEPTORS 
By definition, 5-IIT has a higher affinity for 5-lff1 than for 5-lff2 recognition sites, and 
some effects of 5-lff cannot be blocked by 5-IIT, or 5-IIT3 receptor antagonists; hence 
an international committee proposed the existence of "5-lff,-like" receptors (Bradley et 
a!., 1986). According to their criteria 5-IIT,-like receptors are not blocked by selective 
antagonists at 5-IIT, (ketanserin, cyproheptadine) or 5-IIT3 (MDL 72222 or ICS 205-930) 
receptors, but can be selectively stimulated by 5-carboxamidotryptamine (5-CT). 
Furthermore, methiothepin, a compound with high affinity for both 5-liT1 and 5-IIT, 
recognition sites, must block the effects induced by 5-lff and 5-CT. 
2.2.1 Heterogeneity of the 5-IIT1 binding site 
Since the discovery of 5-IIT, binding sites by Peroutka and Snyder (1979), and further 
subclassification into 5-lfflA and 5-liT18 by Pedigo eta!. (1981), it was already quite 
clear that the 5-HT1B binding site population was a heterogeneous entity. By definition, 
'H-5-IIT labels all5-lff1 recognition sites, and at present, it is admitted that the 5-IIT, 
recognition site entity is highly heterogeneous in nature, as five 5-liT1 binding site 
subtypes (5-HTlA, 5-HT18, 5-HT1c, 5-HT10 and 5-HTlE) have been currently recognized 
(Pedigo eta!., 1981: Peroutka, 1986; Heuring and Peroutka, 1987; Hoyer, 1988a; Waeber 
et el., 1988; Leonhardt et a!., 1989; Gothert and Schlicker, 1990; Saxena and Villalon, 
1990a; Lowther et a!., 1991), and even these binding site subtypes do not seem to 
correspond with some 5-HT,-like receptor-mediated functional responses (see Table 1; 
Saxena and Villalon, 1990a). 
2.2.2 Functiona15-lff1-like receptors nnrelated to the known 5-IIT, binding sites 
Two additional5-HT1-like receptor subtypes have been described by Saxena and Villalon 
(1990a). Although these two receptor subtypes are still unnamed, they will be defined 
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here, in accordance with Saxena and Villalon (1990a) as the 5-HT,. and 5-HT,, receptor 
(Table 1), 
The 5-HT,. receptor-mediated responses can be characterized by the 5-HT, 
receptor agonists 5-CT (Bradley et al., 1986) and sumatriptan (GR 43175; Humphrey et 
al., 1988), 8-0H-DPAT, RU 24969 and indorenate (Saxena and Villalon, 1990a), which 
are antagonized by methiothepin; compounds such as ipsapirone, cyanopindoloL 
mesulergine and metergoline seem to be inactive at this receptor type as either agonists 
or antagonists. The 5-HT"' receptor appears to be present in certain cephalic arteries 
(basilar, pial), on the rabbit and dog saphenous vein, and on the arteriovenous 
anastomoses in the carotid region. Activation of the 5-HT1x receptor results in 
constriction of these blood vessels (Born et al., 1988b, 1989a,b; Connor et a!., 1989; van 
Heuven-Nolsen et a!., 1990; Perren et a!" 1991). Furthermore, 5-HT,. receptors are 
likely to be involved in the 5-HT-induced inhibition of noradrenaline release in response 
to transmural stimulation of postganglionic sympathetic neurons (G6thert et al., 1990). 
The 5-HT,,-receptor-mediated responses can be characterized by the 5-HT, 
receptor agonist 5-CT and the unselective 5-HT receptor antagonists methiothepin and 
methysergide (Saxena and Villalon, 1990a). The 5-HT,, receptor is involved in 
5-HT-induced smooth muscle relaxation in several blood vessels including the cat 
isolated saphenous vein (Feniuk et al., 1983) and porcine arterioles (Saxena and 
Verdouw, 1982, 1985a,b). The 5-HT,-Iike receptor that mediates tachycardia in the cat 
(Saxena et al., 1985b; Saxena, 1988) also seems to be related to the 5-HT,, receptor. 
Therefore, both 5-HT1x and 5-HT1y receptor types share certain similarities with the 
5-HT, binding site, but are not identical to any of the known subtypes described above. 
As a consequence, the discovery of selective 5-HT1 receptor antagonists in the future 
may result in the adaptation of the 5-HT1-like receptor classification. 
2.2.3 Evidence supporting the existence of a new 5-HT receptor type 
In connection with the nature of 5-HT receptors. it should be noticed that the 5-HT 
receptor classification scheme proposed by Bradley et al. (1986) would seem currently 
outdated, as a novel5-HT receptor type positively linked to the adenylate cyclase system 
of mouse embryo colliculi neurons has been described (Dumuis et al.. 1988. 1989). At 
this receptor. 5-HT. 5-methoxytryptamine. a-methyl-5-HT and benzamide derivatives 
such as renzapride, zacopride and cisapride. act as agonists, and only high doses of the 
5-HT, receptor antagonist lCS 205-930 acts as an antagonist (Dumuis eta! .. 1988. 1989). 
In addition, the potency of 5-methoxytryptarnine and the ineffectiveness of 
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2-methyl-5-HT clearly distinguished the site from a 5-HT3 receptor and removed the 
possibility that the low affinity for ICS 205-930 merely represents the disclosure of yet 
another 5-HT 3 receptor subtype. Significantly, in this context, the site is resistant to 
other 5-HT, receptor antagonists such as MDL 72222, granisetron or ondansetron, or to 
5-HT1-like and/or 5-HT2 receptor antagonists. Therefore, this novel receptor type was 
designated as the putative 5-HT, receptor (Dumuis et al., 1988, 1989; Clarke et al., 1989; 
Saxena and Villalon, 1990a). 
2.2.4 Reconsideration of new proposals for the classification of 5-Hf receptors 
Taking into consideration the current evidence (Bradley et al., 1986; Durnuis et aL, 1988, 
1989; Clarke et al., 1989; Humphrey and Feniuk, 1989; Saxena, 1989; Saxena and 
Ferrari, 1989; Feuink and Humphrey, 1990; Fozard, 1990; Mylecbarane, 1990; Saxena 
and Villalon, 1990a, 1991; Saxena et al., 1986a,h), 5-HT receptors can be identified and 
delineated as follows: 
5-Hf1-like receptors. Selective agouist: 5-carhoxarnidortyptantine (5-CT); antagonists: 
methiothepin (metitepine) or methysergide, both of which display even higher affinity 
for 5-HT2 binding sites. 
5-Hf2 receptors. Agouists: a-methyl-5-HT or 1-(2,5-dimethoxy-4-iodophenyl)-
aminopropane (DOl); antagonists: ketanserin, ritanserin or 4-isopropyl-7-methyl-
9-(2-hydroxy-1-methylpropoxycarbonyl)-4,6.6a,7,8,9,10,10a-octa-hydroindolol[4,3-fg] 
quinoline maleate (L Y 53857). 
5-Hf, receptors. Agouists: 2-methyl-5-HT or 1-phenyl-bignanide; 5-methoxyrtyptamine 
must be inactive; antagonists: laH,3a,5aH-trophan-3yl-3,5-dichlorobenzoate 
(MDL 72222), (3a-tropanyi)-1H-indole-3-carboxilic acid ester (ICS 205-930), granisetron 
or ondansetron. 
Putative 5-HT4 receptors. Agonists: 5-methoxytryptamine, a-methyl-5-HT as well as 
certain benzamide derivatives like renzapride, zacopride, cisapride, etc.; 2-methyl-5-HT 
must be inactive; antagonist: high concentrations of ICS 205-930. 
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2.3 ARE THE KNOWN 5-HT RECEPTOR TYPES HOMOGENEOUS 
ENTITIES? 
Nowadays, it is recognized that only the 5-HT, binding site population (and the 
5-HT,-like receptor) is highly heterogeneous in nature (see above). Apparently, only 
5-HT"' receptor-mediated responses can be selectively discriminated by using ligands 
such as 8-0H-DPAT, flesinoxan_ ipsapirone or urapidil (Hoyer, 1988a; Waeber et a!., 
1988; Feniuk and Humphrey, 1990). 
With respect to the other 5-HT receptor types, heterogeneity cannot be ruled out 
for the 5-HT, 5-HT, and 5-HT, receptors, although good evidence is still to be offered. 
Notwithstanding, the current evidence for such heterogeneity is considered to be 
insufficient (Bradley et al, 1986; Dumuis et a!., 1988, 1989; Clarke and Craig, 1989; 
Craig and Clarke, 1990; Saxena and Villalon, 1990a, 1991; present thesis). Thus, the 
ongoing development of drugs with different pharmacological properties may lead to the 
extension of the present 5-HT receptor family (see, for example, Cadogan and 
Humphrey, 1991). 
2.4 FUNCllONAL RESPONSES MEDIATED BY 5-HT RECEPTOR 
ACllVATION 
2.4.1 Introduction 
5-HT and related agonist drugs exert a variety of functional responses, via the 
stimulation of several receptors in the central nervous system (CNS), on the autonomic 
nerve endings and on various smooth muscle containing tissues (see Table 1). The 
multiplicity of 5-HT binding sites raises the question as to whether these sites do indeed 
correspond to receptors, i.e. whether each subtype is coupled to an effector system. 
During the last few years, progress has been made to define the second messenger 
systems that are linked to the putative 5-HT receptors (Table 1; Saxena and Villalon, 
1990a). 
2.42 Responses mediated by 5-HT, receptors 
Except for the 5-HT,c and 5-HT,E receptors, the 5-HT, receptor subtypes have been 
coupled to the modulation of adenylate cyclase (see below). The characterization of 
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functional responses mediated by the 5-HTlA receptor is mainly based on the properties 
of the specific agonist 8-0H-DPAT, though a more recently developed 5-HTlA receptor 
agonist is flesinoxan (Ramage eta!., 1988; Wouters eta!., 1988a,b). So far, the 5-HTlA 
receptor appears to have been identified only in the CNS. However, in the sympathetic 
neurons of the dog external carotid artery, the 5-HTlA receptor subrype may be involved, 
as indicated by the agonist activiry of 5-HT and indorenate (a 5-HTlA receptor ligand; 
Dompert et a!, 1985) and the antagonism by methiothepin and ( ± )-pindolol (Hong and 
Villal6n, 1988), but not by ritanserin (Villa16n and Hong, 1988). Basically, 5-HT"' 
receptors are involved in central cardiovascular regulation as well as in neurogenic, 
behavioral, metabolic and endocrine mechanisms (see Table 1). 
ln contrast with the 5-HT 1A receptor subtype, no specific agonists or antagonists 
have been defined for the 5-HT,8 , 5-HT1c, 5-HT10 or 5-HT18 receptor types. 
Consequently, the characterization of functional responses mediated by these receptor 
rypes has mainly been carried out by the exclusion of the other 5-HT receptor 
mechanisms. Activation of the 5-HT,, receptor, which appears to be entirely confined 
to rodents (see Hoyer, 1986a, 1988a) mediates e.g. inhibition of sympathetic 
neurotransmission in rat vena cava (Molderings et a!., 1987), enhancement of 
neurogenically mediated contraction in mouse bladder (Holt et a!., 1986) and inhibition 
of forskolin-stimnlated adenylate cyclase in rat substantia nigra (Bonhelal et a!., 1988). 
Furthermore, the 5-HT terminal autoreceptor in rat cortex has been delineated as a 
5-HT18 receptor (Engel et al., 1986). ln the brain, the 5-HT10 receptor has been 
identified in those species where little or no 5-HT18 binding could be demonstrated, like 
calf, pig, guinea-pig and human tissue. Although pharmacologically distinct, 5-HT18 and 
5-HT10 receptors show some similarities, and they may be equivalent in the different 
species. For example, like the 5-HTlB receptor in rat substantia nigra (Bonhelal eta!., 
1988), the 5-HT10 receptor in calf substantia nigra is negatively coupled to adenylate 
cyclase (Schoeffter et al., 1988). ln addition, the 5-HT terminal autoreceptor in cortex 
of pig, guinea-pig and human appears to be of the 5-HT10 receptor subrype (Galain et 
al., 1988; Schipper and Tulp, 1988; Schlicker eta!., 1989). ln cats, the 5-HT10 site has 
been implicated in RU 24969-induced emesis (Lucot, 1990); and very recently, the 
5-HT10 receptor has also been localiaed peripherally in the pig, subserving 
endothelium-dependent relaxation of the coronary arteries (Schoeffter and Hoyer, 1990). 
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Table 1. Oassification of and some functional responses mediated by 5-Hr Receptors. 
Rc<eptor -selective• "Selective· Bmdmg Second Some functional responses 
subtype agocists antagonists site messenger 
5-HT1-like 
5-HT,. 5-cr Cyanopindolol 5-HTlA Negative or Behavioral changes, centrally 
8·0H-DPAT Methysergide positive coup- evoked hypotensive response, 
RU24969 Methiothepin ling to adenyl- Some endocrinological effects.. 
5-CH30-T ate cyclase, 
Sumatriptan K" channel 
5-HTrs RU24969 Cyanopindolol 5-HT,. Negative coup- Autoreceptor in the rat brain, 
5-cr Methiothepin ling to adenyl- Inhlbition of acetylcholine and 
5-CH:P-T ate cyclase noradrenaline release in rats. 
Sumatriptan 
5-HT1c., Mesulergin.e S-HT1c Phosphoinosi- Not yet convincingly demonstrated 
Methiothepin tide-specific due to unselective drugs. 
Methysergide phospholipase·C 
5-HTm 5-cr Metergoline 5-HTm Negative coup- Not yet convincingly demonstrated 
RU24969 Metbiothepin ling to adenyl- due to unselective drugs. 
Sumatriptan ate cyclase 
5-HTlE 5-HT GTP-gamma·S 5-HTIE Interaction with Not yet convincingly demonstrated 
a GTP·bmiling due to unselective drugs. 
protein 
5-HTrxl> 5-CT Methiothepin Not yet Not yet Contraction of cephalic arteries 
AH25086< Methysergided founde known (basilar, pial) and arteriovenous 
Sumatriptan anastomoses in the carotid region, 
8-0H·DPAT decrease of neuronal noradrenaline 
RU 24969 release. 
5-HT!y" 5-CT Metlriothepin Not yet Not yet Vascular smooth muscle relaxation. 
Methysergide found~ known hypotension. tachycardia in the cat. 
5-HT, a-CH:;-5-HT Ketanserin 5-HT, Phosphoinosi- Contraction of various vascular, 
Cyproheptadine tide-specific gastrointestinal and bronchial 
Methysergide phospholipase-C smooth muscles, platelet aggregation. 
Metbiothepin Head twitch and convulsion. 
5-HT, 5·HT MDL7= 5-HT3 Cation Membrane depolarization. dermal 
2-CHTS-HT res 205-930 channels pain and flare response. 
Granisetron 
Ondansetron 
5-HT, 5·HT ICS 205-930 5-HT4? Positive coup- Gastrokinetic action, cholinergically 
Renzapride ling to adenyl- mediated guinea-pig ileum 
5-CH30-T cyclase contraction., Myocard.ial stimulation 
a-CH3-5-HT in pigs and humans. 
a, Shows little difference from the 5-HT2 receptor: b, The receptor subtype is as yet unnamed and this name has 
been put for convenience in this manuscript to distinguish between the two unnamed 5-HT1-like receptors~ 
c, Ligand binding profile is not yet reported: d. Partial agonist: e. Does not correlate with 5-HTv •. 5-HTm. 5-HT1c 
or 5-HT10 binding sites. AH25086, 3-am.inoethyl-N-methyl-lH-indole-5-methane carboxamide: 5-CH30-T. 
5-methoxytrypt:am.ine: a-CH3-5-HT. a-methyl-5-HT: GTP -gamma-S, guanosine 5' -0-(3-thiotriphosphate. Modified 
from Saxena and Villal6n (1990a). 
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As far as the 5-HT,c receptor is concerned, this receptor has been identified in 
either rat, pig or human choroid plexus (Pazos eta!., 1985; Yagaloff and Hartig, 1985; 
Hoyer eta!., 1986b) and shows remarkable similarities with the 5-HT, receptor regarding 
molecular, pharmacological and biochemical properties (Schmidt and Peroutka, 1989). 
As a consequence, it is difficult to identify contributions of the 5-HT,c receptor subtype 
to functional responses. Like the 5-HT, receptor, the 5-HT,c receptor has been linked 
to phosphoinositide turnover (Conn eta!., 1986). So far, the 5-HT,c receptor appears 
to be involved in the modulation of the production of cerebrospinal fluid. 
A 5-HT rn binding site has also been described (Leonhardt et a!., 1989). As to 
the binding profile, both 5-HTm and 5-HT,E binding sites are located in human frontal 
cortex, but uolike the 5-HTm binding site, the 5-HT,. binding site displays higber affinity 
for 5-HT and low affinity for 5-CT and ergotamine, and remarkably, interacts with a 
GTP-binding protein, which makes it functionally different from the other 5-HT, binding 
sites (see above). In this respec-c, the non-hydrolysable derivatives of GTP such as 
guanosine 5' -0-(3-thiotriphosphate) (GTP-gamma-S) and 5'-guanylylimidodiphosphate 
[Gpp(NH)p] potently inhibited the binding of PHJ-5-HT to the 5-HTrn binding site, 
while adenosine 5' -0-(3-thiotriphosphate) and 5' -adenylylimidodiphosphate were without 
effect (Leonhardt et a!., 1989). As far as we know, no functional response mediated by 
the 5-HT1E receptor has been delineated in the periphery, whereas second messenger 
systems have not yet been defined for the 5-HT,. and the 5-HT,, receptor subtypes 
(Saxena and Villalon, 1990a). 
2.43 Responses mediated by 5-HT, receptors 
The 5-HT 2 receptor has been linked to the modulation of phosphoinositide (PI) turnover 
(Conn and Sanders-Bush, 1986), and exists both in the periphery and in the CNS. 
Peripherally. 5-HT2 receptors have been involved in vascular smooth muscle contraction, 
e.g. canine basilar arteries (Miiller-Schweinitzer and Engel, 1983); contraction of 
uterine. bronchial, gastro-intestinal and bladder smooth muscle (Saxena and Lawang, 
1985; Saxena et a!., 1985a; Bradley et a!., 1986), platelet aggregation (de Clerk et a!., 
1984). etc. In the CNS 5-HT, receptors mediate responses such as 5-HT-induced 
excitation of rat brain stem neurons (Davies et al., 1988). 5-HT-induced depolarization 
of guinea-pig cortical pyramidal neurons (Davies eta!., 1987), some behavioral responses 
in rodents such as head twitch and wet-dog shakes (Lucki et al., 1984) and the 
hallucinogenic action induced by certain drugs (Glennon, 1990). Furthermore, 5-HT, 
receptors seem to be involved in some neuroendocrine functions such as the secretion 
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of B-endorphin and corticosterone in the rat (Koenig et a!., 1987) as well as the release 
of prolactin in rhesus monkeys (Henioger et aL, 1987). 
2.4.4 Responses mediated by 5-HT, receptors 
In contrast with the other 5-HT receptor families, the 5-HT, receptors are directly 
coupled to a cation channel (Derkach et aL, 1989). Functional 5-HT, receptors have 
been identified in both the peripheral and central nervous system. In the mammalian 
peripheral nervous system, 5-HT is known to excite a variety of neurons via 5-HT, 
receptors, mediating the release of neurotransmitters such as acetylcholine from 
parasympathetic neurons in e.g. the rabbit heart (Fozard, 1984a,b) and cat urinary 
bladder (Saxena et aL, 1985a), noradrenaline from sympathetic neurons in e.g. the 
rabbit heart (Fozard and Mwaluko, 1976) and the superior cervical ganglion (Wallis and 
North, 1978), and substance P from enteric neurons in e.g. the gnioea pig ileum (Bradley 
eta!, 1986). 5-HT3 receptors mediate also 5-HT-induced pain sensation in human skin, 
the cardiovascular von Bezold-Jarisch reflex and depolarization of C-fibres in the nodose 
ganglion and vagus nerve (Richardson et aL, 1985). In the CNS, 5-HT, receptors are 
involved in the anxiogenic effects of some drugs in rats, mice and marmosets (Tyers et 
a!., 1987), and the cytotoxic drug-induced emesis (Higgins et a!., 1989). 
2.45 Responses mediated by the putative 5-HT, receptor 
The putative 5-HT, receptor has been positively linked to adenylate cyclase in both the 
mouse and gnioea-pig CNS (Dumuis et aL, 1988, 1989; Bockaert et a!., 1990), and has 
been involved in the increase in electroencephalographic energy produced by zacopride 
and renzapride when applied i.c.v. in the rat (Boddeke and Kalkman, 1990). In the 
periphery, the 5-HT, receptor is involved in e.g. the activation of cholinergically 
mediated contractions in the gnioea-pig ileum (Clarke et aL, 1989; Craig and Clarke, 
1990). 
From the foregoing information, it is obvious that the actions of 5-HT in the 
organism are extremely complex (see for example Bradley et a!., 1986; Saxena and 
Villalon, 1990a, 1991). There are still a lot of unanswered questions concerniog the 
nature of the mechanisms underlying the central and peripheral effects of 5-HT, for 
example, in the cardiovascular system of several species including man; accordingly. a 
review of the cardiovascular effects of 5-HT (and related drugs) will be detailed. 
CHAPTER 3 
5-HT AND THE CARDIOVASCULAR SYSTEM 
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CHAPTER3 
5-Hf AND THE CARDIOVASCULAR SYSTEM 
3.1 INTRODUCllON 
In general terms, the primary role of the cardiovascular system is to ensure at every 
moment the survival of all cells of the body. These cells must receive nutrients and 
eliminate their waste substances so that there must be a continuous stream of nutrients 
from the outside world to the extracellular fluid, and a continuous stream of waste 
substances from the cells to the outside world. Therefore, the organism needs 
specialized tissues for exchange (lungs, gut and kidneys) and a transport (cardiovascular) 
system (blood, blood vessels and heart) to link these tissues with the individual cells. 
3.2 PHYSIOLOGICALREGULATION OFTHECARDIOVASCULARSYSTEM 
The mechanisms involved io the control of the functions of the cardiovascular system 
are under nervous, humoral and/or local regulation. All of them together adjust the 
total peripheral resistance and cardiac output io such a way as to maiotaio the blood 
pressure gradient required for adequate flow through the vascular system. Thus, the 
central nervous system (CNS) unifies the ioformation gathered from several sensors 
within the cardiovascular system and modulates the fuoction of its components by means 
of the autonomic nervous system (sympathetic and parasympathetic; see Kuntz, 1953) 
and certaio endocrine glands. Summarizing, the regulation of the cardiovascular system 
consists of: 
3.2.1 Nervous Regulation 
There exist numerous peripheral receptors within the circulation, which sense either 
changes io blood pressure (mechanoreceptors) or variations io the chemical composition 
of the blood (chemoreceptors). The degree of activity of these receptors is conveyed 
by afferent nerves to centres in the brain stem which control the function of the heart 
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and blood vessels by altering the activity of the noradrenergic and cholinergic nerves. 
When the activity of the former is increased. the neurotransmitter noradrenaline is 
released, which stimulates the heart (B-adrenoceptors) and constricts the blood vessels 
( a-adrenoceptors ). When the cholinergic nerves are activated. the released acetylcholine 
depresses the heart (muscarinic cholinoceptors). Certain cardiovascular changes may 
initiate compensatory reflex adjustments, such as the baroreceptor reflex, 
cardiopulmonary reflex, chemoreflexes (e.g. the von Bezold-Jarisch reflex) and spinal 
reflexes. Activation of each of these reflexes results in changes in sympathetic and/ or 
parasympathetic outflow in order to modify the cardiovascular function. 
3.22 Humoral Regulation 
The activity of both heart and blood vessels is also modulated by substances released 
into the circulation from endocrine glands, e.g. adrenaline from the adrenal medulla, 
which, amongst other effects: 1. increases both rate and contraction force of the heart; 
2. constricts most systemic resistance vessels; 3. dilates resistance vessels of skeletal 
muscles, etc. 
3.2.3 Local Regulation 
In the tissues. products of cellular metabolism (H\ HCO;, ADP, adenosine, etc.) 
regulate the local blood flow in accordance with their needs. In addition, the autacoids 
(prostaglandins, kinins, angiotensin, histamine, 5-HT) can induce vasoconstriction and/ or 
vasodilatation by themselves (see for example Vanhoutte et al., 1981), and may modify 
cardiac function. Likewise, it must be highlighted that certain metabolites and the 
autocoids (notably 5-HT) can also modulate the activity of central, sympathetic and/ or 
parasympathetic nerves either stimulating or inhibiting the release of their respective 
neurotransmitters (for references, see Langer, 1980), and consequently, will modify the 
cardiovascular function. It is interesting to note that 5-HT can interact in all 
components of the cardiovascular system in a variety of ways, acting on practically all 
types of 5-HT receptors delineated so far (Saxena, 1986; Saxena and Villalon, 1990a, 
1991). 
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33 CARDIOVASCULAR EFFECTS OF 5-HT AND RELATED DRUGS 
It is well known that 5-HT elicits complex changes in the cardiovascular system 
comprising bradycardia or tachycardia, hypotension or hypertension aod vasodilatation 
or vasoconstriction (Saxena and Villalon, 1990a,b, 1991). The eventual response depends 
- amongst other factors - upon the species, the basal vascular tone, the vascular bed 
under study, dose employed and, most importantly, the nature of the 5-HT receptors 
involved. With the recent discovery of a variety of drugs acting selectively at 5-HT 
receptors (see Chapter 1 ), it is nowadays clear that the cardiovascular aod, indeed, other 
effects of 5-HT seem to be mediated by the previously described four types of 5-HT 
receptors. 
5-Hr and related agonist drugs exert a variety of functional responses via 
stimulation of the different 5-HT receptors in the central nervous system, on the 
autonomic nerve endings, on various smooth muscle containing tissues and on the 
cardiac tissue (see Table 1; Saxena aod Villalon, 1990a,b, 1991). 
3.3.1 Cardiovascular reflex responses to 5-HT and related drugs 
5-HT has long been known to elicit a variety of cardiovascular reflexes by acting mainly 
on the carotid body arterial chemoreceptors, cardiopulmonary receptors and pulmonary 
J (deflation) receptors (McQueen, 1990). These reflex responses will obviously 
contribute to the all-over effect of 5-HT as follows: 
Carotid body arterial chemoreceptors. Stimulation of carotid body chemoreceptors, 
quite marked in dogs but weak in cats (Black et al., 1952), consists of bradycardia and 
hypotension followed by tachycardia, hypertension and hyperventilation ( Ginze~ 1958; 
Skinner and Whelan, 1962; McQueen and Ungar, 1971). Because both 
1-phenylbiguauide and 2-methyl-5-HT mimic 5-HT, and MDL 72222 and ICS 205-930 
each antagonize these reflex responses, the receptor involved is of the 5-HT3 type 
(McQueen, 1990). 
Cardiopulmonary receptors. Stimulation by 5-HT of sensory receptors in the heart 
and lungs elicits reflex responses leading to bradycardia, hypotension. tachypnoea and 
nausea. Usually, one such reflex (von Bezold-Jarisch-like reflex). evoked mainly from 
the cardiac receptors (left and right ventricular pressure, type A and B left atrial and 
type A right atrial and epicardial receptors) on C-fibre afferents. results in pronounced 
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bradycardia, hypotension and apnoea (Thoren, 1979). This reflex is mediated mainly by 
the vagus nerve and, in case of 5-HT and related drugs, involves 5-HT3 receptors 
(McQueen, 1990). 
Pulmonary J receptors. 5-HT and 1-phenylbiguanide can increase the activity of the 
type J vagal afferent fibres (Paintal, 1977). Injection of these drugs into the right atrium 
(Armstrong et a!., 1986a) and pulmonary embolism (Armstrong et a!., 1986b) in 
anaesthetized rabbits results in bradycardia, hypotension and rapid shallow breathing, 
typical of J receptor stimulation, via 5-HT, receptors. 
33.2 Blood pressure responses to 5-HT and related drugs 
5-HT has a triphasic effect on arterial blood pressure (Table 2), comprising an initial 
intense, but brief, hypotension followed by a moderate hypertension and, finally, a 
longer-lasting hypotension (Page and McCubbin, 1953; Kalkman et a!., 1984 ). Contrary 
to the connotation conveyed by the word "serotonin", 5-HT is much more potent in 
eliciting the late longer-lasting hypotensive phase than in evoking the initial hypotensive 
phase or the pressor response (Saxena and Lawang, 1985) and, therefore, more readily 
deserves the name "serodilin". 
The hypertensive phase varies quantitatively depending upon the species and the 
experimental conditions; for instance, rabbits (Schneider and Yonkman, 1954; Bolt and 
Saxena, 1985; Wright and Angus, 1989), cats (Schneider and Yonkman, 1954; Saxena et 
a!, 1985b) and pigs (Saxena and Verdouw, 1982, 1985b; Saxena eta!., 1986a) exhibit a 
poor hypertensive phase, while it is prominent in the dog (Schneider and Yonkman, 
1954) particularly after ganglion bloc~de (Feniuk et a!., 1981). As delineated below, 
these differences may be due to the type of receptors and their distribution in the 
different species. 
Initial transient depressor response. The initial hypotensive response to 5-HT is the 
result of an abrupt bradycardia (and the consequent decrease in cardiac output) 
following stimulation of 5-HT, receptors on afferent cardiac vagal nerve endings 
(Table 2). However, there is some evidence that a short-lasting vasodilatation may be 
obtained via 5-HT, receptors, which probably invokes an axon-like reflex (Blauw et a!., 
1988). 
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Table 2: 5-Hf receptors mediating effects on arterial blood pressure in different 
species. 
Species Condition 
initial depressor response 
Rat Intact 
Cat Intact 
Pressor response 
Rat Intact 
Rat Pithed 
Cat B-Adrenoceptor block 
Cat Spinal 
Dog Ganglion-blockade 
Late depressor responsea 
Rat Intact 
Rat Pithed 
Rat Atropinized 
Cat B-Adrenoceptor block 
Pia 0 Intact 
3
, Most sensitive response. 
Receptor 
5-Hf, 
5-Hf, 
5-Hf, 
5-Hf, 
5-Hf, 
5-Hf, 
5-Hf, 
5-Hf,-like 
5-Hf,-like 
5-Hf,-like 
5-Hf,-like 
5-Hf,-like 
Taken from Saxena and Villalon (1990a). 
Main mechanism 
von Bezold-Jariscb reflex 
von Bezold-Jariscb reflex 
Vascular effect 
Vascular effect 
. Vascular effect 
Vascular effect 
Adrenal catecholamine release 
Vascular effect 
Vascular effect 
Vascular effect 
Vascular effect 
Vascular effect 
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Table 3: 5-Hf receptors mediating vascular contractions in different species. 
Species Vessel Condition Receptor 
Rat Basilar artery Isolated 5-Hf, 
Rat Jugular vein Isolated 5-Hf, 
Rat Portal vein Isolated 5-Hf, 
Rat Aorta Isolated 5-Hf, 
Rat Caudal artery Perfused 5-Hf, 
Rabbit Aorta Isolated 5-Hf, 
Rabbit Common carotid artery Isolated 5-Hf, 
Rabbit Femoral artery Isolated 5-Hf, 
Cat Middle cerebral artery Isolated 5-Hf, 
Cat Pial arteries In situ 5-Hf, 
Cat Saphenous vein Isolated 5-Hf, 
Dog Basilar artery Isolated 5-Hf2a 
Dog Middle cerebral artery Isolated 5-Hf, 
Dog External carotid artery Isolated 5-Hf, 
Dog Coronary artery Isolated 5-Hf, 
Dog Femoral artery Isolated 5-Hf, 
Dog Femoral artery In vivo 5-Hf, 
Pig Common carotid artery In vivo 5-Hf, 
Calf Coronary artery Isolated 5-Hf, 
Calf Pulmonary artery Isolated 5-Hf, 
Monkey Basilar artery Isolated 5-HTzn 
Human Umbilical artery Isolated 5-Hf, 
Human Femoral artery Isolated 5-Hf, 
Guinea-pig Basilar artery Isolated 5-Hf,-like 
Cat Cranial A VAs In vivo 5-Hf,-like 
Dog Saphenous vein Isolated 5-Hf,-like 
Dog Basilar artery Isolated 5-Hf,-like" 
Dog Auricular artery Isolated 5-Hf,-like 
Pig Cranial A VAs In vivo 5-Hf,-like 
Monkey Basilar artery Isolated 5-Hf,-like" 
Human Basilar artery Isolated 5-Hf,-like 
Rabbit Ear artery Isolated a-adrenoceptor 
Rabbit External carotid artery Isolated a-adrenoceptor 
3
, both 5-HT1-like and 5-HT2 receptors seem to mediate contraction. 
A VAs, arteriovenous anastomoses. 
Taken from Saxena and Villalon (1990a). 
Pressor response. The pressor component, amenable to blockade by ketanserio-like 
drugs. is due to activation of 5-Hf, receptors (Table 2), mainly on the blood vessels in, 
for example, the rat (Kalkman et al., 1983, 1984; Saxena and Lawang, 1985; Dalton et 
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a!, 1986; Dabire et a!., 1989a,b) and cat (Saxena et a!., 1985b; Connor et a!., 1986; 
Saxena, 1988) or, as in tbe dog, on tbe adrenal medulla to release catecholamines 
(Feniuk et a!., 1981; Kimura and Sato, 1983). 
Accordingly, tbe contractile effects on botb arteries and veins are generally 
mediated by 5-HT, receptors (Table 3; Apperley eta!., 1980; Black eta!., 1981; Leysen, 
1981; Cohen et a!., 1981; Cohen et a!, 1983; Feniuk et a!., 1983; Miiller-Schweinitzer 
and Engel, 1983; Van Nueten, 1983; Frenken and Kaurnann, 1984; Glusa and 
Markwardt, 1984; Lemberger eta!., 1984; Saxena and Verdouw, 1984; Thompson eta!, 
1984; Van Nueten eta!., 1984; Verdouw eta!., 1984; Blackshear eta!, 1985; Clancy and 
Maayani, 1985; McGratb et a!., 1985; Young et a!., 1986; Chang, 1987; Chang and 
Owman, 1989a,b); drugs such as ketanserin, cyproheptadine, pizotifen and metbysergide 
are competitive antagonists witb pA, being similar to tbeir pK, values determined in 
5-HT, binding assay (Leysen, 1981; Bradley et a!., 1986). However, in cranial blood 
vessels of <lifferent species, including humans, as well as tbe dog saphenous vein, 
5-HT,-like receptors mediate vasoconstrictor responses (Table 3; Engel et a!., 1983; 
Peroutka et a!., 1983; Peroutka and Kuhar, 1984; Verdouw et a!., 1985; Taylor et a!, 
1986; Humphrey et a!, 1988; Chang and Owman, 1989a,b; Connor et a!., 1989; Parsons 
et a!., 1989; Perren et a!., 1989). In some cases, botb 5-HT,-like and 5-HT, receptors 
seem to mediate contractile effects in tbe same vessel, for example tbe dog 
(Miiller-Schweinitzer and Engel, 1983; Peroutka eta!., 1983; Peroutka and Kuhar, 1984; 
Van Nueten eta!., 1984; Taylor eta!., 1986; Connor eta!., 1989) and monkey (Peroutka 
and Kuhar, 1984; Chang, 1987; Connor et a!., 1989; Parsons et a!, 1989) basilar arteries 
and, perhaps to a lesser extent, tbe pig carotid arteriovenous anastomoses (Saxena and 
Verdouw, 1982, 1984; Verdouw et a!., 1984; Saxena et a!., 1986a). In rarer instances, 
5-HT may act directly on tbe a-adrenoceptors in rabbit ear and external carotid arteries 
(Apperley et a!., 1976; Black et a!., 1981, Van Nueten, 1983) (Table 3). In addition, 
there is some limited evidence that in the rat coronary arteries, 5-HT may also release 
a contractile substance from the endothelium. The nature of this substance is not known 
(Vanboutte et a!., 1990). 
It may also be pointed out here that 5-HT has, in addition to a central 
vasodepressor effect (see below), an excitatory effect on preganglionic sympatbetic 
activity via ponte-medullary serotonergic patbways and 5-HT, receptors (see Mir and 
Fozard, 1990). These nerves, however, do not seem to exert a tonic influence and, 
moreover, spinal5-HT2 receptors can also increase sympatbetic nervous activity (Mir and 
Fozard, 1990). 
The 5-HT-induced increase in tbe sympatbetic nerve activity may also involve 
a 5-HT,-like receptor; such an effect is minticked by intratbecal administration of 5-CT 
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(but not 8-0H-DPAT), and remains unaffected by ketanserin, MDL 72222 or 
ICS 205 930 (Yusof and Coote, 1988). 
Late depressor response: The late depressor effect of 5-HT is not affected by 
selective 5-HT, or 5-HT, receptor antagonists, but is antagonized by methysergide or 
methiothepin (Kalkman et al, 1984; Saxena and Lawang, 1985; Dalton et al., 1986; 
Saxena, 1988). A similar depressor response can be evoked by 5-CT and this effect is 
also blocked by methysergide or methiothepin (Saxena and Lawang, 1985; Saxena et al., 
1985a; Saxena, 1988). Finally, there is a good correlation between the hypotensive 
activity of tryptamine derivatives and their affinity for the 5-HT, binding site (Kalkman 
et al, 1983). Therefore, the late hypotensive phase is mediated by 5-HT1-like receptors 
(Table 2), but several mechanisms probably contribute to different degrees in different 
experimental situations and species. These 5-HT1-like receptor-mediated mechanisms 
are: 
Central vasomotor inhibition: Injection of 5-HT into the central nervous 
system has been reported to cause depressor, pressor or biphasic responses (Bhargava 
and Tangri, 1959; Smit et al, 1978; Krstic', 1985; Dalton et al., 1986; Yusof and Coote, 
1988; Mir and Fozard, 1990). The magnitude and the nature of the response (pressor, 
depressor or biphasic) to centrally administered 5-HT largely depends upon the exact 
site of application, the dose employed or whether conscious or anaesthetized and 
normotensive or hypertensive animals are used (Sukamoto et al., 1984; Krstic', 1985; 
Wolf et al, 1985; Dalton et al., 1986; Mir and Fozard, 1990). This discrepancy may be 
because 5-HT neurones in different brain areas have divergent effects; that is, dorsal and 
median raphe, anterior hypothalamus, and ventrolateral medullary raphe areas seem to 
be associated with pressor effects, whereas midline medullary raphe nuclei produce 
either pressor or depressor effects (Wolf et al., 1985; Ramage et al., 1988). These 
central pressor and depressor effects of 5-HT seem to be mediated via different 5-HT 
receptors in the central nervous system (Mir and Fozard, 1990). 
Recently, severalagonists at5-HT1A receptors -8-0H-DPAT (Main et al., 1984; 
Gradin et al., 1985a,b; Martin and Lis, 1985; Fozard et al., 1987; Ramage and Fozard, 
1987; Doods et al, 1988; Mir and Fozard, 1990), flesinoxan (Wouters et al., 1988a,b; 
Dreteler et al., 1989; Coote, 1990), N,N-dipropyi-5-CT (Doods et al_ 1988; Mir and 
Fozard, 1990), urapidil (Doods et al., 1988; Gillis et a!., 1988; Sanders et a!., 1988; 
Kolassa et a!., 1989; Mir and Fozard, 1990) - have been found to decrease arterial 
blood pressure and heart rate (see above) in different animal species (Mir and Fozard, 
1990). Though urapidil also possesses a,-adrenoceptor antagonist properties. the 5-HT,A 
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agonist activity does contribute to the action of the drug (Sanders et al., 1988; Kolassa 
et a!., 1989). 
The involvement of the central nervous system in the cardiovascular responses 
to putative 5-Hr '-'receptor agonists is supported by several observations: Administration 
of 8-0H-DPAT, flesinoxan and urapidil into the central nervous system (via either the 
vertebral arteries, the atlanta-occipital membrane or topically to the ventral surface of 
the medulla) decreases heart rate and blood pressure, and their potency considerably 
increases as compared to the intravenous administration in cats (Doods et a!., 1988; 
Gillis et al., 1988; Wouters et al, 1988a,b; Kolassa et al., 1989; Mir and Fozard, 1990). 
The cardiovascular responses to these drugs are effectively blocked by central 
administration of a putative 5-HT'-' receptor antagonist, 8-MeO-CIEPAT, spiroxatrine, 
methiothepin and/or (-)-pindolol (Dabire et al., 1987; Fozard eta!., 1987; Doods eta!., 
1988; Sanders et al., 1988; Mir and Fozard, 1990). Furthermore, 8-0H-DPAT, 
flesinoxan and/ or urapidil reduce sympathetic neural activity (Ramage, 1986; McCall et 
al., 1987; Ramage and Fozard, 1987; Coote, 1990; Mir and Fozard, 1990), particularly 
of the renal nerves (Ramage and Wilkinson, 1988) which leads to renal vasodilatation 
(Dreteler eta!., 1989; Hof and Fozard, 1989). Hypotension, along with bradycardia and 
a decrease in the renal nerve activity, has also been shown to occur with the 
administration of 5-Hr into the fourth ventricle in the cat (Wolf et al., 1985), as has the 
centrally-induced increase in the vagal tone in the rat (Wolf et al., 1985; Dalton et al, 
1986). 
5-HT also seems to act at the spinal leveL 5-Hf2 receptors may be involved in 
the inhibitory effect on the sympathetic nerve activity, because such an effect is 
minticked by intrathecal administration of a-methyl-5-Hr and antagonized by ketanserin, 
but unaffected by prazosin, MDL 72222 or ICS 205 930 (Yusof and Coote, 1988). 
Inhibition of noradrenergic neurones: 5-Hr has a dual action on 
postganglionic sympathetic neurons in the dog isolated saphenous vein; lower 
concentrations inhibit the release of noradrenaline in response to transmural stimulation, 
and high concentrations provoke catecholantine release by a tyrantine-like action 
(McGrath, 1977). The inhibitory action of 5-Hr and related drugs on the transmitter 
release from postganglionic sympathetic nerves has now been confirmed in many organs 
of different species (Gothert et al., 1990), such as the canine and human saphenous vein 
(McGrath, 1977; Gothert et al., 1990), canine coronary (Cohen, 1985) and carotid (Hong 
and Villalon, 1988; Mylecharane and Phillips, 1989) arteries, and rat kidney (Charlton 
et al., 1986). vena cava (Molderings et al., 1987) and heart (G6thert et al., 1986) and 
porcine coronary artery (Molderings et al., 1989). The involvement of 5-Hr1-like 
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receptors (Giithert et al, 1990), except in the pig coronary sympathetic neurones where 
a 'novel' receptor may exist (Molderings et al, 1989; Gothen et at, 1990), is favoured 
by the high agonist potency of 5-Cf and 5-HT (Cohen, 1985; Charlton et al, 1986; 
Molderings et a!., 1987) and the antagonism by methiothepin, metergoline and 
methysergide (Lorenz and Vaohoutte, 1985; Charlton et al, 1986; Gothert eta!., 1986), 
but not ketanserin, LY 53857 (Cohen, 1985; Charlton et al, 1986; Gothert et a!., 1986) 
or metocloprantide (Charlton et a!, 1986). 
Obviously, the interference with the sympathetic neurotransntission by 5-HT will 
modify its direct cardiovascular effects; namely, 5-HT has been reported to cause 
vasodilatation in the external carotid vascular bed of the dog when the sympathetic 
vascnlar tone is high, and vasoconstriction when it is low (Mena and Vidrio, 1979; Hong 
and Villalon, 1988). 
Vascnlar smooth muscle responses: The vascular relaxation elicited by 5-HT 
is exclusively mediated via 5~HT1-like receptors in several vessels, for example, in vitro 
in the cat saphenous vein (Feniuk eta!., 1983), dog coronary artery (Cohen et al., 1983; 
Van Nueten et al., 1984) and pig vena cava (Trevethik et al., 1984) and in vivo in the 
dog femoral (Blackshear et a!., 1985) and pig carotid arterioles (Saxena and Verdouw, 
1982, 1984, 1985a,b; Verdouw et al., 1984; Verdouw et al, 1985; Saxena et al, 1986a,b); 
both 5-HT and 5-Cf are potent agonists and methysergide and methiothepin are 
antagonists, whereas ketanserin is ineffective. 
In the blood vessels, where both 5-HT,-like and 5-HT, receptors are present and 
elicit opposing effects (relaxation by 5-HT,-like receptors and contraction by 5-HT, 
receptors), the ultimate response to 5-HT depends upon the pre,.xisting vascular tone, 
the dose employed, and the proportions in which the two receptors types are distributed. 
In vivo, studies in our laboratory (Saxena and Verdouw, 1982, 1984; Verdouw et al., 
1984) and elsewhere (Blackshear et al, 1985) indicate that the number of 5-HT,-like and 
5-HT, receptors varies in different segments of a vascular bed. The vasodilator 
5-HT,-like receptor is located primarily on resistance vessels (arterioles), the 
vasoconstrictor 5-HT1-like receptor on non-nutrient vessels (arteriovenous anastomoses), 
while the vasoconstrictor 5-HT 2 receptor is mainly present on large conducting vessels. 
Therefore, 5-HT redistributes arterial blood flow in such a way that, despite a decrease 
in the total blood flow, the arteriolar component, particularly in the skin, increases 
(Saxena and Verdouw, 1982, 1984, 1985b; Verdouw et al, 1984). The segmental 
distribution of 5-HT receptors is also, at least partly, responsible for the fact that in vitro 
studies, performed mainly with large conducting vessels. generally show a 5-HT, 
receptor-mediated contractile response. In vivo, where presynaptic (see above) aod 
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reflex effects of 5-Hf may modify the vascular responses, the amine causes 
vasodilatation in some vascular beds and vasoconstriction in others (Takacs and Vajda, 
1963; Saxena et al., 1978; Zinner et al., 1983). 
Release of endothelium-derived relaxing factor (EDRF): In the absence of 
endothelium the relaxant effect of 5-Hf is attenuated while the contractions are 
exaggerated in isolated coronary and other vessels of the pig, dog, chick and rabbit 
(Cocks and Angus, 1983; Cohen et a!., 1983; Imaizumi et al., 1984; Leff et al., 1987; 
Martinet a!., 1987; Houston and Vanhoutte, 1988). These findings indicate that 5-Hf 
can release EDRF and this effect is mediated by 5-Hf1-like receptors (Cocks and Angus, 
1983; Cohen et a!., 1983; Martin et al., 1987; Houston and Vanhoutte, 1988). In vivo, 
the 5-Hf-induced endothelium-dependent vasodilatation has thus far been studied 
indirectly by showing that the contractile responses to 5-Hf, but not to angiotensin II 
or phenylephrine, in the canine left anterior descending artery, are enhanced after 
damage to the endothelium (Lamping et al., 1985). 

CHAPTER4 
CARDIAC RESPONSES TO 5-HT AND RELATED DRUGS 

49 
CHAPTER4 
CARDIAC RESPONSES TO 5-HT AND RELATED DRUGS 
4.1 INTRODUCTION 
As previously stated, 5-HT can elicit either bradycardia or tachycardia. The nature of 
the 5-HT receptors and the underlying mechanisms involved in the heart rate responses 
to 5-HT have been generally well worked out (Saxena, 1986, 1989; Saxena and Villalon, 
1990a, 1991; see Table 4). 
4.2 BRADYCARDIAC ACTION 
The overwhelming effect of 5-HT in different species with intact central nervous system 
and vagi is an intense, but transient, bradycardia, which is abolished by ganglion 
blockade, vagotomy or spinal section (Saxena, 1986, 1989; Saxena and Villalon, 1990a, 
1991) and is, therefore, due to a von Bezold-Jarisch-like reflex originating from 
depolarization of afferent cardiac neurons (see above: McQueen, 1990). However, 
bradycardia can be obtained via a central or a presynaptic action on sympathetic 
(inhibition) and/or cholinergic (stimulation) neurons. 
4.2.1 von Bezold-Jarisch-like reflex 
In the anaesthetized rats, intravenous bolus injections of 5-HT, 1-phenylbiguanide and 
2-methyl-5-HT (Richardson et al., 1985; Dalton et al .. 1986) elicit a short-lasting 
bradycardia that is effectively antagonized by metoclopramide (Fozard, 1984a). 
MDL 72222 (Fozard, 1984a,b ), ICS 205-930 (Richardson et al .. 1985) and a variety of 
other 5-HT, receptor antagonists (Cohen, 1990; Fozard, 1990). A similar 
agonist-antagonist action is also observed with respect to the depolarization of the rat 
cervical vagus nerve fibres (Ireland and Tyers. 1987). 
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Table 4: Heart rate responses to 5-HT and related drugs and the mechanisms involved 
in different species. 
Species Condition Receptor Main mechanism of action 
Bradycardia 
Rat Intacta 5-HT, Afferent neuronal stimulation° 
Rabbit Intact 5-HT, Afferent neuronal sti.mulation° 
Cat Intact 5-HT, Afferent neuronal stimulation° 
Dog Intact Unknown Afferent neuronal stimulationc 
Rat Intact 5-HT"' Central autonomic changesd 
Cat Intact 5-HTlA Central autonomic changescl 
Rat Intact Unknown Inhibition of sympathetic neurones 
Dog Intact 5-HT,-like? Inhibition of sympathetic neurones 
Rabbit Isolated heart' 5-HT, Cholinergic stimulation 
Tachycardia 
Guinea-pig Spinal Tyramine-like action' 
Dog Isolated atria Tyrantine-like action' 
Dog Intact Tyramine-like actionf 
Cat Spinal 5-HT,-like Myocardial effect 
Cat B-Adr. block' 5-HT,-like Myocardial effect 
Rat Ganglion-block 5-HT, Myocardial effect 
Rat Intact/ pithed 5-HT,' Myocardial effect 
Dog Ganglion-block 5-HT, Adrenal catecholantine release 
Rabbit Isolated heart 5-HT, Neuronal catecholamine release 
Dog Conscious 5-HT, Not via autonomic nervous system 
Pig Intact 5-HT,? Myocardial effect 
Mollusc Isolated heart Unknown Unknown 
Hamster Intact Unknown Unknown 
Man1 Intact Unknown Unknown 
!;1, Intact means anaesthetized or conscious animal: b, von-Bezold-jarisch-like reflex; 
c. cardiogenic hypertensive reflex: ct, inhibition of sympathetic neural activity plus 
augmentation of vagal tone: c. prior reserpinization: t, high concentrations are needed; 
;\ B-adrenoceptor blockade; \ receptor may differ from the usual 5-HT2 receptor and 
high concentration may release catecholarnines; '. 5-HT4 receptors may mediate inotropic 
effects in isolated human atria (Kaumann et al .. 1990a,b). Taken from Saxena and 
Villalon (1990a). 
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5-HT also elicits bradycardia in the rabbit (Dawes and Mort, 1950; Bolt and Saxena_ 
1985; Wright and Angus, 1989). Tills effect is mimicked by 1-phenylbiguanide (Dawes 
and Mort, 1950; Wright and Angus. 1989) and 5-CT (probably by releasing platelet 5-HT; 
Wright and Angus, 1989), and antagonized by methylscopolamine (Wright and Angus, 
1989), MDL 72222 (Wright and Angus, 1989), 2-naphtyl-guanidine and bufotenine 
(Fastier et a!., 1959), but not by ketanserin (Wright and Angus, 1989). 
Rapid bolus injections of 5-HT in the cat evoke bradycardiac effects that can be 
blocked by bilateral vagotomy, procaine, atropine, 2-methyl,3-ethy1,5-amino indole and 
MDL 72222 (Comroe eta!, 1953; Saxena eta!., 1985b). injections of 5-HT into the left 
ventricle (Kottegoda and Mott, 1955), left coronary artery (Zakusov, 1962) or pericardia! 
sac (Mohr et a!., 1987), but not into the ascending aorta (Kottegoda and Mort, 1955), 
also induce reflex bradycardia. MDL 72222 blocks the effects of 5-HT without 
attenuating that of nicotine (Mohr et a!., 1987). 
The above findings clearly show that bradycardia due to 5-HT mainly results from 
an effect on cardiac sensory receptors (von Bezold-Jarisch-like reflex) belonging to the 
5-HT, type. 
4.2.2 Cardiogenic hypertensive chemoreflex 
In the dog 5-HT induces a cardiogenic hypertensive chemoreflex which increases 
efferent vagal and sympathetic nerve activities, leading to an initial transient decrease 
in heart rate, followed by tachycardia (James, 1964; James et a!., 1975). Curiously, 
cyproheptadine abolished the cardiogenic hypertensive reflex in atropine-pretreated dogs, 
but methysergide was reported to be ineffective (Hageman et a!., 1977, 1980). A 
possible role of 5-HT3 receptors in the cardiogenic hypertensive chemoreflex, because 
of antagonism by ICS 205-930, has also been described (Berthold eta!., 1989). 
4.2.3 Central 5-HT"' mechanism 
8-0H-DPAT, a 5-HT"' receptor ligand (Table 1) reduces heart rate in both 
normotensive and two-kidney Goldblatt, DOCA-salt or spontaneously hypertensive rats; 
this response was not blocked by LY 53857, metergoline, methysergide, methiothepin, 
cinanserin or pirenperone, but was antagonized by pimozide (partly) or atropine + 
propranolol (completely) (Main eta!., 1984; Gradin eta! .. 1985a_b). In contrast. Martin 
and Lis (1985) found that methiothepin (but not cyproheptadine or metergoline) blocked 
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the bradycardiac effectS of 8-0H-DPAT in spontaneous hypertensive rats. More 
recently, a detailed analysis by Fozard et al (1987) showed that the bradycardiac and 
hypotensive responses to 8-0H-DPAT in spontaneous hypertensive rats are 
centrally-mediated, and is not affected by p-chloro-phenylalanine, prazosin, ketanserin 
(0.1 mg/kg, s.c.) or MDL 72222, but are antagonized by 8-methoxy-2-(N-2-chloroethyi-
N-n propyl) aruinotetralin (8-MeO-CIEPAT), atropine, metergoline, methiothepin, 
( ± )-pindolol, ( ± )-cyanopindolol, buspirone, yohimbine, idazoxan and WY 26392. 
Employing higher doses of metergoline and methiothepin than the earlier investigators 
(Gradin et al, 1985a,b; Martin and Lis, 1985), Fozard could conclude that the central 
effect of 8-0H-DPAT is apparently mediated via 5-HT,.. receptors on neurons that 
synapse distally via a 2-adrenoceptors (F ozard et al., 1987). Methysergide, but not 
cyproheptadine, also lowers heart rate in spontaneous hypertensive rats by a central 
action (Antonaccio and Cote, 1976). 
In cats several agonist compounds having a high affinity for 5-HT,.. recognition sites, 
like 8-0H-DPAT, N,N-dipropyi-5-CT, flesinoxan, ipsapirone, p-aruinophenyl-ethyl-
m-trifluoromethylphenyl piperazine, 1-(2-methoxyphenyl) piperazine, lower heart rate 
whereas compounds with a higher affinity for 5-HT,B recognition sites -
1-(3-trifluoromethyl) piperazine (TFMPP), 5-HT1c recognition sites [(1-(3-chlorophenyl) 
piperazine (mCPP)] or 5-HT2 recognition sites [1-(2,5-dimethoxy-4-iodophenyl)-
2-aruinopropane (DOl) and piperazinyl-6-chloropyrazine (MK 212)] are ineffective 
(Ramage, 1985a,b; McCall et al., 1987; Ramage and Fozard, 1987; Doods et al., 1988; 
Wouters et al., 1988a,b). 
The above results indicate that activation of central5-HT,.. receptors increase vagal 
but decrease sympathetic tone to elicit bradycardia and hypotension; tbis 
pharmacological approach is of particular interest for the development of novel drugs 
with potential therapeutic usefulness in the treatment of hypertension (see Saxena and 
Villalon, 1990b ). 
4.2.4 Presynaptic inhibition of sympathetic activity 
In rat (vagotomized, pithed or pretreated with atropine, captopril and ketanserin), 
preganglionic stimulation of the sympathetic nerves results in an increase in heart rate, 
which can be reduced by 5-methoxytryptaruine (G6thert et al., 1986). The exact nature 
of the receptor involved has to be established. 
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In dogs 5-HT can attenuate the tachycardia induced by electrical stimulation of the 
ansa subclavia (Kimura and Satoh, 1983). This effect cannot be blocked by pretreattnent 
by cyproheptadine suggesting the involvement of non-5-HT, receptors. 
4.25 Stimulation of cholinergic neurones 
In isolated perfused heart, obtained from reserpine-treated rabbits, 5-HT elicits a 
MDL 72222-susceptible bradycardia, which has been ascribed to the presence of 5-HT3 
receptors on postganglionic cholinergic nerve endings (Fozard, 1984a.,b ). However, it is 
likely that these 5-HT3 receptors are located on cardiac vagal ganglia, since 5-HT3 
receptors have been fouod on parasympathetic ganglia (Saxena et a!., 1985a; Bradley et 
a!., 1986). 
4.3 TACHYCARDIAC ACTION 
The tachycardiac effect of 5-HT is notoriously species-dependent and the responses are 
mediated by a variety of mechanisms, namely: 
4.3.1 Tyramine-like action 
In the spinal guinea pig intravenous administration of 5-HT elicits tachycardia, and this 
response is not modified by methiothepia., ketanserin or MDL 72222, but is antagonized 
by Jl-adrenoceptor antagonists (propranolol and atenolol) or by the 5-HT -uptake 
inhibitor indalpine. Pretreatment with reserpine did not affect the first challenge with 
5-HT but the responses to the subsequent doses showed rapid tachyphylaxis (Dhasmana 
eta!., 1988). In the guinea-pig isolated atrium, results similar to those in spinal animals, 
were reported except that reserpine was not able to influence the responses to 5-HT 
(Eglen and Whiting. 1989). However, it is not known if these authors administered 5-HT 
repeatedly in reserpinized atria as was done in an earlier study (Dhasmana et a!., 1988). 
At this stage it would appear that the main action of 5-HT on the guinea-pig heart is via 
a release of catecholamines by a mechanism similar, but not identical, to that of 
tyramine. In addition, it is possible that 5-HT may release calcitonin gene-related 
peptide, which is present in the guinea pig sinus node and has a positive chronotropic 
action (Saito et a!., 1986). 
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In atria obtained from the dog, the chronotropic response to 5-HT is attenuated by 
both desipramine and 8-adrenoceptor antagonists, suggesting an indirect 
sympathomimetic action (Chiba, 1977; Chiba eta!., 1978). Similar findings have been 
obtained with high doses of 5-HT in vivo (Fillion et a!., 1971). 
4.3.2 5-HT,-like receptor stimnlation 
In an excellent investigation Trendelenburg (1960) reported that the 5-HT-induced 
cardiostimulation in the cat isolated atria, being antagonized by lysergide but not by 
reserpine, dichloroisoprena!ine or cocaine, involves "D" 5-HT receptors (Gaddum and 
Picarelli, 1957), which may belong to either the 5-HT,-Iike or the 5-HT, type (Saxena, 
1989; Saxena and Ferrari, 1989). Accordingly, the responses to 5-HT in the 
reserpine-pretreated kitten atria can be blocked by phenoxybenzamine or methysergide, 
but not by ketanserin, MDL 72222 or yohimbine (Kaumann, 1985). 
In a detailed analysis in spinal cats (Saxena et a!., 1985b ), it was established that the 
5-HT-induced tachycardia is not or only slightly susceptible to blockade by guanethidine, 
propranolol, burimamide, 5-HT, receptor antagonists (cyproheptadine, ketanserin, 
ritanserin, pizotifen and mianserin) or bilateral adrenalectomy, despite the fact that 
5-HT may sometimes release catecholamines from the adrenal medulla (Reid, 1952). 
This response is effectively blocked by mixed 5-HT,-Iike and 5-HT, receptor antagonists 
(methiothepin, methysergide, mesulergine) and mimicked by 5-CT, to establish that 
5-HT,-Iike receptors mediate tachycardia in the cat (Saxena eta!., 1985b; Connor eta!., 
1986; Saxena, 1988) 
4.3.3 5-HT, receptor stimulation 
In pithed rats 5-HT (100 ,ug/kg) increases heart rate and blood pressure and these 
responses are effectively antagonized by cyproheptadine but, in contrast, another 5-HT, 
receptor antagonist 3-{2-[ 4-( 4-fluoro benzoyl)-1-piperidinyl] ethy I }-2-methyl-
4H-pyrido[1,2-a] pyrimidin-4-one (R 50656) suppressed the pressor response but not the 
tachycardia (Krstic' and Katusic, 1982). Subsequently, Saxena and Lawang (1985) 
showed that 5-CT, in contrast to 5-HT, does not increase heart rate in ganglion-blocked 
rats and the tachycardia elicited by 5-HT (6.25-200 ,ug/kg) is blocked by ketanserin (0.5 
mg/kg) or cyproheptadine (0.5 mg/kg), suggesting the involvement of 5-HT2 receptors. 
Accordingly, in pithed normotensive and/ or spontaneously hypertensive rats. 
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5-methoxytryptamine and 5-HT, but not 5-CT, 8-0H-DPAT, ipsapirone, RU 24969, 
5-methoxy-N,N-dirnethyltryptamine, TFMPP or DOI, cause tachycardia which is 
susceptible to blockade by ketanserin, LY 53857, met.ltysergide or methiothepin, but not 
by MDL 72222, propranolol or desipramine (Giithert et al., 1986; Docherty, 1988; 
Dabire et al., 1989a,b ). It is interesting to note that DO I, which exhibited a partial 
agonist action at 5-HT2 receptors mediating pressor responses, neither elicited 
tachycardia nor antagonized the tachycardiac action of 5-HT (Dabire et al., 1989a, b). 
The ineffectiveness of DOl (Dabire et al., 1989a,b) and R 50656 (Krstic' and Katusic, 
1982) suggests that the 5-HT2 receptors mediating tachycardia in the rat are 'atypical' in 
nature. However, at high doses (100 ,ug/kg and above) 5-HT can also increase heart 
rate probably by a tyramine-like action, which can be reduced by desipramine or 
propranolol (Docherty, 1988). 
Many investigators have reported that 5-HT elicits tachycardia in anaesthetized dogs 
(Maxwell et al., 1959; Noble and Nanson, 1959); this effect is accompanied by an 
increase in noradrenaline concentration in the coronary sinus and vena caval blood and 
is absent after autonomic blockade (Fillion et al., 1971). Subsequently, it was shown that 
5-HT is capable of eliciting tachycardiac responses (antagonized by cyproheptadine or 
bufetolol) in vagotontized and cardiac decentralized dogs (Kimura and Satoh, 1983), and 
the 5-HT-induced tachycardia in ganglion-blocked dogs is accompanied by a release of 
noradrenaline and adrenaline into the blood and suppressed not only by cyproheptadine 
and methysergide, but also by syrosingopine (a catecholamine depleting agent) and 
bilateral adrenalectomy ( 43% reduction) (Feniuk et al., 1981; Kimura and Sato, 1983). 
It therefore appears that 5-HT elicits tachycardia by a tyramine-like action as well as by 
a 5-HT, receptor-mediated release of catecholamines from the adrenomedullary 
chromaffin cells. 
4.3.4 5-HT, receptor stimulation 
The tachycardiac effect of 5-HT in the rabbit isolated atria is mediated by noradrenaline 
release (Trendelenburg. 1960) and detailed analyses in the perfused heart have revealed 
that reserpine, propranolol, cocaine, MDL 72222, !CS 205-930, but not desipramine, 
methiothepin or methysergide, inhibit the increase in heart rate by 5-HT (Fozard aod 
Mwaluko, 1976; Gothen and Diihrsen. 1979; Fozard, 1984b; Richardson et al., 1985). 
Therefore. the cardiostimulatory effect of 5-HT in the rabbit is due to a 5-HT3 
receptor-mediated release of noradrenaline from the postganglionic cardi<::Lc sympathetic 
nerve fibres. The action of 5-HT is mimicked by 2-methyl-5-HT and 
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5,7-dihyilroxytryptamine (Gothert and Diihrsen, 1979; Richardson et al., 1985). 
Recently, Wllson et a!. (1990) have described that 5-HT, receptors mediate tachycardia 
in the conscious dog. 
435 Stimulation of a novel 5-HT receptor 
It has been previously reported that the tachycardia induced by 5-HT in the 
anaesthetized pig is not antagonized by drugs affecting autonomic receptors, histamine 
H1 and H, receptors, dopamine receptors, calcium channels, 5-HT,-like, 5-HT, and/ or 
5-HT, receptors (Duncker eta!., 1985; Bam et al., 1988a). Moreover, selective agonists 
at 5-HT,-like or 5-HT, receptors do not elicit tachycardia (see Table 5). Therefore, the 
tachycardiac action of 5-HT in the pig does not involve endogenous catecholamines or 
histamine, Ca2 + transp:>rt into the sinoatrial node cells or the 5-HT1-like, 5-HT2 or 5-HT3 
receptors, but seems to be mediated by a new type of 5-HT receptor (Duncker et a!., 
1985; Born et al., 1988a). 
In this context, Dumnis and her colleagues (1988, 1989), working with cultured 
neurones from mouse embryo colliculi, described a novel receptor site (designated as 
5-HT ,), where 5-methoxytryptamine and certain benzamide derivatives (metoclopramide, 
renzapride, cisapride ), but not 5-Cf, a-methyl-5-HT or 2-methyl-5-HT, have high affinity 
and increase adenylate cyclase activity; ICS 205-930 (in high concentrations; pA,: 
63--65), but not MDL 72222 or ondansetron, behaves as an antagonist (see also Clarke 
et al., 1989). In the cardiovascular system this novei5-HT receptor seems to be involved 
in the positive inotropic action of 5-HT on human atria; the response to 5-HT is not 
modified by ketanserin, methysergide, lysergide, methiothepin, yohimbine, 
(:!:)propranoloL (-)pindolol or MDL 72222, but was blocked by a high concentration (2 
,uM) of ICS 205-930 (Kaumann eta!., 1990a,b). 
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Table 5: Capacity of drugs to cause tachycardia or to antagonize 5-HT-induced 
tachycardia in the anaesthetized pig. 
Drug Dose Drug profile Activity as 
(,ug/kg) agonist or 
antagonist 
Agonists 
5-CH,O-tryptamine 3-30 5-HTlA, 5-Hf1B, 5-HT1c, 5-HTrn, 5-HT2, 
5-HT, Yes 
Renzapride 3-100 5-HT, Yes 
5-CT 1-100 5-h'T"', 5-HT1s, 5-HTm No 
8-0H-DPAT 1000 5-HT"' No 
RU 24969 1000 5-HTlA, 5-HTlB, 5-HTm No 
BEA 1654 1000 5-HT,A No 
2-CH,-5-HT 30-100 5-HT, No 
a-CH,-5-HT 3-100 5-HT,c, 5-HT,, 5-HT, Yes 
Antagonists 
Phentolamine 1000 a-Adrenoceptor No 
Propranolol 500 B-Adrenoceptors No 
Atropine 500 Muscarinic cholinergic No 
Hexamethonium 10000 Nicotine1 cholinergic No 
Mepyramine 1000 Histamine H, No 
Cimetidine 1000 Histamine H, No 
Haloperidol 1000 Dopamine Dh D2 No 
Verapamil 100' Calcium channels No 
Phenoxybenzamine 1000 Adrenergic, cholinergic, 5-HT No 
Methiothepin 500 5-HT"', 5-HT,8, 5-HT,c, 5-HT10, 5-HT, No 
Methysergide 500 5-HTlA, 5-HT1c, 5-HTm, 5-HT2 No 
Metergoline 500 5-HTw 5-HTlB, 5-HT,c, 5-HT10, 5-HT, No 
Mesulergine 500 5-HT,0 5-HT, No 
Mianserin 500 5-HT,c, 5-HT, No 
Pizotifen 500 5-HT1c, 5-HT, No 
Cyproheptadine 500 5-HT, No 
Ketanserin 500 5-HT, No 
MDL 72'222 300 5-HT, No 
ICS 205-930 300 5-HT, No 
',dose followed by 0.01 mg/kg.min. Based on data from Born et aL (1988a) aod Saxena 
and Villalon (1990a). 
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43.6 Unidentified mechanisms 
The hearts of certain lamellibranch and gastropod species (Mercenaria mercinaria .. Tapes 
watlingi, Patella vulgata, Helix, Aplysia) are extremely sensitive to 5-HT (threshold 
concentration 0.1 nM; for references, see Walker, 1985) and in Aplysia heart 5-HT 
increases cAMP accumulation (Sawada et aL, 1984 ). In the Mercenaria heart 
tryptamine derivatives increase the rate and contraction with the following order of 
actlVlty (equipotent molar ratio; 5-HT=1): N,N-dimethyi-5-HT (0.028), 
N-methyltryptamine (3.7), a-methyi-5-HT (6.0), N,N-diethyltryptamine (7.9), a-methyl-
tryptamine (8.6), N-ethyltryptamine (9.1), tryptamine (9.9), N,N-dimethyltryptamine 
(10.7), 2-methyl-5-HT (31.4). The effect of 5-HT is antagonized by methysergide and 
2-bromolysergide, but lysergide mimics 5-HT with incredible potency (threshold 
concentration 1 fM). There is evidence that 5-HT is an excitatory transmitter in the 
Mercenari.a heart; stimulation of the ca.rdioaccelerator nerve releases 5-HT and the its 
effects are reduced by methysergide, 2-bromolysergide and reserpine (Walker, 1985). 
In hamster isolated atria, 5-HT increases heart rate, probably by combination of a 
direct effect on the myocardium and an indirect effect via the liberation of 
noradrenaline from cardiac sympathetic nerves, since the responses are not much 
affected by phentolamine + propranolol or phenoxybenzamine (Gonrilez and Garcia, 
1977, 1978). 
In humans, slow intravenous infusions of 5-HT elicit tachycardia before any changes 
in arterial blood pressure occur (Hollander et al., 1957, LeMessurier et al., 1959; Harris 
et al., 1960}. 
In conclusion, from the aforementioned studies it is clear that 5-HT can induce heart 
rate changes by a whole spectrum of mechanisms and receptors, whereas the 
mechanisms involved in 5-HT-induced changes in cardiac contractile force are still 
ill-understood. 
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As in other vascular beds, 5-HT can elicit either vasodilatation or vasoconstriction in the 
carotid vascular bed. The eventual response depends ..amongst other factors- upon the 
species, dose, vascular segment under study and, most importantly, the nature of 5-Hr 
receptors involved. 
52 EFFECT OF 5-HT IN THE CAROTID BLOOD FLOW OF SEVERAL 
SPECIES 
lntracarotid administration of 5-Hr in the intact dog increases external carotid blood 
flow, but decreases internal carotid blood flow (Vidrio and Hong, 1976), the former 
response being dependent on the vascular tone as can be reverted to vasoconstriction 
when vascular tone is abolished by vagotomy or stellectomy (Saxena, 1972; Mena and 
Vidrio, 1979), whereas the latter is independent of vascular tone (Vidrio and Hong, 
1976; Mena and Vidrio, 1979). Similar differential effects of 5-Hr have been reported 
in primates (Grimson et al., 1969). In contrast, 5-Hr elicits a decrease of the carotid 
blood flow in humans (Lance et al., 1967) and cats (Saxena and Verdouw, 1983). ln the 
latter, such effect is related to a decrease in arteriovenous anastomotic blood flow which 
is resistant to blockade by cyproheptadine (Saxena and Verdouw, 1983). More recently, 
Hong and Villalon (1988) have reported that 5-Hr,-like receptors are involved in the 
vasodilatation and vasoconstriction induced by 5-HT in the canine external carotid 
artery. 
In the anaesthetized bilaterally vagotontized pig, intracarotid infusion of 5-Hr 
decreases common carotid blood flow by reducing arteriovenous anastomotic 
(non-nutrient) flow, whereas arteriolar flow to the head tissues, mainly to the skin and 
ears. is increased (Saxena and Verdouw, 1982, 1985b). 
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5.3 EFFECI'S OF 5-IIT RECEPTOR AGONISTS AND ANTAGONISTS IN THE 
PORCINE CAROTID BLOOD FLOW AND ITS DISTRIBUTION 
The effects of 5-Hf in the porcine carotid circulation, as previously described, are 
mimicked by the 5-Hf,-like receptor agonist 5-carboxamidotryptamine (Saxena and 
Verdouw, 1985a) and antagonized by methiothepin (Saxena et at, 1986a), which blocks 
both 5-Hf,-like and 5-Hf, receptors (see Hoyer, 1988a; Saxena and Villalon, 1990a), but 
not appreciably by the 5-Hf, receptor antagonist ketanserin (Verdouw et at, 1984) or 
the 5-Hf, receptor antagonist laH.3a,5aH-tropan-3yl-3,-5-dicblorobenzoate 
(MDL 72222) (Saxena et at, 1986a). Therefore, according to the classification proposed 
by Bradley et al. (1986), the constriction of arteriovenous anastomoses (A VAs) as well 
as the dilatation of arterioles are mediated by 5-Hf,-like receptors (Saxena et al., 
1986a). However, the 5-Hf,-like receptors in the carotid circulation of the pig seem to 
belong to two different categories since, unlike 5-Hf (Saxena and Verdouw, 1982) or 
5-carboxamidotryptamine (Saxena and Verdouw, 1985a), the reductions of the 
arteriovenous anastomotic blood flow induced by methysergide (Saxena and V erdouw 
1984), the putative 5-Hf"' receptor agonists 8-0H-DPAT (Born et at, 1989a) and 
N-(3-acetylaminophenyl) piperazine hydrochloride (BEA 1654) (Verdouw et al., 1985), 
and the putative 5-Hf"' and 5-Hr,. receptor agonist RU 24969 (Born et al., 1989b), are 
not or only sligbtly accompanied by increases in the arteriolar blood flow. Furthermore, 
despite the effectiveness of 8-0H-DPAT, BEA 1654 and RU 24969, the 5-Hf,-like 
receptor mediating arteriovenous anastomotic constriction does not appear to be related 
to either the 5-Hf"' or 5-Hf,. binding sites because, as we reported recently (Born et 
at, 1989b), the effects of RU 24969 are not antagonized by the putative 5-Hf"' and 
5-Hf, receptor antagonist, ( :': )-pindolol (Hoyer et al., 1985; Hoyer, 1988a). Within this 
framework, it is of particular importance to characterize drugs with higb selectivity to 
decrease cranial AVA blood flow, as this is one of the few experimental models that 
conld make it possible to develop drugs. with potential therapeutic usefulness in the 
treatment of migraine (see Saxena and Ferrari, 1989; Saxena, 1990). Indeed, some drugs 
with established antimigraine efficacy decrease porcine cranial AVA blood flow (see 
below; Saxena and Ferrari, 1989; Saxena and Den Boer, 1991). 
5.4 MIGRAINE 
Migraine is a debilitating disease which affects up to 10% of the Western World. 
regarded as an episodic syndrome characterized by usually unilateral headache. nausea, 
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vomiting and photophobia, sometimes preceded by certain premonitory aura symptoms 
(Wolff, 1963; Lance, 1982; Lance et aL, 1989). Migraine, like hypertension, is a 
syndrome where the underlying causative factor(s) can vary widely. In this connection, 
theories to explain migraine pathophysiology have evolved from the realms of the 
supernatural into the scientific arena (for references, see Edmeads, 1991), where the 
controversy whether migraine is primarily a vascular or a neurological disfunction has 
been argued for over a hundred years, and the scientific community still appears to 
remain divided. Despite intensification of research in recent years, however, migraine 
aetiology remains elusive (see Lance, 1982; Lance et al., 1967, 1989; Saxena, 1987; 1990; 
Edmeads, 1991; Moskowitz and Buzzi, 1991). 
With respect to the vascular origin of migraine, this syndrome has long been 
considered to result from cephalic vasodilatation, if only because of the throbbing nature 
of the pain (Edmeads, 1991). This concept became established as a result of the 
pioneering work of Graham and Wolff (1938), whose findings implicated the cranial, as 
opposed to the cerebral, component of the cephalic circulation. During a significant 
number of migraine attacks, pulsations in the superficial temporary artery were 
demonstrated using an external tambour, and pain could be relieved either by physical 
compression or by the vasoconstrictor agents ergotamine or dihydroergotamine (Graham 
and Wolff, 1938; Wolff, 1963). 
This "vascular hypothesis" has, in recent times, fallen into disfavour largely because 
many patients exhibit facial pallor during attacks, not flushing (a reflection of cranial 
vasodilatation), and because other researchers have not been able to confirm Wolffs 
findings (Heyck, 1969; see below). However, the involvement of extracranial vessels has 
been confirmed in some patients; for example, Drummond and Lance (1983) 
demonstrated that temporal artery compression reduced pain intensity in about one-third 
of patients, while a further one-third experienced relief following common carotid artery 
compression. These findings are in complete agreement with those reported by Graham 
and Wolff (1938). 
Wolff (1963) was also able to show that extracranial vascular distension was 
associated with perivascular oedema, resulting from sterile inflammation. In this 
connection, the trigeminal nerve has been implicated in the genesis of migraine (for 
references, see Moskowitz and Buzzi, 1991). In support of this "neural hypothesis", it has 
been shown that the trigeminal nerve can release a number of neuropeptides including 
substance P and calcitonin gene-related peptide. and that antidromic activation of the 
trigeminal nerve leads to plasma protein extravasation (and presumably vasodilatation) 
in the dura mater of rats and guinea pigs; interestingly. antimigraine drugs such as 
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ergotamine, dihydroergotamine and sumatriptan inhibit substance P-induced plasma 
protein extravasation in rats (Moskowitz and Buzzi, 1991 ). However, it is possible that 
this inhibitory effect is related to tl:e selective vasoconstriction exerted by these drugs 
in the extracerebral vascular bed (see below). 
5.4.1 5-HT and the pathophysiology of migraine 
Amongst a host of biogenic substances h-nplicated in the pathophysiology of migraine, 
none seems to have a better claim than 5-HT (for references, see Wolff, 1963; Lance, 
1982; Saxena, 1987, 1990, 1991; Lance et a!., 1989; Feniuk et al., 1991). Of particular 
importance were the clinical observations that: i) urinary excretion of 5-HIAA 
(5-hydroxyindoleacetic acid), the main metabolite of 5-HT, increases during migraine 
attacks; ii) both platelet 5-HT and whole blood 5-HT decrease during migraine attacks; 
iii) intramuscular injections of reserpine precipitate migraine-like headaches in 
migraineurs; iv) slow intravenous infusion of 5-HT alleviates both reserpine-induced and 
spontaneous migraine headaches (Lance et a!., 1967; 1989; Sicuteri, 1977; Lance, 1982; 
Saxena, 1987, 1990, 1991; Feniuk et al., 1991). The above findings coupled to the fact 
that the 5-HT,-like receptor agonist sumatriptan aborts migraine headaches and that 
5-HT receptor antagonists, e.g. ketanserin, cyproheptadine and ICS 205-930 are poorly 
effective in migraine (see below), do suggest the involvement of 5-HT in migraine 
aetiology. 
Within the bounds of the 5-HT theory, and keeping in mind u'le foregoing 
controversy about migraine pathogenesis, we would like to draw some attention to the 
following facts: i) distension and sensitivity of extracranial arteries can be demonstrated 
in about one third of migrainous patients (see above; Drummond and Lance, 1983; 
Lance et al., 1989), so that vascular factors cannot be ignored, whether they be primary 
or secondary to neural discharge: li) the neural hypothesis of migraine is theoretical and 
based on animal experimentation, which argnes against a purely neural hypothesis (for 
references, see Lance et al., 1989; Moskowitz and Buzzi, 1991; Saxena and Den boer, 
1991). 
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5.4.2 Reduction in cranial arteriovenous anastomoses (A VAs) blood flow as a 
pharmacological approach for anrimigraine action 
The paradox between the suggested cerebral and extracerebral vasodilatation and some 
clinical features of migraine (facial pallor, venous engorgement and cold skin) prompted 
Heyck (1969) to measure oxygen difference in arterial and venous blood in migraineurs. 
He found that: i) the arteriovenous oxygen saturation difference between arterial and 
jugular venous blood decreased during migraine attacks, suggestiog a higber 
arteriovenous shunting in the territory drained by the jugular vein; and ii) pain relief 
(either spontaneously or after dihydroergotamine treatment) was accompanied by a 
normalization of the arteriovenous oxygen saturation difference. On the basis of these 
results, Heyck (1969) suggested that during migraine attacks cranial A VAs opened and 
lower the diastolic blood pressure, causing greater pulsations and an increased AVA 
fraction of carotid blood flow. 
From the above evidence, cranial arteriovenous anastomoses constriction has been 
proposed as a possible mecbanism for antimigraine action (see Saxena, 1987; 1990; 
Saxena and Ferrari, 1989; Saxena and Den Boer, 1991). Significantly, a number of new 
and established antimigraine drugs interact with 5-HT receptors (see Table 6). Selective 
agonists at the 5-HT,-like receptor subtype mediating contractions of cephalic vessels 
(AH25086, sumatriptan), which do not penetrate into the central nervous system, are 
effective in the treatment of acute migraine attacks (see Perrin eta!, 1989; Saxena and 
Ferrari, 1989; Humphrey et al., 1990; Tfelt-Hanssen and Nielsen, 1990). Some 
antimigraine drugs behave as antagonists at 5-HT, (methysergide, pizotifen, ergotamine, 
dihydroergotamine) and/or 5-HT,-like (methysergide, propranolol) receptors, but many 
5-HT, and/or 5-HT,-like receptor antagonists (ketanserin, ritanserin, cyproheptadine, 
mianserin, methiothepin, metergoliue) have not found much use in migraine therapy. 
It therefore seems likely that additional properties of such antimigraine drugs, for 
example, the vasoconstriction in the extracerebral cephalic circulation with methysergide, 
ergotamine and dihydroergotamine and the antidepressant action with pizotifen, may be 
involved in their therapeutic action (Saxena, 1990). Thougb MDL 722'22, a 5-HT3 
receptor antagonist. has been reported to be effective against migraine (Loisy et al., 
1985), !CS 205-930 (Lataste et a!., 1989) and, probably. other such drugs are not. 
Therefore, within the bounds of serotonergic mechanisms, the antimigraine action seems 
to depend mainly upon agonist action at the 5-HT,-like receptor subtype (5-HT,.; 
Table !) that mediates craniovascular contraction (Saxena, 1990; Saxena and Ferrari, 
1989). 
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Table 6: Profile of potential and proven antimigraine drugs in relation to 5-HT 
receptors. 
Antimigraine drug 5-HT,-like 5-HT, 5-HT3 Penetration 
Receptor Receptor Receptor into the CNS 
AH25086 Agonis~ Inactive Inactive Poor or none 
Sumatriptan Agonista Inactive Inactive Poor or none 
Methysergide Partial agonist"• Antagonist' Inactive Possibly yes 
Ergotamine ? Antagonist Inactive Poor or none 
l)fhydroergotaroine ? Antagonist Inactive ? 
Pizotifen Inactive Antagonist Inactive Possibly yes 
Propranolol Weak antagonist' Inactive Inactive Rapid 
MDL 72222 Inactive Inactive Antagonist<!' ? 
a, Action is selective on 5~HT1-like receptors mediating the contraction of cephalic 
arteries and arteriovenous anastomoses; b, Antagonists of 5-HT1-like receptors 
(methiothepin, metergoline) have no antimigraine activity; ', Many other 5-HT, 
antagonists (ketanserin, retanserin, cyproheptadine) have not proved much effective in 
migraine therapy; ', Other antimigraine £-adrenoceptor antagonists (atenolol, timolol) 
have no affinity for 5-HT,-like receptors; ', ICS 205-930 and probably some other 
antagonists at 5-HT3 receptors are not much effective in migraine, CNS, Central 
nervous system. (For references see Saxena, 1990; Saxena and Den Boer, 1991). 
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CHAPTER6 
AIMS OF THE THESIS 
There exists now an extensive literature dealing with the nature of the 5-HT receptors 
involved in 5-Hf-induced cardiovascular effects. For example, 5-Hf-induced 
tachycardia is notoriously species-dependent and is mediated, directly or indirectly, either 
by 5-Hf,-like (cat), 5-Hf2 (rat, dog) or 5-Hf, (rabbit, dog) receptors, or by tyramine-like 
(guinea-pig) or unidentified mechanisms (pig, Helix aspersa) (see Saxena, 1986; Saxena 
and Villalon, 1990a; 1991). In marked contrast, little is known about the nature of the 
myocardial receptors involved in 5-Hf-induced positive inotropic effects (Kaumann et 
al., 1990a,b ). Therefore, Chapters 7 and 8 of the present thesis deal with the 
mechanism(s) and characteriaation of the 5-Hf receptor type involved in the positive 
chronotropic effects induced by 5-Hf and some indole- and benzamide derivatives in 
the pentobarbitone anaesthetized pig, whereas in Chapter 9 an attempt was made to 
delioeate the receptor involved in the positive inotropic effect by 5-Hf in the same 
species. 
On the other hand, it is has been demonstrated that 5-Hf,-like receptors mediate 
hoth the constriction of porcine cephalic arteriovenous anastomoses and the dilatation 
of arterioles induced by 5-Hf and some 5-Hf,-like receptor agonists, including the 
antimigraine drug sumatriptan (Saxena et al., 1989; Saxena and Villalon, 1990a; Den 
Boer et al., 1991); however, it has not yet been fully identified which specific 5-Hf, 
receptor subtype (5-HflA, 5-Hf16, 5-Hf1c or 5-Hf10 ) is involved in such effects (Born 
et al., 1989a,b; Saxena and Villalon, 1990a). For this reason in Chapter 10 of this 
dissertation we have further attempted to study the possible involvement of 5-Hf lA• 
5-Hf,., 5-Hf1c and/or 5-Hf10 receptors in the distribution of common carotid artery 
blood flow into arteriolar (nutrient) and arteriovenous anastomotic (non-nutrient) parts 
in the pig by using indorenate~ a tryptamine derivative with antihypenensive properties 
(Hong et al., 1978; Hong, 1981) as well as a high affinity for the 5-Hf 1A binding site 
(Dompert et al., 1985; Hoyer et al., 1985). Ketanserin. methiothepin and metergolioe 
were used as potential antagonists. 
Finally, in view of the involvement of cranial arteriovenous anastomoses constriction 
as a possible mechaoism for antirnigraine action (see Saxena and Ferrari, 1989). the last 
part of the present dissertation is devoted to the analysis of the effects of 
dihydroergotamine (an established antimigraine drug). and S9977 (a potential 
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antimigraine drug) on the distribution of the porcine total common carotid artery blood 
flow (Chapter 11), and accordingly, highligbts the possible mechanisms that migbt 
explain the action of the antimigraine drugs, 
PARTU 
CHAPTER 7 
MEDIATION OF 5-HYDROXYTRYPTAMINE-INDUCED 
TACHYCARDIA IN THE PIG BY THE PUTATIVE 5-HT4 
RECEPTOR 
Villalon, C.M., den Boer, M.O., Heiligers, J.P.C. and Saxena, P.R. 
Br. J_ Pll.armacoL (Special Report), 100, 665-667, 1990. 
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Mediation of 5-hydroxytryptamine-induced tachycardia in the 
pig by the putative 5-HT4 receptor 
Carlos M. Villa16n. Marien 0. den Boer, Jan P.C. Heiligers & 1Pramod R. Saxena 
Derartment of Pharmacology. Faculty of Medicine and Health Sciences., Erasmus University Rotterdam, Post Box 1738. 3000 
OR Rotterdam, The Netherlands 
Intravenous bolus 'injections of 5-hydroxytryptam.ine (:5-HT; 3, 10 and JOp:gkg- 1), 5-roetboxytryptamine 
(5-McO-T; 3, 10 and 30.ugkg-'), renzapride (BRL 24924: 3. 10, 30 and IOO,ugkg-') and isoprenaline 
(0.03. 0.1 and O.J,ugkg- 1) to anaesthetized pigs increased heart rate by, respectively, 22 ± 3, 44 ± 3 and 
65±4 be:ltsmin- 1 (5-HT: n-; 17); 12± 1, 26±2 and 44±4 beatsmin- 1 (5-MeO-T; n= IS), 5±2. 
II± 2. 18 ± 4 and 37 ± 5 beats min·' {renzapride; n""" 8) and 17 ± 2. 46 ± 3 and 75 ± 3 beats min-• 
(isoprenaline; n = 13). The response-; to 5-HT. 5-MeO-T and renzapride were antagonized by res 205-930 
(I and 3mgkg" 1, i.v.). which did not modify the increases in heart rate by isoprenaline. Rcnzapride 
showed tachyphylaxis and attenuated the respon_~es to 5-HT. These findings indicate that 5-HT elicits 
tachycardia in the pig by acting on a novel receptor. either similar or identical to the 5-HT4 receptor 
identified in mouse brain colliculi. 
Introduction The mechanism of tachycardia elicited by 5-
hydroxytryptamine (5-HT) is notoriously species-dependent 
and is mediated. directly or indirectly, either by 5-HT ,-like 
(cat). 5-HT~ (rat. dog) or 5-HT ~(rabbit. dog) receptors. or by 
tyramine-like (guinea-pig) or unidentified mechanisms (see 
Saxena. 1986: Saxena & VillalOn. 1990). In the pig. we have 
found that !he 5-HT-induccd tachycardia is mediated by a 
novel receptor type different from either the 5-HT,-likc. 
5-HTz or 5-HTJ receptor {Duncker et al_ 1985: Borner al .• 
198!1). Recently. a novel 5-HT receptor site. coupled positively 
to adenylate cyda.~ and designated as 5-HT .. , ha.<> been 
located in cultured neurones from mouse embryo colliculi 
(Dumuis er al .• 1988: 1989: Clarke er al .• 1989). The purpose of 
this inve.<;tigation was to determine whether the porcine heart 
5-HT receptor is similar to the putative 5-HT 4 receptor in the 
mouse brain. 
Methods As described in detail previously (Born eta/ .• 1988), 
21 Yorkshire pigs (15-20kg) were. after sedation with aza-
perone (120mg. i.m.) and metomidate (120-!50mg. i.v.). intu-
bated for positive pressure ventilation with a mixture of room 
air (70%) and 0~ (30%). The anaesthesia was maintained with 
a continuous infusion of pentobarbitone sodium (15-
20mgkg" 1 h" '. i.v.). Both vagosympathetic trunks were cut 
and aortic blood pressure and heart rate were recorded. The 
right jugub.r vein was cannulated for drug injections. The 
body temperature of the animals was maintained around 37"C 
and arterial hlood gases and pH were kept within the normal 
limits. After the animals had been in a stable haemodynamic 
condition for at least 30 min. they received bel us injections of 
5-HT. S..methoxytryptamine (S..MeO-T), renza.pride and/or 
i.<>oprenaline. Subsequently, three dose.~ of ICS 205-930 
(cumulativcly: 0.3, 1.0 and 3.0mgkg" 1) or equivalent volumes 
of physiological saline were administered and the responses to 
the four agonist::; were elicited again (for doses and number of 
observations in each case. see Results\. 
The drugs. used in this study were 5-HT creatinine sulphate 
(Sigma Chemica! Company. St. Louis. MO. U.S.A.). 5-MeO-T 
hydrochloride (Janssen Pharmaceutica. Beersc, Belgium). ren-
z.a.pride hydrochloride (BRL 24924: gift: Dr GJ. Sanger. 
Beecham Pharmaceuticals. Harlow. Essex. England), isoprena-
Hne sulphate (Pharmacy Department. Erasmus University. 
Rotterdam. The Netherlands) and (3c:-tropanyl}-l H-indole-3-
carboJ~yl acid ester (ICS 205-.930). The doses of 5-HT and 
5-MeO-T are given as free base. The percentage changes from 
' Author for correspondence. 
the initial agonist response in the saltne- and ICS 205-930-
treated animals were compared by Student's t tes1. Statistic:l.l 
significance was accepted at P < 0.05. A\1 da!a are reported as 
mean ± s.e..mean. 
Results Initial b/OQd pres.~we and heart rate changes by 
agonist drugs Ba.-.elim: values of mean arterial blood pressure 
and heart rate in the 21 pigs were 84 ± 4mmHg and 102 ± 5 
beatsmin"'. respectively. The change.~ in the mean arterial 
blood pressure were: S..liT(--17 ± 1. -16± 2and -10 ± 3 
followed by +5 ± I mmHg after 3. 10 and 30pgkg" 1, respec-
tively: n = 17), 5-MeO-T ( -18 ± 3. -17 ± 2 and -16 ± 2 
followed by +6 ± 2mmHg after 3. 10 and 30pgkg-•. respec-
tively; n= 15) and ren..-.apride(+l ± 1, +4± I. +8 ±I and 
+9 ± 1 mmHg after 3, 10. 30 and HX}pgkg·'. respectively; 
n = 8). These effects were not evaluated further. 
A:s shown in Figure 1. 5-HT. S..MeO-T. ren..-.apride and iso-
prenaline caused dose-dependent increases in heart rate. Iso-
prenaline was about 2 log units mote potent than 5-HT. 
which was itself more potent than S..MeO-T or renzapride. At 
the doses used the duration of action ofrcnzapride (10.8 ± 29. 
25.7 ± 3.6. 36.8 ± 3.9 and 45.7 ± 28min) w;tS much longer 
than that of S..MeO-T {4.2 ± 0.7. 8.3 ± 1.0 and 125 ± L3min) 
or S..HT (3.4 ± 0.5. 6.0 ± 0.7 and 8.4 ± 0.9 min). 
Modification of heart rate responses by physiological $0/ine or 
ICS 205-930 The tachycardia produced in response to 5-HT. 
5-MeO-T and isoprenaline remained es..~ential!y unchanged in 
control animals receiving saline. In the animals where ICS 
205-930 was administered, the responses to both S..HT and 
5-MeO-T remained unchanged after the lowest dose 
(0.3mgkg- 1). but were clearly antagoni..-.cd by the two higher 
doses (I and 3mgkg- 1). The responses to repeated doses of 
ren7.apride in the control animals were progres..~ively reduced; 
neverthc\ess, tachycardia due to renzapride was more inhib-
ited after ICS 205-930 than after saline. The isoprenaline-
induced tachycardia wa.~ unaffected by ICS 205-930 when 
compared to the saline-treated animals {Figure 2). 
In the saline-treated animals where S..HT wa.~ administered 
before and after the !a.~t set of injections of 5-MeO-T or ren-
zapride (n = 5 each). the responses to S..HT (3. 10 and 
30pgkg- 1} remained unaltered aftor 5-MeO-T (14 ± 4, 39 ± 4 
and 63±5beatsmin" 1 before and 15±4. 4!±6 and 
59± Sbeatsmin-• after 5-MeO-T. respectively), but were 
reduced by renzapride (27 ± 5. 50 ± 5 and 69 ± 5 beats min -• 
before and 11 ± 3. 22 ± 3 and 31 ± 2 beats min- 1 and after 
rcnzapride. respectively). 
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Diseussioo ln previous publica.tions (Duncker et a/., 1985: 
Bom ct al~ 1988) we showed that the 5-HT-induced tachy-
cardia in the pig is not antngonizc:d by drugs that act as 
antagonists at various receptors: 5-HT, and/or 5-HT:>. 
(mcthiothcpin, methysergide. ketanserin): S-HT3 (MDL 72222. 
ICS 205-930): adrcnoceptors (phcnoxybenzamine, 
propranolol): dopamine (haloperidol~ histamine 
(mepyrnmine, cimetidine). Since, in addition, 5-
carl>oxyamidotryptaminc, 8-0H-DPAT. RU 24969. 2-methyl-
5-HT do not mimic" 5-HT and the responses to 5-HT are 
potentiated by the 5-HT-uptak.e blockers indalpine Uiid flu-
voxetine, it was concluded that 5-HT elicit~ tachycardia in the 
pig via a novel 5-HT receptor (Bom ct al .• 1988). The present 
investigation showed that 5-MeO-T and, to a lesser extent, 
rcnzapride mimic 5-HT and high doses (I and 3mgkg-') of 
ICS 205-930. but not 0.3mgkg- 1 as al~o reported earlier 
(Born <'t al., 1988). antagoni7.e the tachycardiac responses. 
Taken together, the above findings strongly suggest the 
involvement or a receptor similar or identical with the 
putative 5-HT 4 receptor located in the mouse brain. AI this 
receptor, 5-MeO-T :1nd certain bcnzamide derivatives 
(renzapride. cisapride). but not 5-carboxamidotryptamine., a:-
methyl-5-HT or 2-methyl-5-HT, are agonists and ICS 205-930 
(in high concentration~: pA~: 6.3---6.5), but not MDL 72222 or 
ondansetron. act a~ ant:~gonists (Dumui~ cl a/., !9RR: !9R9; 
Clarke l?f a/., 19R9). The 5-HT., receptor probably also medi-
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Figure 2 The eO'ects of JCS 20$-930 (b) (0. control; A. 0.3 mgkg-'; +. 1.0 mgkg·' and 11111. J.Omg kg-') or the corresponding 
volumes of saline (a) on the tachycardiac responses to $-hydroxytryptamine ($-HT. n "' 5. saline; n = 7. JCS 205·930). 5-
methoxytryptamine (5-MeO-T. n = 5, saline; n = 5. ICS 205-930). rem:apride (n = 5, ~aline; n = 3, lCS 20$-930) :~nd iwprenaline 
{n "" 3. saline; n "" 5, JCS 205-930). HR. hc:lrt rate. • Signifio;ant change (P < 0.05) in the control response to the agOnist drug by ICS 
205-930 as compared to the corresponding injection of saline. 
ates the 5-HT-induced enhancement of cholinergic activity in 
the guinea-pig isolated ileum (Sanger, 1987; Craig & Oarke. 
1989) and the ·inotropic action in the human isolated atria 
(Kaumann el al~ 1989).. However, our findings are the first 
demonstration of a functional response to the putative 5-HT,... 
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Further characterization, by use of tryptamine and benzamide 
derivatives, of the putative 5-HT 4 receptor mediating 
tachycardia in the pig 
Carlos M. VillalOn, Marien 0. den Boer, Jan P.C. Heiligers & 1 Pramod R. Saxena 
Department of Pharmacology. Faculty of Medicine and Health Sciences, Erasmus University Rotterdam. Post Box 1738, 3000 
DR Rotterdam. The Netherl:tnds 
1 It has recently been shown that the taehyeardie response to 5-hydroxytryptamine (S.HT) in the anaes-
thetized pig. being mimicked by 5-methoxytryptamine and renzapride and blocked by high doses of ICS 
205-930. is mediated by the putative 5-HT4 receptor. In the present investigation we have further charac-
terized this receptor. 
2 Intravenous bolus injections of the tryptamine derivatives, 5-HT (3, 10 and 30pgkg- 1), S. 
methoxytryptamine (3. 10 and 30}lgkg' 1 ) and o:-mcthyl-5-hydroxytryptamine (o:-methyl-S.HT; 3, 10,30 
and IOOpgkg-'). resulted in dose-dependent increa~es in he:u1 rate of, respectively, 25 ± 2. 48 ± 3 and 
68 ± 3 beatsmin' 1 (5-HT: n"' 35): 15 ± 1, 32 ± 2 and 57± 3 beat<;min' 1 (S.methoxylryptamine: 
n = 30); 6 ± 4, 18 ± 6, 34 ± 6 and 64 ± II beats min ' 1 (o:-methyi-5-HT; n = 3). 
3 The incre:1ses in heart rate following i.v. administration of certain suhstitutcd bcw.umidc derivatives 
were gcncrcally les.~ marked and not dose-dependent: 1 ± 5, II± 3 and 10 ± 5 beat,. min-• after 300, 
1000 and 3000pgkg·' of metoelopramide. respectively, (n = 8): 21 ± 4, !9 ± 2 and 2 ± 2 beats min-' 
after JOO. 300 and 1000pgkg-' or cisarride, respectively. (n"' 5): 6 ± 2. 14 ± 2. 37 ± 6, 43 ± 8 and, 
34 ± 10 beatsmin- 1 after 10, 30, 100, 300 and lOOOpgkg·' ofzacopride. respectively, (n = 6); and I ± I, 
2 ± 1 and 5 ± 2 beat~ min·' after 300, 1000 and 3000pgkg·' of dazopride, respectively, (n = 4). These 
drugs behaved as partial agonists. antagonizing the responses to 5-HT and 5-metho~ytryptamine dose· 
dependently. 
4 The 5-HT3 receptor agonist 1-phcnyl-biguanide (100. 300 and IOOOpgkg- 1) induced only slight 
increases in heart rate of I ± I, 6 ± 2 and II ± l beats min-', respectively. (n = 3). These effects were not 
antagonized by the selective 5-HT3 receptor antagonist &ranisetron (3mgkg- 1). In addition. 1-phcnyl-
biguanidc (!OOOpgkg· 'l did not modify the tachycardia induced by either 5-HT- or 5-
methoxytryptamine. 
5 High doses (3mgkg' 1) of !CS 205-930, a 5-HT 3 receptor antagonist with an indole group and devoid 
of effects on porcine heart rate per $1?, antagonized the stimulatory etfect.~ of 5-HT, 5-methoxytryptamine, 
o:-Me-5-HT. metoelopramide, ci:mpride, zacopridc, dazopride and 1-pheny!-biguanide. However, the 
5-HT l receptor antagonist ketanserin (0.5 mg kg- 1). the 5-HT 3 receptor antagonists granisetron (3mgkg- 1) and MDL 72222 (3mgkg- 1) and the dopamine 0 2 receptor antagonist domperidone (3mgkg- 1) had no antagonist activity. 
6 The above result" support our contention that 5-HT, 5-methoxytryptamine, a.-Me-5-HT nnd the sub-
stituted benzamide derivatives increase porcine heart rate by a direct action on the cardiae pacemaker. via 
the activation of a putative 5-HT 4 receptor. The pharrn:l.co\ogieal profile of this n<>vel 5-HT receptor is 
similar (neurone.~ from mouse brain colliculi and human heart) or, perhaps. even identical (guinea-pig 
cholinergic neurones) to other putative 5-HT 4 receptors. 
Introduction 
5-Hydro~ytryptamine (5-HT) e::tn exert multiple cardiac effects 
including both increa= and decrea.~es in heart rate. In most 
species, bradycardia induced by 5-HT is mediated by 5-HT 3 
receptors, via the activation of the von Bezold Jarisch refle~. 
In marked contrast. the mechanism of 5-HT-induced tachy-
e::trdia is notoriously species-dependent and is mediated, 
directly or indirectly. either by 5-HT 1-likc (cat). 5-HT~ (rat. 
dog) or 5-HT3 (rabbit. dog) receptors. or by tyramine-Eke (guinea-pig) or unidentified mechanisms (see Saxena. 1986; 
Saxena & VillalOn, 1990). In the pig. we have reported that the 
5-HT-induced tachycardia is mediated by a novel receptor 
type which differs from 5-HT1-like, 5-HT~ and 5-HTl recep-
tors{Duncker eta/~ 1985: Born cl a/ .. 1988). but rescmhles the 
putative 5-HT4 receptor (VillalOn ct al .• 1990) mediating 
stimulation or adcnylatc cyclase in both mou~e embryo col-
1 Author for com:spondenee. 
liculi neurones and guinea-pig hippocampal membranes 
(Oumuis eta/~ 1988: 1989; Oarke et at~ 1989). In the present 
study. we have further characteri7.ed the porcine heart 5-HT 
receptor using se~·eral agonist and antagonist drugs. including 
some substituted bem·..amide derh·atives. 
Methods 
General 
After an overnight fast, 40 young Yorkshire pigs (15-20kg) 
were sedated with a?,.aperone (120mg. i.m.) and metomidate 
(120 150mt:. i.v.). After intubation, the animals were con· 
ne<.1ed to a respirator for intermittent positive pres.~ure venti-
lation with a mixture of room air (70'~Q) and 0! (30%). The 
anaesthesia was maintained with a continuous infusion or 
pentobarbitone sodium (15-20 mgkg ·' h -•. i.v.). Aortic blood 
pres.~ure and heart rate were recorded with. respectively. a 
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Statham pre:~sure transducer and a tachograph. All drugs were 
injected into the right jugular vein. The body temperature of 
the animals was maintained around 37~(' by using an electric 
blanket and arterial blood g:a.~cs and pH were kept within the 
normallimiL~ (Po~> 90mmHg; Pc:o~ 30-40mmlig: pH 7.35-
7.45) by adjusting respirotory rate and tidal volume or by 
infu._~ing 4.2% sodium bicarbonate solution. 
Experimental protocol 
After the animals had been in a stable hacmodynamic con-
dition for at lea.<:.! 45 min, they rec<::ivcd intravenous bolus 
injections of 5-HT (3, 10 and 30J.Igkg- 1} and 
5-mcthoxytryptamine (3. 10 and 30pgkg- 1). Subsequently, 
several doses of c:--methy!-5-HT (3. 10, 30 and !OO;,gkg- '), 
1-phenyl-biguanide (30, 100, 300 and 1000 JlS kg- 1 ), mctodop· 
ramide (300, !000 and 3000pgkg- 1). cisapride (30. 100. 300 
and I000;1gkg-'). zacopride (10. 30. 100. 300 and 
IOOOpgkg-') or dazopride {300, 1000 and 3000pgks- 'l were 
given. and after each dose or the highest dose (1-phenyl-hig-
uanide). the respon5es to 5-HT and 5-methoxytryptamine 
were elicited again (for number of experiments and other spe-
cificatiOn.", sec Result~). Jn addition. taehvordie rctpon~ to 
5·HT- and 5-methoxytryptamine were induced before and 
after pretreatment with 3mgkg'' of either MDL 72222, gran-
isetron or domperidone. ln another set of experiment~. the 
taehycardie respon~es to 5-HT. 5-methoxytryptamine and :>:-
methyl-5-HT were analyzed before and after pretreatment 
with either ketanserin (O.Smgkg- 1) or ICS 205-930 
(3mgkg- 1). Lastly, the dose of each benzamide derivative 
eliciting the maximum increa.<;C in heart rate was cho:;en and 
given to a new group of animals {without previou$ adminis-
tration of any of the benzamide derivatives) after pretreatment 
with 3mgkg-' ofiCS 205-930. 
The interval between the different dose$ of the compounds 
used as agonists and/or antagonists depended on the duration 
of tachycardia produ~ by the prCC~.:ding dose. as in each case 
we waited until hC:lrt rate had returned completely or nearly 
to baseline values. The dose-intervals for the di/Terent drugs 
were as follows; tryptamine derivatives. between 5 and I5min: 
benzamide derivatives and 1-phenyl-biguanide. usually 
between 15 and 30min. but sometimes even longer than 
60min (cisapride and za.copride): and other antagonists (ICS 
205-930, MDL 72222. granisetron. ketanserin and 
domperidone). between 10 and !5min. The dosing with ICS 
205-930 was cumulative (given as 0.3. 0.7 and 2.0mgkg-'). 
whereas that with aU other drugs was sequential. 
Drugs 
The drugs used in this study were: eisapride (gift: Dr J.AJ. 
Schuurkes. Janssen Pharmaceutiea. Beer:o;e. Belgium). (±)-
dazopride (A.H. Robbins Co .• Richmond. VA. U.S.A.). dom-
peridone {gift: Dr J.AJ. Schuurkes. Jans.~en Pharmaceutica. 
Beerse, Belgium). granisetron (gift: Dr GJ. Sanger, Smith 
Kline Beecham, Harlow. U.K.}. 5-hydroxytryptamine cre-
atinine sulphate {Sigma Chemical Company. St. Loui:s. MO. 
U.S.A.), ketanserin tartrate (gift: Dr J.M. Van Nueten. Janssen 
Pharmaceutica. Beer~ Belgium). 5-methoxytryptaminc 
hydrochloride (Janssen Chimica, Beene, Belgium). ( ± )-S-z-
methy!-5-HT (gift: Dr P.P.A. Humphrey. Glaxo Group 
Reseatch. Ware. U.K.). metoclopramide hydrochloride 
(Pharmacy Department, Erasmus University. Rotterdam, The 
Netherlands). l·phenyl-biguanide (Research Biochemicals !nc.. 
Nathick. MA. U.S.A.). lo:HJ~X.5zH-tropan-3y!-3,5-diehloro­
benzoate {MDL 722.22: gift: Merrei-Dow Research Institute. 
Strasbourg. · France); (31':-tropanyl)- I H·indole-3-earboxylie 
acid eaer {ICS 205-930), and ( ±)-zacopride (A.H. Robbins Co., 
Richmond. VA, U.S.A.). The doses of cisapridc. dazopride, 
5-HT. 5-methoxytryptamine. o:-methy-5-HT. 1-phenyl-big-
uanide and zaeopride are given as free ba.~e. 
Dar a prcscnration and analysis 
All data in the text. figures and tables are presented a.~ 
mean ± s.e.mean. The peak changes in heart rate induced by 
the different doses or hoth tryptamine- and ben7.amide deriv-
atives were determined. The inerC:lSCS in heart rate just before 
and after a particular antagonist drug were compared by 
Duncan's new multiple range test. once an analysis of variance 
(randomized block design) revealed that the samples rep-
resented different populations {Saxena. 1985). The effects of 
agonist drugs in the different groups of animals were com· 
pared by use of the unpaired Student's I te.~t. A P value of0.05 
or I= (two-t1i!cd) wa.o; considered statistically significant. 
Results 
Initial blood pressure and heart rate changes hy 5-HT 
agonist drugs 
Baseline values of mean arterial blood pre:;..'>ure and heart rate 
in the 40 pi& .. were 84±4mmHg a.nd 101 ±4 beatsmin·'. 
respectively. The changes indu~ in mean l.lrterial blood pres-
sure by each 5-HT :1gonist drug were: 5-HT ( ~ 18 ± 1 
~ !8 ±!and ~ 16 ±I followed by +2 ±! mmHg arter 3. ll 
and 30 Jlf!. kg- 1• resreetive!y: n ,... 35), 5-methoxytryptamine 
(-20 ±I. -JR ± 2 and -15 ± 2 fo!lowed by +2 ± J mmHg 
after 3. !0 and 30pgkg-'. respectively: n = 30). o:-methyl-5-
HT (-20 ±I. -14 ± 2. + 10 ± 3 and +41 ± S:nmHg after 
3. 10. 30 and IOOpgkg·'. respectively; n = 3). metoelopra-
mide {+5±2. +8±1 and +3±3mmHg after 300.1000 
and 3000;1gkg · '. respectively; n = 8). eisapride ( +4 ± 4, 
+I! ± 2. + 5 ± 3 and -8 ± 5mmHg after 30. 100. 300 and 
!OOOpgkg-'. respectively: n = 5). 7.acopride (+5 ± 2. 
+10±2. +14±3and +12±2mmHgafler 10,30.100and 
300pgkg- 1, respectively; n = 6). d!lzopride ( + 1 ± 1, +2 ± ! 
and +4 ± 2mmHg after 300. 1000 and 3000pgkg·'. respec-
tively: n = 4). and l-pbeny1-biguanide (0 ± 0. 0 ± 0. +4 ±I 
and +9 ± 2 after 30. 100.300 and 1000pgkg-'. respectively; 
n = 3). These efl'ects were not evaluated further. 
As shown in Figure I. intravenous bolus injections of the 
above-mentioned 5-f IT agonist drugs caused increa.o;e; in 
heart rate o( diverse magnitude: the order of potency was 
5-HT ~ 5-methoxytryptamine >J:~:-methyi-5-HT > zacopride 
> eisapride > metoclopramide = 1-phenyl-biguanide > 
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(Iii!, n = 6). cisapride (6. n = 51. metodopramide. (0. n = 8:). !-phenyl-
biguanide ( +. n = 3) and d:,zopride (A. n = 4) in the anaesthetiz.ed 
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dazopride. At the doses used. the durittion of action of cis-
apride (>60min at lOO.ugkg- 1) was longer than that of 
zacopride (17 ± I. 23 ± 1, 43 ± 17 and 50 ± 8 min). metoclop-
ramide (II ± I. 15 ± 2 and 21 ± 5min), dazopride (I ± I, 
5 ±2 and >30min), 1-phenyl-biguanide (0 ± 0, 0 ± 0, 5 ± 3 
and 30 ± 3 min), 5-methoxylryptamine {5.9 ± 0.3. 9.6 ± 0.5 
and 13.7 ± 0.6min). 5-HT (2.2 ± 0.2. 4.5 ± 0.3 and 
7.6 ± 0.7min) or a-methyi-5-HT {0.4 ± 0.1. 0.9 ± 0.1. 4.3 ± 1.3 
and 7.3 ± 1.3min). 
M odifica!ion of tachycardia in response ru 5-HT and 
5-methoxycryptamine induced by benzamide derivatives 
In a previous publication. we have reported that the tachy-
cardia induced by repeated administrations of 5-HT and 5-
methoxytryptamine remained essentially unchanged in control 
animals receiving physiological sa.line (Vil!aiOn et al., 1990). In 
marked contrast, the administration of several doses of either 
zacopride, cisapride, metoclopramide or dazopride antago-
nized the tachycardia induced by 5-HT {Figure 2) or 5-
methoxytryptamine (Figure 3) in a dose-dependent manner; 
the order of potency for blockade of both 5-HT- and 5-
methoxytryptamine-induced tachycardia was similar to that of 
their tachycardic response {sec above): zacopride = cisapride 
~ metoclopramidc > dazopride. 
Tachycardia induced by ben:: amide derivatives after I CS 
205-930 
Because of the fact that the responses to the higher doses of 
the benzamide derivatives were usual!y less than the 
maximum response achieved (see Figure I). the dose of each 
bcnzamide derivative eliciting the ma;.;imum increase in heart 
rate was administered to animals after treatment with 
3mgkg- 1 of ICS 205-930. This dose of ICS 205-930 antago-
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Figure 2 The effects of {a) zaeopride In "' S). (b) el<arride {n = Sl. (e) 
daropride (n ~ 4) and (d) metoelopramide (n = S) on the tachyc;ardie 
responses to S-HT. The doses of the antagonists were: (Q) Omgkf(" 1 
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Figure 3 The etTeet.~ of (a) zacopride (n = 4). (b) cisapride (n = 4). (c) 
dazopride (n = 4) and (d) metodopramide (n = 5) on the taehycardic 
responses to S.methoxytryptamine. The doses of the antagoni.~ts were: 
(Q). Omgkg"' (control); (A) 0.1 mgkg"': (+) 0.3mgkg" 1: (IIi) 
1.0 mg kg" 1 and (0) 3.0mgkg- 1• "Significantly different from the 
corresponding control response to S-methoxytrypt:omine (P < 0.05) . 
nizes the tachycardie res]')Onses to 5-HT. 5-methoxy-
tryptamine and renzapride. but not that to isoprenaline 
(VIllalOn et al., 1990). As shown in Figure 4. the increase in 
heart rate induced by either zaeopride. cisa.pride, dazopride or 
metoclopramide was markedly antagonized by ICS 205-930. 
Tachycardia induced by 5-HT or 5-methoxytrypramine 
after administration of some agonist and an.tagonisr drugs 
Inasmuch as all putative antagonists at this novd cardiae 
receptor also display high affinity for the 5-HT 3 receptors, we 
decided to invc..~tig:1.te the e!Tect of high doses of ot~er sclC{:tive 
5~HT ~ receptor agonists and antagonist~ on the tachyca.rdic 
responses induced by 5-HT or 5-methoxytryptamine: the 
l I~ 11 1· 
Oaloprlde M'>IOdCpramodc 
Fi)!ur..- 4 The tachyenrdic reopon.<es to 7.:>eopride (0.3 mg kg" 1). cis-
apnde 10.3 mgkg" '). metoelt>pramide (3 mgkg" ') and dazopride 
(J mg kg" 'l in untreated control pig'~ (Open columns, n '-' 6. S,l'l nnd 4. 
re;;pectivcly) and pig.< treated with ICS :!OS-930 (solid columns, n = 6, 
6, 5 and 6. reo;pe<:tively). • Sif:llifieantly different from the CO!Te'lpond· 
ing rc,;pon~e in the untreated animals (P < O.OS). 
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Table l Effett of MDL 72222, gra.nisetron, 1-phenyl-biguanide or domperidone on 5-HT- and 5-methoxytryptuminc-induced increases 
in heart rate in the pig 
lnr«a.<e in hl'arl rate (beat~ min"') 
Dw Jl'gkg"' !Opgkg"' 30pgkg"' 
Anta{lonlSl (mgkg" 1) Before After Before Afu::r Before After 
5-IfT 
MDL 72222 3.0 6 26 ± 5 2J ± 6 49 ±9 40 ± 8 69 ± 12 63 ± 11 
Grnnisetron 3.0 J 32 ± 10 31 ± 10 58± ]4 SJ ± 13 77 ± l7 69 ± 16 
1-Pheny!-biguanide 1.0 3 32 ± 10 33 ± 10 58± ]4 56± 15 77 ± 17 74 ±IS 
[)Qmperidone 3.0 6 26 ± 5 2<) = 6 49 ± 9 50± 7 69 ± 12 69 + 6 
5-Mcthoxytrypraminr 
MDL 72"..12 J.O 6 18±4 18 ±4 35 ± 6 33 ± 5 61 ± lO 57± lO 
Gmnisetron 3.0 3 15 ± 2 14± 2 32 + 7 28 ± 5 62 ± 8 54± 8 
1-Phenyl-biguanide 1.0 3 15 ± 2 14 ± 3 32 ± 7 30 ± 7 62 ± 8 60 ± 8 
Domperidone 3.0 6 18 ±4 18 ± 5 35 ± 6 38± 5 61 ± 10 58± 7 
All data are mean ± s.e.mean. None oft he responses o.fter anta~toni~t drug"< diiTer«< significantly from those t>efor~ amagoni~l (P > O.OS). 
selective dopamine~ (D~) receptor antagonist dompcridone. 
as some benzamidc derivatives (metoclopramide) also show 
affinity for D 1 receptors. As shown in Table I, the responses 
to both 5~HT and 5~methoxytryptamine remained unchanged 
after administration of MDL 72222 (Jmgkg-'). gr:misetron 
(3mgkg- 1). 1-phenyl-biguanide (I mgkg- 1) or domperidone 
(3mgkg-'). 
Since C~:-methyl-5-HT (a 5-HT2 and. to some extent, 
5-HT 1-like receptor agonist) did induce quite consistent 
increases in heart rate (see Figure I). we explored by phann;L-
cological means the possible mechanisms involved in such an 
effect. In control animals where 5-HT and 5-methoxy-
tryptamine were admini$tered before :md after the last set of 
injections of ~r:-methyl-5-HT {3. 10. 30 and lOOJigkg- 1). the 
tachyeardic responses induced by both 5-HT (3. 10 and 
30.ugkg- 1) and 5-metboxytryptamine (3. 10 and 30Jlgkg-'l 
remained unchanged after a-methyl-5-HT (Cor 5-HT: 40 ± 9, 
66± II. and 88 ± 13 beats min-' before and 36+ 5. 62+ 10 
and 82 ± 12 bc:-.tsmin- 1 after <I-mcthy!-5-HT {n:::; 3). resPec-
tively: for 5-methoxytrypt:-.mine: 21 ± 7. 37 ± 8 and 67 ± II 
beatsmin- 1 before and 17±5. 32±7 and 59± 11 
beats min-' :-.ncr <I-methyl-5-HT (n = 3), respectively]. Like-
wise. the increases in heart rate induced by 5·HT. 5-
methoxytryptamine and ~r:-methyi·5-HT were unaiTe<::ted by 
ketanserin (O.Smgkg- 1). but were markedly antagonb:ed by 
ICS 205-930 (3 mgkg- 1) {Figure 5). 
Lastly. it may be noted that the 5-HT) receptor agonist 1-
phenyl-bigu:-.nide (30. 100. 300 and lOOOpgkg- 1) induced a 
small increase in porcine he:-.rt rate (n "" 3); this e!Tect wa$ not 
blocked after administration of 3mgkg-' of the selective 
:5-HT3 receptor antagonist granisetron (0 ± 0. I ±I. 6 ± 2 
'" '" '" ;c J E 75 75 
·Y 75 J 
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fiture 5 The tachycardic re,po)nses to 5·HT (n ~ 3J. 5· 
methoxytryptamine (n = 3) and ::-methyl-5-HT (::·Me-5-HT) (n ~ 31 
before (control. OJ and after inj~tions 0f kctan~erin (0.5 mg kg 1, A). 
and lCS 20$-930 (3mgkg-'. +J. "Signifu::.ntly di(ferent fLom 
respon~e in untre::tted ::tnimah (P < 0.05) 
and ll ±I beats min-• before and 0 ± 0. 5 ± 3. 11 :t 3 :-.nd 
16 ± I bents min-' :-.rtcr granisetron, re:;pectively). Notwith-
standing. this e!Tcct appeared to be ::tnt:-.goni7..ed by 3mgkg-• 
of ICS ZOS-930 (0 ±0. 5 ±3.11 ±3 and !6 ±I beats min-' 
before ;md 0±0. 3± 1. 4± 1 and 7± 1 Ocats min- 1 after 
!CS 205-930. respectively). 
We have shown that the 5-HT-induced t:-.chycardia in the 
pig is neither mimicked by agonists at 5-HT,-like (5-car-
boxamidotryptamine. 8-hydroxy-2·(di-n-propyl:-.mino)tetdlin. 
RU 24969) and 5-HT3 (2-mcthy!-5-HT) receptors. nor antago-
nized by drugs th:-.t act at various receptors: 5-HT, and/or 
5-HT 2 (methiothepin. methysergide, ketanserin); 5-HT3 (MDL 72122. JCS 205-930); adrcnoccptors (phenoxy-
benzamine. propranolol); dop:-.minc (h:-.Joperidol); histamine 
(mepyramine.cimetidine) (sec Duncker ct a/.. 1985; Born ct a! .• 
1988). More recently. we found that the tachycardic effects of 
5-HT in the pig. being mimicked by 5-methoxytryptamine and 
ren7A1pridc (Villall>n c1 a/ .• 1990), but not by indorcnate or 
sumatriptan (VilblOn ('/ al~ 1991). and blocked by high doses 
(>I mgkg- 'l of ICS 205-930 (VillalOn ct al .• 1990), arc medi-
:-.ted hy a putative 5-HT4 1eceptor which resemble,; the one 
mediating increases in :-.dcnosine 3':5'-cyclic monopho~phate 
(cyclic AMP) in mouse embryo colliculi neuroncs and guinea-
pig hippocampal membranes (Oumuis er al .• 19R~: 1989: 
Clarke el al .• 1989). The present investiption extends these 
findings :-.nd clearly demont.tratcs that the porcine heart 5-HT 
receptor (i) can be stimul:-.ted by ll:-methyl-5--liT and some 
benzamidc derivative,;; (ii) docs not resemble either 5-HT2 , 
5-HT ~or dopamine receptors; :-.nd (iii) resembles that present 
on the guinea-pig enteric neuroncs (Craig & Clarke. 1990) and 
human hc:-.rt (Kaumann el a/., !990). 
Agonist action of':X-mcthyl-5-HT and some ben:;amidc 
dericatives on the porcine /t('art 5-HT receptor 
Like 5-HT and 5-mcthoxytrypt;;unine, it wa.'> observed that ~r:­
mcthyl-5-HT beh:tved a.'> a potent :-.gonist and elicited a dose-
dependent tachycardia in the pig. The <.!rug wa.'> also 
short-la.'>ting in action and wa.'> devoid of :-.ny antagonist 
action against 5-1-JT or 5-methoxytryptamine. In contra.'\!, the 
tachyC.'lrdic action of the ben7~1mide derivatives 7~1copride. cis· 
apride, mctoclopramidc and dazopride. was less marked. but 
longcr-!:tsting. and not strictly dosc·dcpcndcnt. In :-tddition, 
c:tch of these drugs antagonized the c!Tects of 5-HT and 5-
mcthoxytryptaminc in :1 <.lose-dependent manner. It h:L'\ to be 
emphasized that the t:-.chycardic e!Tects of 5-HT and 5-
mcthoxytrypt:tminc were not 'masked' by the incre:-.sc in heart 
mlc indu~d by The- t>cn7.amide derivatives as the· re>;ponscs to 
5-l !T and S·metlH'xytryptamine were elicited at the time when 
the tachycardic etT~t of the bert7.amides had worn off (data 
not shown). Therefore. as previously found with renzapride 
(VillalOn el a/., 1990). the benzamide derivatives employed 
here al~o behaved a.~ partial agoni.~ts. at the 5-BT 4 receptors in 
the porcine heart. 
In our previous investiption. tachyphylaxis was observed 
with the tachycardic e/Tect of renzapride (VillalOn ct al .• 1990). 
Though the present study was not designed for this purpose. 
we did observe tachyphylaxis in some preliminary experi-
menl~ with the benzamide derivatives used here. Indeed. for 
this rea.~on the antagonist effect of res 205-930 against the 
tachycardia induced by zacopride. cisapride. dazopride and 
metoclopramide was analyzed separately in control animals 
and in animal~ pretreated with res 205-930 (see Figure 4). 
Lack of resemblance •'fthe porcine hcart5-HT receptor 
with either 5-HT;:. 5-HT 3 or dopamine 0 1 receptors 
Both 5-methoxytryptamine and a:-methyl-5-HT can interact 
with 5-HT2 (and 5-HT,-Jike) receptors (Richardson & Engel. 
1986: Martin er al .• 1987; Hoyer, 1988). However. the tachy-
cardic action of 5-methoxytryptamine and o:-methyl-5-HT. as 
well a~ that of 5-HT (see also Born ct at_ 1988). was not modi-
fied after a dose of ketanserin (0.5 mg kg- 1) that is sufficient to 
block 5-HT: receptors (Van Nueten et al .• 1981; Saxena & 
Lawang. 1985). Therefore. the possibility that 5-HT;: receptors 
might be involved in the;e effects is practically ruled out. 
Unlike ketanserin. 3mgkg-• of ICS 205-930 markedly 
antagonized the tachyc.1.rdic responses to 5-HT. 5-
methoxytryptamine and a:-methyl-5-HT (see Figure 5), which 
again suggests the involvement of the 5-HT 4 receptor. 
Admittedly. ICS 205-930 and the benzamide derivatives 
used here have the ability to block potently 5-HT J receptors 
(for reference.~ see Fozard, 1990). However. as previously dis-
cussed (Born ct al .• 1988; VillalOn et al .• 1990). several results 
of this study clearly indicate that this novel 5-HT receptor in 
the pig heart docs not belong to the 5-HT3 receptor family. 
Firstly, besides the potency of 5-HT as a distinguishing factor. 
l:>oth o:-methyl-5-HT and 5-methoxytryptamine are totally 
inactive at 5-HT3 receptors (Richardson cl a/., 1985: Richard-
son & Engel. 1986: Fozard, 1990). Secondly. the selective 
5-HT3 receptor agonists 2-mcthyl-5-HT and 1-phenyl-big-
uanide (Fozard, 1990) were practically inactive in the stimu-
lation or 5-HT3 receptors (Born eta/., 1988; present results). 
Thirdly, high doses of other selecth·~ 5-HT3 r~tor antago-
nists (except ICS 205-930) such as granisetron {an indazole 
derivative; Sanger & Nelson. 1989; F07..J.rd, 1990) or MDL 
72222 (a dichlorobenzoate derivative; Fo7.ard, 1984; 1990) 
were completely inactive {see Table I). La.~tly. it must be taken 
into consideration that the affinity of lCS 205-930 for the 
5-HT .. receptor involved in the stimulation of cyclic AMP 
production in mouse embryo colliculi neuroncs is much lower 
{pK1 "" 6--6.3; Dumuis er al.. 1989) than its affinity for 5-HT J 
receptors (pA: = 8-10; Richardson ct al .• 1985: Richardson & 
Engel. 1986). 
Most of the ben7.amide derivatives ana!y7.ed in the present 
study are currently used as prokinctic drugs (Schuurkes <'I a/., 
1985; Alphin eta/ .. 1986; Cooper eta/ .. 1986; van Daele l'l al .• 
1986; Sanger, 1987). Apart from metoclopramide. which also 
displays high affinity for central d<'paminc receptor.:> (Cooper 
N al., 1986), the other ben7.amidc derivatives are devoid of 
important dopamine blocking activity. However. JCS 205-930. 
zacopride and other 5-HT 3 receptor antagonists arc able to 
inhibit the release of dopamine by 5-HT and 2-methyi-5-HT 
in the central nervous system (Blandina rr a/~ 1988; Trick-
lebank. 1989). It is for these reasons. although haloperidol h::td 
been found ineffective (Born cr al .. 1988). that we decided to 
determine whether dompcridone. :l potent D;: receptor 
antagonist (Kohli et at_ 1983) with g::tstrokinetic action, 
antagonizes the 5-HT-induced tachycardia or itself causes 
tachycardia in the pig. A.~ shown in Table 1. domperidon~ 
(3mgkg- 1) did not modify the tachycardic responses to either 
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5-HT or 5-methoxytrypta.mine. Therefore. the positive chro-
notropic effect induced by the tryptamine- and be=..amide 
derivatives in the pig heart is unrelated to a possible action 
via dopaminergie pathways and/or rettptors. Moreover. since 
domperidone failed to affect ba.o;ul heart rate in the pig. the-
drug does not interact with the pig heart 5-HT.., receptor. 
Resemblance of the porcine heart 5-HT receptor to other 
putative 5-HT4 receptors 
At the 5-HT .. receptor id;-:ntified in the neurones from mouse 
embryo co!lieuli on the basis of increase in cyclic AMP, 5-
methoxytryptamine. 5-carboxamidotryptamine {low affinity) 
and certain benzamidc derivatives {renzapride. metoclopra-
mide. cisapride). but not !l:-methyl-5-HT or 2-methyi-5-HT. 
::tre agonist.~; and res 205-930 (in high concentrations). but 
not MDL 72222. granisetron or ondansetron. acts as an· 
antagonist (Dumuis cl a!~ 1988; 1989; Clarke ct a/., 1989). The 
pharm::tcological characteristics of thi.~ receptor. though 
exhibiting several similarities, differ in some important 
respects. For example. 5-carl:>ox::unidOtryptamine. apparently 
because of its low affinity. does not show activity in the pig 
heart (Dunckcr cl a/ .• 1985; Born et al .• 19&8) in doses which 
are highly active in the cat heart (Saxen::t ct a/~ J9g5; Connor 
el a/., !986). Secondly, o:-methyl-5-HT. which has little activity 
on the neuroncs from mouse embryo eolliculi (Oumuis ct a/~ 
198&; 1989), is highly active in our experiments. Thirdly. 
the agonist potency order reported by Dumuis ct a/. {19&9) 
using mouse embryo collieu1i (cis::tpride > rcn7.apride > 
zaeopride > 5-HT > metoclopramide). differs from that 
found in the pig heart (5-HT > 5-methoxytryptamine > a-
methyi-5-HT > zacopridc ;. renzapride > cisapride > 
metodopramide > dazopride; indorenate and sumatriptan. 
inactive at 1 and 3mgkg- 1) (VillalOn ct al .• 1990: 1991; 
present results). Lastly, the ben7.amide derivatives cisapride 
and renzapride. which are full agonists at the mouse brain 
receptor. behaved as partial agonists at the pig heart receptor. 
Severa! possible explanations for these differences in agonist 
potencies may include: use of'second mes.~enger' (cyclic AMP) 
and functional (tachycardia) responses; tiswe-dcpcndent 
factors such as the number of receptors and coupling effi-
ciency; and/or drug-deycndent factors such as the affinity of 
5-HT and related agonists for each of these novel receptors. 
The 5-HT4 receptor may ::tl'>O mediate the 5-HT-induced 
enhancement of cholinctgic activity iil the guinea-pig isolated 
ileum (Sanger, 1987; Craig & Clarke. 1990) and ascending 
colon {Eiswood et al~ !990). as well as relaxation or the rat 
oesophagus (Ba.xter & Clarke, 1990). A.~ in the present experi-
ments, the tryptamine derivatives 5-methoxytrypt:unine. O:· 
methyi-5-HT and some benz.a.mides mimic. and JCS 205-930 
antagonizes 5-HT at the 5-HT .. receptor in the guinea-pig gas-
trointestinal tract (Craig & Clarke. !990: Elswood ct a/., 1990) 
::tnd the rat oesophagus (Baxter & C!::trke. 1990). Moreover. 
the order of potency at the cholinergic neurones in the guinea-
pig ileum (5-HT > 5-mcthoxytryptamine > renzapride > a:-
methyl-5-HT > 7.aeopride """ cisapridc; Craig & Clarke. 1990) 
is practically identical to that found by us in the porcine heart. 
The 5-HT 4 receptor is also apparently involved in the ino-
tropic action of 5-HT. mediated via cyclic AMP increase in 
the human atri:1. The positive inotropic rc.<:J'(Inse to 5-l-IT is 
not modi(ied by ket:mserin. mcthysergide. lysergide. methio-
thepin. yohimbine (±)·propranol, (-)-pindolol or MDL 
72222. but is blocked by a high concentration (2JtM) of ICS 
205-930 (Kaumann cr a!., 1990). The pr~ise role of these 
receptors in cardiac function and cardiovascular p::tthologics 
remains to be determined. 
In summary. the present investiption demon.~trates that the 
tachycardie res-ponse to i.v. administered 5-HT in the anaes--
thetized pig can be mimicked 'oy the trypt::tmine derivatives 
5-methoxytryptaminc and o:-mcthyl-5-HT. and to a lesser 
extent by the parti::t! agonist benzamide derivatives (in order 
of potency) z::tcopridc. cisapridc. metoelopramide 'and da-zop-
84 
C.M. VILLAL6N et aL 
ride. High doses of ICS 205-930, but not ketanserin, gmn-
isetton or MDL 72222. acted a.~ an antagonist. These result~ 
rurther confirm the involvement of a putative 5-HT 4 recc:ptor 
in the J)O!';itive ehronotropic action of 5-HT in the anaes-
thetized pig. 
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1 It has recently been shown that the tachycardiac response to 5-Hf in the 
anaesthetized pig, being mimicked by tryptamine- (5-methoxytryptamine and 
a-methyl-5-Hf) and benzamide- (renzapride, cisapride, zacopride, metOclopramide and 
dazopride) derivatives, and blocked by high doses of ICS 205-930, is mediated by the 
putative 5-Hf, receptor. This study analyzes the inotropic effects of 5-Hf, 
5-methoxytryptamine and renzapride using the maximum rate of rise in left ventricular 
pressure (LV dP I dt_) in anaesthetized pigs during or in the absence of atrial pacing 
(150 beats min"'). 
2 In the absence of atrial pacing, intravenous bolus injections of 5-Hf and 
5-methoxytryptamine (both 3, 10 and 30 p.g kg·') caused dose-dependent increases in 
heart rate (24±3, 46±3 and 65±3 and 9±1, 27±3 and 40±1 beats min·', respectively), 
LVdP/dt= (484±117, 712±123 and 843±120 and 181±42. 367±58 and 560±95 
mmHg sec·'. respectively) and cardiac output (210±60, 360±70 and 310±100 and 
130±70, 150±80 and 260± 110 mJ min·'). The effects of renzapride (3, 10, 30, 100 and 
300 g kg·') were generally longer-lasting, but less marked (heart rate: 1±1, 2±1, 8±2, 
14±2 and 20±2 beats min·': LVdP/dt,~: 30±20, 80±51, 180±77, 307±93 and 530±152 
mmHg sec·'; and cardiac output: 20±20,40±20, 80±40, 130±100 and 200±80 mJ min"'). 
Renzapride behaved as a partial agonist, antagonizing the responses to both 5-HT and 
5-methoxytryptamine, but not those to isoprenaline. 
3 When the heart rate was kept constant by atrial pacing (150 beats min"'). both 5-Hf 
and 5-methoxytryptamine still increased LVdP/dt,. and cardiac output, but the effects 
were slightly less than in unpaced animals. Renzapride was devoid of any effect when 
dosed for a second rime during atrial pacing. probably because of tachyphylaxis. 
However, when given for the first time during atrial pacing, renzapride did increase 
LVdP/dt_ and cardiac output and behaved again as a partial agonist, attenuating the 
responses to both 5-Hf and 5-methoxytryptamine. 
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4 The present results are consistent with the contention that 5-HT, 
5-methoxytryptamine and renzapride increase LV dP I dt,. and cardiac output by a 
positive inotropic effect via an interaction with the putative 5-ffC receptor. 
Introduction 
5-Hydroxytryptamine (5-Hf) exerts profound effects on heart rate and cardiac 
contractile force in a variety of animal species including humans. Although the 
mechanisms and receptors involved in 5-HT-induced positive chronotropic effects in 
several species have been extensively reviewed (see Saxena & Villalon. 1990; 1991), the 
knowledge about the mechanisms involved in 5-HT -induced changes in cardiac 
contractile force is rather limited. For example, in molluscs (Venus merceuaria, ~ 
kw:ll!lJ!i, Helix a:;persa, etc.) 5-HT increases myocardial contractions with high potency 
(Greenberg, 1960) through receptors that seem to be positively coupled to the adenylate 
cyclase system (Sawada eta!., 1984), but which apparently do not resemble any of the 
previously described four categories for vertebrate 5-HT receptors (Cadogan & 
Humphrey, 1991). With respect to mammals, 5-HT elicits positive inotropic effects in 
the rabbit atria indirectly by releasing noradrenaline via stimulation of neuronal 5-HT3 
receptors (Trendelenburg, 1960; Fozard, 1984). 5-HT has also been reported to induce 
positive inotropic effects in human right atria via stimulation of a cyclic AMP-dependent 
protein kinase (Kaumann et a!., 1990a,b) by the putative 5-HT, receptor. 
Interestingly, in the cat heart, the receptors involved in 5-HT-induced positive 
inotropic effects on left atrium (sensitive to blockade by phenoxybenzantine and 
methysergide) and papillary muscle (right ventricle; resistant to blockade by 
phenoxybenzamine, methysergide, ketanserin or MDL 72272) do not display the same 
pharmacological profile (Kaumann. 1985; Kaumann et a/., 1990b ). This information 
coupled to the fact that the putative 5-HT, receptor mediates both positive inotropic 
effects in the piglet left atria (Kaumann eta!., 1991) and positive chronotropic effects 
in the anaesthetized pig (Duncker et a/., 1985; Born et a/., 1988; Villalon et a/., 1990; 
1991a) raise questions as to the nature of the mechanisms and receptors involved in 
5-HT-induced positive inotropic effects in the porcine myocardium. However, to our 
knowledge, the possible effects of 5-HT and related drugs on myocardial contractility 
in vivo have not yet been investigated and, as in the cat heart, the nature of the 
contractile 5-HT myocardial receptor in the pig remains elusive. Therefore. in the 
present study, we set out to investigate the haemodynamic actions of 5-HT in 
anaesthetized, open-chest pigs, and compare these to those of 5-methoxytryptamine. 
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renzapride and isoprenaline, paying particular attention to the maximum rate of rise in 
left ventricular pressure (LVdPidtm~), which can be considered as an index of 
myocardial contractility. A preliminary account of these results has been presented to 
the British Pharmacological Society (Villalon eta!., 1991b). 
Methods 
General 
After an overnight fast, young Yorkshire pigs (16-18 kg) were sedated with ketamine 
(20 mglkg, i.rr-). Subsequently, they received 150 mg metomidate via a dorsal ear vein. 
After intubation, the animals were connected to a respirator for intermittent positive 
pressure ventilation with a mixture of O, (33%) and N20 (67%). The anaesthesia was 
maintained with a continuous infusion of pentobarbitone sodium (15-20 mg kg·' h"', i.v.). 
All drugs were injected into the left jugular vein. The body temperature of the animals 
was maintained around 37•c by using an electric blanket and arterial blood gases and 
pH were kept within the normal limits (PO,> 90 mmHg; PC02 30-40 mmHg; pH 
7.35-7.45) by adjusting respiratory rate and tidal volume. A catheter was placed in the 
aortic arch via a femoral artery, connected to a Statham pressure transducer (!'?...3 De, 
Hato Rey, Puerto Rico) for the measurement of arterial blood pressure. Left ventricular 
pressure was measured with a microtipped catheter placed into the left ventricle via the 
left carotid artery (Honeywell-Phyllips, Best, the Netherlands). The catheters were 
flushed with heparin to prevent clorting. The ECG leads were monitored throughout 
the experiment in order to determine heart rate. 
After the heart had been exposed via the left third intercostal space, an 
electromagnetic flow probe (Skalar, Delft, the Netherlands) was placed around the 
ascending aorta. Finally, a pacing wire was fixed on the left atrium. 
Experimental protocol 
Once the surgical procedures were completed and the animals (n=8) had been in a 
stable haemodynamic condition for at least 45 min, baseline data were obtained at the 
animal's own sinus rhythm. These data consisted of: electrocardiogram, arterial blood 
pressure, left ventricular pressure (and its first derivative; LV dP I d~) and cardiac 
output (ascending aortic blood flow). 
After collection of these data, in 6 animals chosen at random, the effect of atrial 
pacing (120, 150 and 180 beats min·' for 3 min each) on LV dP I d~ and cardiac output 
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was determined before administration of any drug. These values of atrial pacing were 
selected on the basis of our previous findings concerning the dose-dependent 
tachycardiac responses induced by isoprenaline (Villalon et al., 1990). 
Once the atrial pacing was interrupted, a stabilization period of 15 minutes was 
allowed. The animals received intravenous bolus injections of 5-Hf (3, 10 and 30 
J.tg kg·'), 5-methoxytryptamine (3, 10 and 30 J.tg kg"') and isoprenaline (0.01, 0.03 and 0.10 
J.tg kg"'). Subsequently, a 3 m1 bolus of physiological saline was given, and the responses 
to the different doses of 5-Hf, 5-methoxytryptamine and isoprenaline were elicited 
again. After recovery of the haemodynamic baseline values, the heart rate was raised 
to 150 beats min"' by atrial pacing, and the responses to 5-HT, 5-methoxytryptarn.ine and 
isoprenaline were elicited after physiological saline following the same procedure, as 
described above. 
As of here, the animals were divided into 2 groups. In the first group (n=5), the 
atrial pacing was interrupted, and a 10 min interval was allowed for recovery at the 
animal's own sinus rhythm. Subsequently, intravenous bolus injections of renzapride (3, 
10, 30, 100 and 300 J.tg kg·', given cumulatively) were administered. Once the 
haemodynamic parameters returned to baseline values, the responses to the different 
doses of 5-Hf, 5-methoxytryptamine and isoprenaline were analyzed (for other 
specifications, see Results). In the second group (n=3), the above-mentioned doses of 
renzapride were given during atrial pacing, and after recovery of the haemodynamic 
parameters to baseline level, the responses to 5-Hf, 5-methoxytryptarn.ine and 
isoprenaline were elicited again. 
The interval between the different doses of the compounds used as agonists and/ or 
antagonists depended on the duration of tachycardia and/ or the increase in L VdP I dt_ 
produced by the preceding dose, as in each case we waited until such parameters had 
returned completely or nearly to the baseline values. The dose-intervals for the 
different drugs were as follows: tryptamine derivatives, berneen 5 and 15 min; 
renzapride usually between 15 and 30 min, but as its actions were longer-lasting, we 
decided to dose cumulatively between doses, and therefore, we will refer to the recovery 
period after the last dose, which was longer than 90 min). The doses mentioned in the 
text are cumulative for renzapride (given as 3, 7 and 20, 70 and 200 J.tg kg·'); and 
sequential for 5-Hf. 5-methoxytryptamine and isoprenaline. 
Drugs 
The drugs used in this study were: 5-hydroxytryptamine creatinine sulphate (Sigma 
Chemical Company. St. Lonis. MO. U.S.A.). 5-methoxytryptarn.ine hydrochloride 
(Janssen Chimica, Beerse, Belgium). renzapride hydrochloride (BRL 24924; gift: 
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Dr. GJ. Sanger, Beecham Pharmaceuticals, Harlow, Essex, England), isoprenaline 
sulphate (Pharmacy Department, Erasmus University, Rotterdam, The Netherlands) and 
heparin sodium (Thromboliquine, Organon TeknikaB.V., Boxtel, The Netherlands). All 
drugs were dissolved in physiological saline, which had no effect on the haemodynarnic 
parameters. The doses of 5-HT and 5-methoxytryptamine are mentioned in terms of the 
free base. 
Data presentation and analysis 
All data in the text, figures and tables are presented as mean± s.e.mean. The peak 
change in heart rate (in the absence of atrial pacing) and/or LVdP/dt,. and cardiac 
output induced by the different doses of 5-HT, 5-methoxytryptarnine, renzapride and 
isoprenaline were determined. The increases in heart rate, LV dP I dt,. and cardiac 
output just before and after a particular (partial) antagonist drug were compared by 
Duncan's new multiple range test, once an analysis of variance (randomized block 
design) revealed that the samples represented different populations (Saxena, 1985). The 
effects of agonist drugs in the different groups of animals were compared by using 
unpaired Student's t-test. A P value of 0.05 or less (two-tailed) was considered 
statistically significant. 
Results 
initial blood pressure and heart rate changes by 5-HT agonist drugs 
Baseline values of mean arterial blood pressure, heart rate, LV dP I dt,. and cardiac 
output in the 8 pigs were 81±4 mmHg, 103±3 beats min"\ 1692±83 mmHg sec·1 and 
2.0±0.3 I min"\ respectively. The changes induced in mean arterial blood pressure by 
each 5-HT agonist drug were: 5-HT (-17:<:1, -16:<:1 and -14:<:1 followed by +2:<:1 mmHg 
after 3, 10 and 30 pg kg·'. respectively; n=8): 5-methoxytryptarnine (-19:<: 1, -17:':2 and 
-14:<:2 followed by +2:<:1 mmHg after 3, 10 and 30 pg kg·', respectively; n=8), and 
renzapride ( + 1:<: 1, +3:<:2. + 7:<:3, + 10:<:3 and + 13:<:5 mmHg after 3, 10, 30, 100 and 
300 pg kg·'_ respectively; n=5). These effects were not evaluated fnrther. 
In the absence of atrial pacing.. intravenous bolus injections of either 5-HT, 
5-methoxytryptamine, renzapride or isoprenaline caused dose-dependent increases in 
cardiac output (see Table 1). LVdP/dt~ and heart rate (Figure 1) of diverse magnitude. 
Isoprenaline was much more potent than 5-HT, which was itself more potent than 
5-methoxytryptamine or renzapride. At the doses used, the duration of action of 
renzapride on LVdP/dt,~ (> 60 min at 300 pg kg-') was much longer than that of the 
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three doses of 5-methoxytryptamine (6.2:!:0.4, 103:!:0.6 and 14.8:!:0.7 min) or 5-Hr 
(2.4±0.2, 4.5±0.3 and 83±0.7 min). The duration of action of these drugs on cardiac 
output and heart rate was practically similar (data not shown). 
Table 1 Effect of renzapride (03 mg kg-') on the increases in cardiac out (ml min·') by 
5-Hr, 5-methoxytryptamine (5-MeO-T) and isoprenaline in pigs without or during 
atrial pacing (150 beats min·'). 
Agonist Dose Unpaced (n=S) Paced (n=3) 
(.ug kg'') 
Before After Before After 
renzapride renzapride 
5-Hf 3 210±60 90±40* 183±44 183±44 
10 360±70 110±80* 283±44 200±58 
30 310±100 80±80* 483±101 150±76* 
5-MeO-T 3 130:!:70 50±50* 167±44 67±33* 
10 150±80 50±50* 267±44 217±44 
30 260±110 100±60* 433± 109 153±29* 
Isoprenaline 0.01 360±120 310±70 357:t54 300:!:50 
0.03 700±150 610±100 550±153 500±104 
0.1 860±110 1000±110 952±198 933±233 
*, P < 0.05, after vs before. 
Modification of 5-HT- and 5-methoxytryptamine-induced im:reases in LVdP/dtm,• 
cardiac output and heart rate by physiological saline or renzapride in the absence of atrial 
pacing 
At the animal's own heart rate. intravenous administration of either 5-HT. 
5-methoxytryptamine or isoprenaline elicited dose-dependent increases in heart rate (see 
Figure 1 and Table 2). These responses remained essentially unchanged in control 
animals after receiving physiological saline, as previously reported (Villalon et al., 1990). 
X 
"' 
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Similarly, 5-HT-, 5-methoxytryptamine- and isoprenaline-induced increases in both 
LVdP/dt_ and cardiac output remained unaltered after the administration of 
physiological saline (Figure 2; see Table 1 for cardiac output). In marked contrast, the 
increases in heart rate, LVdP/dt_ and cardiac output induced by 3, 10, 30, 100 and 300 
p,g kg·1 of renzapride under baseline conditions (l:tl, 2:!::1, 8±2, 14:t2 and 20±2 
beats min·'; 30±20, 80±51, 180±77, 307±93 and 530±152 mmHg sec·'; and 20±20, 
40±20, 80±40, 130±100 and 200±80 m1 min·', respectively; n=5) disappeared when 
given again after administration of physiological saline (0±0, 0±0, 0±0, 0±0 and 0±0 
for heart rate, LV dP I dt_ and cardiac output, respectively; n = 5). 
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Figure L The effects of 5-HT, 5-methoxytryptamine (5-MeO-T), renzapride and 
isopre!laline in the anaesthetized pig (n=5) on heart rate (HR; beats min'') and 
LVdP/dt.~ (mmHg sec·') in the absence of atrial pacing. 
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Notwithstanding, renzapride (300 pg kg·') did potently antagonize both 5-HT- and 
5-methoxytryptanrine-induced increases in heart rate (fable 2), LVdP/dt, (Figure 2) 
and cardiac output (Table 1), but not isoprenaline-induced increases in heart rate (Table 
2), LVdP/dt_ (Figure 2) or cardiac output (Table 1). 
It may be noted that unlike renzapride, in the saline-treated animals where 5-HT 
was administered before and after the last set of injections of 5-methoxytryptanrine 
(n =5; see description of experimental protocol), the increases in L VdP I dt, induced by 
3, 10 and 30 pg kg·' of 5-HT (484:t 117, 712:t 123 and 843:t 120 mmHg sec·', respectively; 
n=5) remained unaltered after 5-methoxytryptanrine (460:t142, 715:t161 and 897:t154 
mmHg sec·', respectively; n =5). Similarly, the increases in both cardiac output and heart 
rate induced by 5-HT were not modified after 5-methoxytryptanrine (not shown, but see 
baseline data in Tables 1 and 2, respectively). 
Table 2 Effect of renzapride (0.3 mg kg"') on the increases in heart rate (beats min·') 
by 5-HT, 5-methoxytryptanrine (5-MeO-T) and isoprenaline (ISO) in pigs without 
atrial pacing. 
Agonist 3 pg kg·' 10 ,.,.g kg"' 30 f.'g kg·' 
Before After Before After Before After 
renzapride renzapride renzapride 
5-HT 24::!::3 5±2* 46±3 16::!::3* 65±3 29±3* 
5-MeO-T 9:t1 5±2* 27:t3 12::!::2* 40:t 1 23::!:: 1* 
ISO' ll:t6 5:t4 23::!::9 l7:t7 45:t9 34± 11 
' The doses of isoprenaline were 0.01. 0.03 and 0.1 pg kg·'. • P < 0.05. after 
renzapride vs before renzapride. 
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Figure 2. The effects of salioe (n=5) or renzapride (300 fig kg"'; n=5) on the increases 
in LVdP/dt_ (mm sec·') induced by 5-HT, 5-rnethoxytryptamine (5-MeO-T) and 
isoprenaline in the absence of atrial pacing. *. Significantly different from the 
corresponding control response to the agonist drug (P < 0.05). 
Effect of the increase in heart rate by electrical stimulation of the atrium (atrial pacing) 
at different rates on myocardial contractility (LV dP I dt~ and cardiac output 
Since the increase in heart rate by the above drugs can have a direct influence on the 
increase in LV dP I dt..n..x_, we decided to investigate the effect of increasing heart rate by 
electrical stimulation of the atrium at different rates (120, 150 and 180 beats min·') on 
LV dP I dt_ and cardiac output. As shown in Figure 3, the selected rates of atrial pacing 
exerted ouly a weak effect on LVdP/dt_ and cardiac output, which was not dependent 
on the rate of stimulation. Furthermore, it is important to highlight that atrial pacing 
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at 180 beats min"' was not tolerated by the animals when maintained for more than 5 
min, since intense tremor was observed. Ibis finding coupled to the fact that the 
absolute values of increase in heart rate induced by the different agonist drugs were not 
higher than 150 beats min·' (see Table 2), led us to select the atrial pacing rate of 150 
beats min·' in orderto investigate the effects of agonist drugs on LVdP/dt,. and cardiac 
output. 
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Figure 3. Effect of atrial pacing on LVdP/dt,. and cardiac output (CO). B. Baseline 
heart rate (100:t3 beats.min"'): *. P < 0.05 vs baseline value. 
97 
Modification of 5-HT- and 5-methoxytryptamine-induced increases in LVdP/dt'!!O£ by 
physiological saline or renzapride during atrial pacing 
During atrial pacing to a frequency of 150 beats mm·', intravenous bolus injections of 
5-HT, 5-methoxytryptamine, renzapride and isoprenaline were also able to induce 
dose-dependent increases in cardiac output (Table 1) and LVdP/dt,. (Figure 4). As 
shown in Figure 4, there was an apparent attenuation of these responses when compared 
with those previously induced in the absence of atrial pacing (Villalon et al., 199lb ). 
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Fwthermore, the increases in LVdP/dt,., induced by 5-Hf, 5-methoxynyptamine and 
isoprenaline during atrial pacing remained essentially unchanged after administration of 
physiological saline (Figure 5; n=3). In marked contrast, renzapride-induced increases 
inLVdP/dt,., (20±20, 70±20, 125±25, 200±50 and 165±115 mmHg min"') and cardiac 
output (0±0, 20±20, 40±40, 100±0, 100±50 ml min·') disappeared when given after 
administration of physiological saline (0±0, 0±0, 0±0, 0±0 and 0±0 for both 
LVdP/dt,., and cardiac output; n=2). Interestingly, renzapride (300 l"g kg"') slightly 
blunted the increases in LV dP I dt_ induced by either 5-Hf or 5-methoxytryptamine, but 
not those by isoprenaline (Figure 5). 
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Figure 5. The effects of saline (n=5) or renzspride (300 Jl£ kg"'; n=3)) on the 
increases in LVdP/dtm~ (mm Hg sec·') induced by 5-Hf. 5-methoxytryptamine 
(5-MeO-T) and isoprenaline during atrial pacing (150 beats min"'). 
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It is prudent to note that, in contrast to the ability of renzapride to elicit increases in 
heart rate, LVdP/dt.,.. and cardiac output at the animal's own heart rate (see Figure 1 
and the above data), the responses to the benzamide virtually disappeared when given 
again during atrial pacing (0:!:0, 0:!:0, 0:!:0, 0:!:0 and 0:!:0 for heart rate, cardiac output 
and LVdP/dt_ after 3, 10, 30, 100 and 300 fl-8 kg"' of renzapride, respectively; n=5). 
For this reason, the effects of renzapride during atrial pacing were analyzed separately 
in control animals at their own sinus rhythm and in animals during atrial pacing. Under 
the latter experimental circumstances, renzapride did induce dose-dependent increases 
in LVdP/dt,~ {see Figure 4). The rank order of potency .was 5-HT > 
5-methoxytryptanrine > renzapride, as previously described in the absence of atrial 
pacing. 
Lastly, the possible attenuation of the responses to 5-HT by 5-methoxytryptamine 
was investigated. 1n the saline-treated animals where 5-HT was administered before and 
after the last set of injections of 5-rnethoxytryptanrine {see description of experimental 
protocol), the increases in LVdP/dt_ induced by 3, 10 and 30 J.tg kg"' of 5-HT (233:!:86, 
511:!:80 and 631:!:84 mm.Hg sec·', respectively; n=3) remained unaltered after 
5-methoxytryptanrine (325:!: 80, 492:!: 126 and 603:!: 136 mm.Hg sec·', respectively; n=3), 
indicating that 5-methoxytryptamine does not behave as a partial agonist. 
Discussion 
The putative 5-HT, receptor is involved in 5-HT-induced positive chronotropic effects 
in the anaesthetized pig (Duncker et aL, 1985; Born et aL, 1988; Villalon et al., 1990, 
1991a) and in 5-HT-induced positive inotropic effects in human right atria, via 
stimulation of the adenylate cyclase system (Kaumann et al., 1990a,b,d). The putative 
5-HT, receptor also mediates positive inotropic effects in the piglet left atrium 
(Kaumann et al., 1991), but it is still unknown whether 5-HT is able to increase 
myocardial contractility in vivo in the pig. The present investigation in anaesthetized 
pigs clearly demonstrates that 5-HT, 5-methoxytryptanrine and renzapride increased 
LVdP/dt_ and that renzapride also antagonized the responses to 5-HT and 
5-methoxytryptamine. Thus, the ventricular 5-HT receptors in the pig seem to have a 
pharmacological profile resembling that of the putative 5-HT, receptor present on the 
porcine cardiac pacemaker (Duncker et al., 1985; Born et al., 1988; Villalon et al., 1990; 
1991a), human right atrium (Kaumann et al., 1990a,b,d), piglet left atrium (Kaumann et 
a/., 1991) and guinea-pig enteric neurons (Craig & Clarke, 1990). 
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interpretation of the increases induced in LVdP/dtm~ and cardiac output by 5-HT, 
5-methorytryptamine and renzapride 
In pentobarbital anaesthetized, open-chest pigs, intravenous bolus injections of 5-HT, 
5-methoxytryptamine and renzapride elicited dose-dependent increases in heart rate (as 
previously reported; Villalon et al., 1990, 1991a), together with dose-dependent increases 
in LVdP/dt_ and cardiac output in the absence of atrial pacing (Figures 1 and 2; Table 
1); the increases in cardiac output induced by the above agonist drugs were due to both 
positive chronotropic and positive inotropic effects. Since these drugs also induced 
dose-dependent increases in LVdP/dt_ and cardiac output even when the heart rate 
was fixed at 150 beats min"' by atrial pacing (see Figures 4 and 5 and Table 1), it could 
be suggested that the effects of these drugs on LV dP I dt_ were due to their positive 
inotropic effects. Indeed, this contention is further supported by the fact that electrical 
pacing of the heart rate (atrial pacing) at 120, 150 and 180 beats min·' did not elicit 
similar increases in LVdP/dt_ and cardiac output (see Figure 3). The rank order of 
potency for the increase in myocardial contractility was: 5-HT > 5-methoxytryptamine 
> renzapride (either in the absence or during atrial pacing). 
Partial agonist action of renzapride 
In contrast to 5-HT and 5-methoxytryptamine, the increases in LVdP/dt_ and cardiac 
output induced by renzapride (both in the absence and during atrial pacing} were less 
marked, but longer-lasting, and not strictly dose-dependent. In addition, renzapride 
antagonized the effects of 5-HT and 5-methoxytryptamine (either in the absence or 
during atrial pacing). This antagonism was apparently not due to a 'masking' of the 
effect as a result of the renzapride-induced increase in LVdP/dt_ as 5-HT and 
5-methoxytryptamine had been administered at the time when the inotropic effect of 
renzapride had worn off. Therefore, as previously found with several benzamide 
derivatives, including renzapride, with regard to the tachycardiac action of 5-HT and 
5-methoxytryptamine in the pig (Villalon et al., 1990; 199la), renzapride also behaved 
as a partial agonist at the porcine 5-HT receptor mediating the positive inotropic action. 
It should be noted that in w.,e absence of atrial paci...ng isoprenaline-induced increases in 
heart rate and contractility were little affected by 300 1'£ kg·' of renzapride. 
Resemblance of the porcine myocardial 5-HT receptor to other putative 5-HT~ receptors 
At the 5-HT4 receptor identified in the neurones from mouse embryo colliculi on the 
basis of the increase in cAMP. the tryptamine derivatives 5-methoxytryptamine, 
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5-carboxamidotryptamine (low affinity) and certain benzamide derivatives (renzapride, 
metoclopramide, cisapride), but not a-methyl-5-HT or 2-methyl-5-HT, are agonists; and 
ICS 205-930 (in high concentrations), but not MDL 72222, granisetron or ondansetron, 
acts as an antagonist (Dumnis et al., 1988; 1989; Clarke et al., 1989). These 
pharmacological characteristics exhibit several similarities with those of other 5-HT, 
receptors. However, the rank order of potency for tryptamine- and benzamide 
derivatives reported by Dumuis et al. (1989) using mouse embryo colliculi neurons 
(cisapride > renzapride > zacopride > 5-HT > metoclopramide), differs from that 
found at the porcine cardiac pacemaker either in vivo (5-HT > 5-methoxytryptamine > 
a-methyl-5-HT > renzapride ;, zacopride > cisapride > metoclopramide > dazopride; 
indorenate and sumatriptan, both inactive at 1 and 3 mg kg·' (Villalon et al., 1990; 
1991a) or in vitro (5-HT > renzapride > cisapride > 5-Cf; Kaumann, 1990c); piglet left 
atrium (5-HT > renzapride; Kaumann et al., 1991); human right atrium (5-HT > 
renzapride; Kaumann et al., 1990d); and cholinergic neurons of guinea-pig ileum (5-HT 
> 5-methoxytryptamine > renzapride > a-methyi-5-HT > zacopride = cisapride; Craig 
& Clark. 1990). Several possible explanations for these differences in agonist potencies 
may include: use of "second messenger" (cAMP) and functional (positive chronotropic 
and/ or inotropic) responses; tissue-dependent factors such as the number of receptors 
and coupling efficiency; and/ or drug-dependent factors such as the affinity of 5-HT and 
related agonists for each of these novel receptors. The 5-HT, receptor may also mediate 
the 5-HT-induced relaxation of the rat oesophagus (Baxter & Clarke, 1990) and 
enhancement of cholinergic activity in guinea-pig ascending colon (Elswood et al., 1991); 
in these tissues, the tryptamine derivatives 5-methoxytryptamine, a-methyl-5-HT and 
some benzamides minllc, and ICS 205-930 acts as an antagonist. 
In the present experiments the positive inotropic effects of 5-HT were minllcked by 
5-methoxytryptamine and renzapride (potency order: 5-HT > 5-methoxytryptamine > 
renzapride ), and renzapride selectively antagonized the responses to 5-HT and 
5-methoxytryptamine without affecting the responses to isoprenaline. Furthermore, 
tachyphylaxis was observed with the inotropic effects of renzapride both in the absence 
and during atrial pacing. In this connection, a similar fading pattern with renzapride has 
been reponed earlier with renzapride-induced increases in cyclic AMP in mouse embryo 
colliculi neurons (Dumuis et a!., 1989) and heart rate in the pig (Villalon et al., 1990, 
199la). These findings suggest that the porcine 5-HT receptor mediating cardiotonic 
responses also belongs to the putative 5-HT4 receptor category. 
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Constriction of porcine arteriovenous anastomoses by indorenate is unrelated 
to 5-HT1A, 5-HT18, 5-HT1c or 5-HTm receptor subtypes 1 
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The: study concerns the effects of indorcnatc., a tryptamine derivative w!th antihypertensive properties as wdl as 
high affinity for the 5~HT1A binding site. on carotid haemodyn:1mics in an:1esthetizcd pigs. Intra~rotid infusions of 
indorenate (0.3, 1.0, 3.0 and !0.0 p.g· kg- 1 • min- 1 for 10 min each) ca.used dose-related dccrC:lses in total common 
carotid artery blood now due almost exclusively to a reduction in arteriovenous 3nastomotic now. These effects of 
indorenate were not appreciably modified after tre:Jtment with the 5-HT~ receptor antagonist k<:tanscrin (0.5 mg ·kg- 1 
i.a.), but were markedly reduced after treatment with methiothepin (1.0 mg-kg- 1 i.a.). which antagonizes not only 
5-HTz receptors. but also the putative S~HT1A, 5-HTm 5-HT1c and 5-HT10 subtypes or 5~HT1~like receptors.. 
Nonetheles.-.. metergoline (1 mg ·kg- 1 i.a.). a drug with higher nffinity than methiothepin for the above 5~HT1 receptor 
subtypes. failed to significantly modify the responses to indorenate. It is therefore concluded that. like 8~hydrox:y-2-
(di-n-propylamino)tetralin (8~0H-DPA T) and 5~methox:y~3~(1,2,3,6~tetrahydr<r4-pyridiny1)~ 1 H-indole (RU 24969), 
indorenate reduces both total common carotid and cephalic nrteriovcnous anastomotic blood now in the pig by 
stimulating 5~HT1~!ikc receptors: these receptors. however. do not seem to cmrcs)"'l-Ond to either 5-HT1", 5~HT11~. 
5-HT1c or 5~HT10 binding sites. 
Arteriovenous anastomoses: Blood now (carotid): 5-HT (5-hydroxytryptnminc. serotonin); 5-HTclike receptors: 
lndorenate; Migraine 
1. Introduction 
It has been demonstrated that intracarotid in-
fusion of 5-hydroxytryptamine (5-HT) into anaes~ 
thetized pigs decreases common carotid blood now 
1 Partially ~pported by a grant from Gla;>;o Group Research, 
Ware. England. 
::: Supported by a Science and Technology fellow:;hip from the 
EEC. 
Correspondence to: P.R. Sa;>;ena. Department of Ph;mnacol-
ogy. Faculty or Medicine and Health Sciences, Erasmus Uni-
versity Rotterdam, P.O. Box 1738, 3000 DR Rotterdam. The 
Netherlands. 
by reducing arteriovenous anastomotic (non~nutri­
ent now, whereas arlcriolar flow to the head tis~ 
sues. mainly to the skin and ears, is increased 
(Saxena and Verdouw, 1982). These effects of 
5-HT are mimicked by the 5-HT1-like receptor 
agonist 5~carboxamidotryptamine (Saxena and 
Verdouw. 19&5) and ::mtagonized by mcthiothepin 
(Saxena et al.. 1986). which blocks both 5-HT1-like 
and 5-HT2 receptors. but are not appreciably 
antagonized by the 5-HT2 receptor antagonist 
ketanserin (Verdouw et a!.. 1984) or the 5-HT, 
receptor antagonist laH,3o:.5o:H-tropan-3yl~3.5-
dichlorobenzoate (MDL 72222) (Saxena et al.. 
1986). Thcrefore, according to the classification 
0014-2999/90/$03.50"' 1990 Elsevier Science Publi~h=- B.V. (Biomedical Divi~ion) 
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proposed by Bradley et al. (1986). the constriction 
of arteriovenous anastomoses as well as the dilata~ 
tion of arterioles are mediated by 5-HT1-like re-
ceptors (Saxena et al.. 1986). However, the 5-HT1-
like receptors in the carotid circulation of the pig 
seem to belong to two different categories since, 
unlike 5-HT (Saxena and Verdouw. 1982) or 5-
carboxamidotryptamine (Saxena and Verdouw. 
1985). the reduction in arteriovenous ana..<:tomotic 
blood flow induced by methyscrgide (Saxena and 
Verdouw 1984). the put.1.tive 5-HT1A receptor 
agonists 8-hydroxy-2-( di-n-propylamino )tctrali n 
(8-0H-DPA'I) (Born et al., 1989a) and N-(3-
acetylaminophenyl) piperazine hydrochloride 
(BEA 1654) (Verdouw et al., 1985). and the puta-
tive 5-HT1A and 5-HT18 receptor agonist 5-
methoxy-3-(1.2.3,6-tetrahydro-4-pytidi nyl)--1 H -in-
dole (RU 24969) (Born et al., 1989b) is not or only 
slightly accompanied by increases in the arteriolar 
blood flow. Furthennore. despite the effectiveness 
of 8-0H-DPAT. BEA 1654 and RU 24969. the 
5-HT1-like receptor mediating arteriovenous 
an.:J.Stomotic constriction does not appear to be 
related to either 5-HT1A or 5-HT16 binding sites 
because, as we reported recently (Born et al.. 
1989b). the effects of RU 24969 are not antago-
nized by the putative 5-HT1A and 5-HTw receptor 
antagonist. ( ± )-pindolol (Jloycr et al.. 1985; 
Hoyer. 1988). In this investigation. we have studied 
the possible involvement of 5-HT;A. 5-HT!l,. 5-
HT1c andjor 5-HT10 receptors in the distribution 
of common carotid artery blood flow in the pig by 
using indorenate. a tryptamine derivative with an-
tihypertensive properties (Hong eta!.. 1978: Hong. 
1981) and high :tffinity for the 5-HT1A binding site 
(Dompert et at.' 1985: Hoyer et a!.. 1985). 
Ketanserin. methiothepin and metergoline were 
used as potential antagonists. Preliminary results 
of this inv€:stigation have been communicated to 
the British Pharmacological Society (VillalOn ct 
al.. 1990). 
2. Materials and methods 
2.1. General 
After an overnight fast. young Yorkshire pigs 
(body weight: 18-22 kg; n = 24) were sedated with 
120 mg (i.m.) azaperone ::md 120-150 mg (i.v.) 
metomidate. intubated and connected to a respira-
tor for intermittent positive pressure ventilation 
with a mixture (1 : 2) of oxygen and nitrous oxide. 
A continuous i.v. infusion of pentobarbitone 
sodium (20-26 mg · kg- 1 • h-I) completed the 
anaesthesia. Respiratory rate and tidal volume 
were adjusted to keep arterial blood gases and pH 
within normal limits (pH. 7.35-7.45; p02• 90-150 
mm Hg: pC02 • 35-45 mm Hg). Aortic blood pres-
sure was recorded with a Statham pressure trans-
ducer (P23 ID) connected to a cannula inserted 
via the right femoral artery. The common carotid 
arteries were dissected free and the cervical vago-
sympathctic trunks were cut to reduce reflex in-
fluences on the carotid circulation. Blood flow in 
one of the common carotid arteries w.:J.S measured 
with a calibrated flow probe (internal diameter: 
2.5 or 3 mm) connected to a sine-wave electromag-
netic blood flow meter (Transflow 601-system. 
Skabr. Delft. The Ncthcrlonds). After ilS hub had 
been removed. a 0.5 mm (external diameter) 
needle. connected to a suitable polyethylene tub-
ing. was in~erted "into this common carotid artery 
for the administration of microspheres and drugs. 
The body temperature of the animals was kept 
around 37°C with an electric blanket. 
2.2. Di.~trihution of common carotid blood flow 
The distribution of common carotid blood flow 
was determined with the radioactive nticrosphere 
method using 15 ± 1 (s.d.) p.m diameter micro-
spheres labelled with either 141 Ce. 1 \JSn. 103 Ru. 
Q~Nb or 4t-Sc (NEN Company. Dreieich. Federal 
Republic of Germany). For each measurement. a 
suspension of 100 000-150 000 microspheres. 
labelled with one of the nuclides. was mechani-
cally agitated and injected against the "direction of 
the carotid blood flow to fncilitate uniform mixing 
with the blood. At the ~nd of the experiment the 
animal was killed and the heart. kidneys. lungs 
and the various tissues of the hc..'l.d were dissected 
out. weighed and placed in vials. The radioactivity 
in these vials was counted for 5-10 min in a 
gamma-scintillation counter (Packard. Minaxi Au-
togamma 5000) with suitable windows to detect 
the different isotopes. The amount of carotid blood 
now distributed to the individual tissues (QH""'i) 
was calculated as described earlier (Saxena et al.. 
1980: Saxen:J. and Verdouw. 1982) by: Ou,lwl (m! 
·min- 1) =(I ,,/I'"') X Q1,.,1. where I'" ;~nd I'"' 
nrc the radioa.ctivity (c.p.m.) in a particular tissue 
and that detected in all ti~~uc.-.,, rc~pcctivdy. ~md 
Q 1 c~•l is carotid blood flow (ml ·min - 1 ). Because 
microspheres passing through the cephalic 
arteriovenous anastomoses in the capilbries of the 
lungs are trapped completely. the values de~ 
termined for the lungs provide an index of the 
amount of the common carotid arterial blood flow 
that passed through the arteriovenous anastomo~ 
ses (see Johnston and Saxena. 1978: Saxena et aL. 
1980: Saxena and Verdouw. 1982). 
2.3. Experimental protocol 
In all experiments baseline values of heart rate. 
blood pressure and carotid blood flow were ob~ 
tained after the animal had been stabk for at least 
45 min after completion of the surgical procedure. 
l11e animals were then divided into four groups 
(n = 6 each): untreated control group and groups 
treated with either ketanserin (0.05 mg- kg- 1 • 
min- 1 ). methiothepin {0.1 mg-kg- 1 -min- 1 ) or 
metergoline (0.1 mg- kg - 1 - min- 1• administered 
into the carotid artery at a rate of 1.0 ml- min 1 
during a period of 10 min (total dose: 0.5. 1.0 and 
1.0 mg- kg~ 1 i.:J. .• respectively). Drug administra~ 
tion was fo!lowed by a 10 min period of in~ 
traearotEd infusion of physiological saline. After 
the mco.surement of hco.rt rate. blood pressure and 
carotid blood now and its distribution, all animals 
received const.-cutivc 10 min intracarotid infusions 
of indorenate (0.3, 1.0, 3.o and 10.0 p.g·kg··l. 
min- 1 at the rate of hO ml·min- 1 ) with an 
interval of about 5 min. The haemodynamic mea~ 
surements were repco.ted at the end of co.ch infu~ 
sion period. 
2.4. Data presentation and stati.~tical ct>aluation 
Except where stated otherwise. all data in the 
text and il!us.trations are presented :J.s means± 
S.E.M. The significance of the differences between 
the variables at baseline and after indoren:J.te infu~ 
sions was evaluated by Duncan's new multiple-
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range test once an analysis of variance (rando-
mized block design) had reve..1.lcd that the samples 
represented different populations (Steel and Tor~ 
ric. 19S0). The percent changes by indorenate in 
the antagonist~tre:J.tcd groups were compared with 
th<lse in the untreated control group using Stu~ 
dent's t~tesL Statistical significance was accepted 
at P < 0.05 (two-tailed). 
2.5. Drugs 
Apart from the anaesthetics, the drugs used in 
this study were: indorenate (5~methoxytryp~ 
tamine-,B~methylcarboxylate hydrochloride or 
TR3369 (a gift from Prof. E. Hong. CINVESTAV-
LP.N .• Mexico City. Mexico). ketanserin tartrate 
(a gift from Dr. J.M. Van Nueten. Janssen Phar-
maceutica. Becrse. Belgium), methiothcpi~ maleate 
(a gift from Hoffman La Roche B.V .. Mijdrecht. 
The Netherlands} and metergo!ine base (courtesy 
of Farmitalia Carlo Erba, Torino. Italy). In~ 
dorcnate was Jissolved in physiological saline. 
Kctonserin. methiothepin and metergoline were 
dissolved in distilled water to which 5% propylene 
glycol (ketanserin and methiothepin) or 1% · 
ascorbic acid .(metergoline) was .added. The 
vehicles had no effect on heart rate. blood pres-
~ure or c;m1tid blooJ flow. The doses of in-
don::natc. ketanscrin and methioth'-:pin :trc men~ 
tioncd in terms of the s.alt. 
3. Results 
3.1. S.vstemic haemodynamics 
The values for heart rate. mean arterial blood 
pressure aP.J carotid artery blood now before and 
after the infusion of either ketanserin, methiothe~ 
pin or metergolinc are shown in table L Both 
mean arterial 1->!ood pres~ure and heart rate de-
crt.:ascd after intracarotid infusion of ketanserin 
(0.5 mg ·kg·· 1 ). whereas these variables remained 
unch:mged ·after infusion of methiothepin or 
met<.:rgolinc (each 1.0 mg- kg- 1 ). There was some 
increase in the common carotid blood now after 
the three ant:Jgonists. but the ch:J.nge in each case 
was small and/or short~lasting. 
110 
TABLE l 
Mean arterial blood prC$..._ure. heru-t rate and carotid blood flow 
before and after ketanserin (total dose: 0.:5 mg· kg- 1; n - 6). 
metbiothepin {total dose:: 1.0 mg· kg- 1; n - 6) o~ metergo!ine 
(total dose: 1.0 rng·kg- 1: n -6). Ketanserin, methiothepin 
ar.d metergollne were infused into the carotid artery at a rate: 
of 1 rnl·min- 1 for 10 min. Abbrevi:l.tions and units: MAP, 
mean arterial blood pre<>."ure (mm Hg); HR. heart rate (he:lts· 
min-'): CBF. carotid blood flow (ml·rnin- 1) measured by 
electromagnetic now probe. 
MAP 
HR 
CBF 
Antagonist 
treatment 
None: 
Kc:tanserin 
Methiothepin 
Metc:rgoline 
None 
Ket.a.'lserin 
Methlothepin 
Metergoline 
None: 
Ketanserin 
Metbiothepin 
Metergoline 
Baseline 
value: 
92± 6 
100± 6 
90±11 
91 ± 10 
101± 6 
107± 6 
85± 8 
86± 6 
127±13 
118± 11 
93± 15 
159±20 
lmmedi:llcly 
after 
antagonist 
92± 6 
90± 6 a 
83±10 
87± 9 
101:!: 6 
IOH 6. 
82± s 
80± 6 
127±13 
128± 7 
102± 14. 
176±23. 
10 min after 
antagonist 
96± 7 
86± 5. 
83± 11 
89± 7 
102± 6 
98± 6" 
S2± 3 
83± 4 
128±13 
134± 9 a 
98± 13 
162±20 
a Significantly diUerent (P < 0.05) from the baseline value. 
Mean arterial blood pressure and heart rate 
recorded during the intracarotid infusions of in-
dorenate are summarized in table 2. Only a small 
decrease in mean arterial blood pressure was ob-
TABLE 2 
served with indorenatc in metergoline-treatcd 
animals. Heart rate decreased during the in-
tracarotid infusion of increasing doses of in-
dorenate in all four groups. 
3.2. Caro!id haemodynamics 
3.2.1. Distribution between arteriovenous anasto-
motic and arteriolar flow 
The effects of intracarotid infusions of in-
dorenate on the total common carotid blood flow 
and its distribution between arteriovenous 
anastomotic {non-nutrient) and arteriolar (nutri-
ent) flow are shown in fig. 1. A large fraction of 
the total carotid blood flow was diverted through 
cephalic arteriovenous anastomoses in the un-
treated as well as in the ketanserin-, methiothepin-
or metergolinc-treated animals before infusion of 
indorenate. In the untreated animals. indorenate 
induced a dose-dependent decrease in total com-
mon carotid blood Oow. This effect was directly 
related to the decrease in arteriovenous anasto-
motic blood now. since arteriolar blood now re-
mained practically unchanged at all doses tested 
(no change in the skin colour was observed). The 
effects of indorenate on total common carotid and 
arteriovenous anastomotic blood flow appeared to 
have been slightly attenuated in the ketanserin-
treatcd anima!:> (tota! dose: 0.5 mg · kg- 1 ) and. at 
the highest dose of indorcnate. a small increase in 
Effect of intrac:uotid infusions of indoremne on mean arterial blood pressure and heart rate in untreated control unimals and in 
animals tre:l.ted with ket:mserin (0.5 mg·kg- 1; n- 6). methiothepin (1.0 mg·kg- 1; n- 6) or metergoline (1.0 mg·kg- 1; n -6). 
Indon:n::~te was infused in 10 min periods at a rote of 1.0 ml·min- 1. Abbreviations and unit!>: MAP. mean urteriul blood pressure 
(mm Hg); HR. he:l.rt rute (beats·min- 1). 
Ant:lgoni$1 Ba.<i<:line lndorenate {JLg·kg- 1·min- 1) 
tre:l.tment value . 0.3 1.0 3.0 10.0 
MAP None 96± 7 92± 4 88±4 90±5 92±5 
Ketanserin 86± 5 86± 4 84±3 86±:> 88±3 
Methiothepin 83±11 84±10 83±8 78±7 n±s 
Metergo!ine 89± 7 83± 6 79±6 ~ 77±6h 75±6 ~ 
HR None 102± 6 97± 6" 94±6 h 90±6 b 87±5 b 
Kel:lllserin 98± 6 96± 6 94±6 91 ±6 b 90±6 b 
Methiothepin 82± 8 SO± 7 77±6 b 75±6 b 72±6 b 
Metergoline 83• 4 79± 5 79±6 77±6 h 74±6 h 
• After ant:lgonist tre:ltment; b Significantly different (P < 0.0$) from the bao;eline value. 
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Fig. L Effect~ 0f intracarotid infusion.~ of inJnrcnate (0.). 1.0. 
3.0 and 10.0 p.g· kg -I. min- 1) on t0la1 ~·:;~rotid hk>('ld fl<>w ;md 
it:; di~trihution int<:> artcrinven<>U'> nna~10m01ic (AVA) ~nJ 
aru:riolar (nutrient) fl<>W in untrcatcJ (~nntrol) ;mJ kctan'<:rin 
{0.5 mg·kg-• i.a.)-. mcthic.thcpin (1 mg·l..s 1 i.;t.)- nr 
mctcrgolinc (1.0 mg- kg- 1. i.a.)-trcatcJ pig.~ (n = 6 each). • Sig-
nificantly different(?<: 0.05) from the ha:<eline value. 
arteriolar blood now was noticed. In contr:J.st. in 
the animals treated with methiothcpin (total Jose: 
1.0 mg- kg- 1 ). indorenatc caused no or a sm31l 
(highest dose) dccreo.sc in total carotid blood now, 
a slight increase in arteriovenous anastomotic 
blood now and no change in arteriolar hlood now. 
In the animab treated with metcrgolinc (total dose: 
1.0 mg·kg~ 1 ), the effects of indorcnate on total 
common ca.rotid and arteriovenous anastomotic 
blood flow remained essentially unchanged. The 
total arteriolar b!ood now was higher in the 
metergoline-treated animals and. in these animab, 
infusion of indorcnatc ::tpp:trcntly decreased the 
arteriolar blood now. 
The effects of intracarotid infusions of in-
dorcnatc on vascular conduct::tncc. approxim~ltcd 
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by the ratio of blood now and mean arterial blood 
pressure. arc shown in fig. 2. The effects of in-
dorenate were essentially similar to its effects on 
blood now. 
Figure 3 prc..;;.ents the percentage changes in-
duced hy different doses of indorenatc in the total 
carotid vascular conduc1ancc and its arteriovenous 
anastomotic and arterioktr components in the four 
groups or animals. The decrease in the total C.1.ro-
tiJ conductance by indorenate was comparable in 
kct;.~nserin- and metergoline-trcated animals. but 
was markedly inhibited by methiothepin. The de-
crca.<;c in the arteriovenous anastomotic flow in-
duced by the highest dose of indorcnatc was 
150 
- 150 
-
:········.···.·· .•  .. ·. 
~ :~:- .. 
" ~ 
AVA 
~rial 
1. NUTRIENT 
Salon<' K<;>tan<.<'~ln M<'thlotho>pln Met'l'rgoli""'' 
f'ig. 2. Effect:< of intrac.m>tid infusions of indorenate (0.3. 1.0. 
3.0. 10.0 f<g·l.g · 1• min ., ) on the tot;~l carotid conductance 
"nd arteriovenous :m:1stom<>tic (AVA) :md :l.rteriolar (nutrient) 
now in untreateJ (control) Jnd ket;~nscrin (O.S mg·kg- 1 i.a.}-. 
m.:thiothepin (1 mg·kg- 1 i.a.)- or mctcrgoline (1.0 mg·kg- 1 
i.a.Hrc.,t.:d rig.~ (n ~ 6 each). • Signific:mtly different (P < 
0.05) from the ha~line vnlue. 
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Fig. 3. Percent chn.nges induced by intraearotid infusions of indorenatc (0.3. 1.0. J.O. 10.0 i<S ·kg -l. min- 1) in the totn! carotid 
conductance and arteriovenous rma~tomotic (AVA) and arteriolar (nutrient) O<>w in untreated (control) and ketan:>erin (O.S mg·kg- 1 ) 
i.a.r, methiothepin (l mg·kg- 1 i.a.)- or mctcrgolinc {1.0 mg· kg- 1 i.a.)-lreated pig~ (n = 6 c:•ch). • ? < 0.05 v~. ch;mg•"" in the control 
slightly inhibited by kctanserin and metergolinc. 
Methiothepin, on the other hand. potently 
antagonized the effects of indorcnate on arterio-
venous anastomotic blood now. The arterio!::tr 
(nutrient) fraction of the carotid blood now tended 
to increase after indorenate in the untreated con-
trol animals (P > 0.05). whereas it decreased in the 
metergoline-treated animals. This decrease. how-
ever. may be related to the fact that arteriolar now 
was conspicuously higher ip. the metergolinc-
treated animals than in the other groups (sec fig. 
I). 
3.2.2. Distribution of arteriolar blood flow between 
the different tissues 
group. 
The effect of indorenate on regional carotid 
blood now distribution into the different tis.-;;ues. 
presented in fig. 4 (ear. skin. muscles and tongue) 
and fig. 5 (bones, eyes. brain. fat and salivary 
glands). were rather small in all four groups of 
animals. In the untreated control animals. in-
dorenate increased blood flow to the ears (highest 
dose) and slightly decreased flow to the eyes (two 
highest doses). In the ketanserin-treatcd animals. 
blood flow to the skin. tongue and brain incn:ased 
at the highest does of indorenate: the drug. how-
ever. slightly decreased blood flow to the ears. 
muscles and bones. Finally. after treatment with 
mctcrgolinc. the ovcra[[ arteriolar blood flow was 
higher than in the other groups before infusion of 
indorenatc. lnd{)renate apparently induced a sm~1ll 
decrease in hlood now to the muscles, t(mguc. 
bones and eyes, but increased flow to the skin. 
4. Discussion 
4.1. Systemic hacmodynamic changes 
In contrast to its dfcct in anaesthetized cats 
(Hong et a!.. 1978) as well as renal hypertensive 
dogs (Hong, 1981) and rats (Safdy ct al.. 1982). 
indorenate did not lower blood pressure in the 
anaesthetized rigs. except for a small decrease in 
animals that had been treated with mctergo!ine. 
8-0H-DPAT also does not lower blood pressure 
in anaesthetized pigs (Born et al.. l989a). It is 
possible that the central 5-HT1A receptors mediat-
ing hypotensive responses (sec Saxena and 
Vil!albn. 1990) are not present in the pig. How-
ever. it cannot be ruled out that the absence of a 
clear hypotensive response to 5-HT1" receptor 
stimulation is due to the use of deep anaesthesia 
in our experiments. The decrease in heart rate 
observed by us is probably not. or only partly. 
attributable to indorenatc. since a modest decrease 
in heart rate has also been noticed during the 
course of experiments in which only physiological 
saline was infused: the heart rate (beats· min- 1) 
was 109 ± 13 at baseline and 109 ± 12. 105 ± 12, 
102 ± 11 and 99 ± 10 after the four consecutive 
infusions of physiological saline (Born et aL. 
1989a). 
4.2. Carotid haemodynumic changes 
It has already been shown that carotid blood 
Oow and its distribution rcm::tins unchanged when 
measurements are made with microsphercs in-
jected into anaesthetized pigs receiving four con-
' 0 ~
Ears 10 0. 3 LO 3. 0 10.0 I ndorenate (ug.Kg- 1 .min- 1 ) 
'] 
0 ~=-~~ 
j Skin : ~o=d~ ];M 
J Ton9u• • 
OJ~~~ 
Control Methiothepin 
Ketanserin Meto::-rgoline 
Fig. 4. Effect of inu:ac.arotid infusions of indorenale (0.3. 1.0. 
3.0 and 10.0 }Lg·kg-'·min- 1 ) on the fraction of carotid blood 
flow di."'tributcd to the ear~ head skin. head muscles and 
tongue in o.mtre:~ted (control) and kctanscrin (0.5 mg·kg- 1 
i.a.)-. mcthiothepin (l mg·kg- 1 i.a.}- or mctergoline (1.0 mg· 
kg- 1 i.a.)-treated pig.~ (n ~6 each).'" Significantly different 
(P < 0.05) from the !_,a~eline value. 
I ~·~ lndorenate . _, 3.0 (\Jg.Kg 10.0 
2 Ey<:'S • • 
' 0 J ~ """"""' ~ C"lliEmi. 
113 
' ~ ]i"~L&lid[ 
• ,J '" ~ OJ~~=---~ 
] rd Iii [m Lll t:"" 
Control Methloth<:'pin 
K<:'t:tns,-,rln M,-,t.,.rgoli,...,. 
Fig. 5. Effect of intracarOtid infusions of indorenate (0.3. LO. 
3.0 anJ 10.0 p.g kg- 1·min -I) on the fraction of carotid blood 
flow distributed to the bones, eyes, total brain. fat and salivary 
glands in untreated {control) and ketanserin (0.5 mg·kg- 1 
i.a.)-. methiothepin (l mg·kg- 1 i.a.)- or mctergoline (LO mg· 
kg- 1 i.:t.)-treated pigs (n ~ 6 each).~ Scale for the mc:tergoline 
group. • Significantly different (P < 0.05) from the baseline 
value. 
sccutive inCu~ions of physiological saline for a 
period or 10 min each (Born et aL. 1989a). There-
fore. the major findings in this study are: (i) 
indorenate caused dose-related decreases in the 
total carotid blood flow and conductance. which 
were selective for arteriovenous anastomotic flow 
as arteriobr (nutrient) flow w:is not significantly 
modified. and (ii) the responses to indorenate were 
only slightly attenuated by ketanscrin or metcrgo-
line. but were potently antagonized by methio-
thepin. Ap::trt rrom the implications discussed be-
low. these findings show that indorenatc acts as an 
agonist mainly ::tt 5~HT1 -like receptors which 
mediate the constriction of arteriovenous anas-
tomoses. However, .1s dc..:;cribcd previously for 
5-HT (Saxena and Vcrdouw. 1982; Verdouw eta!.. 
1984), we cannot completely exclude the possibil-
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ity that 5~HT2 receptors migh: abo be inv<llvcd to 
a le."-<:ef extent, or that ketanserin h.a~ some affinity 
for these 5~HT1 -like receptors. Indeed. this conciu-
sion is also supported by the affinity profile of 
indorenatc. which has pK 0 values of 7.80, 5.39. 
6.49, 6.69 and < 5.0. respectively. for 5-HT1A. 
5-HTIB• 5-HTlC, 5-HT10 and 5-HT2 binding sites 
(Hoyer et al.. 1985; Hoyer, personal communica-
tion). 
4.2.1. Heterogeneity of the 5-H0-Iike receptors in 
the carotid circulation 
We have demonstrated that, in the porcine 
carotid vascular bed, 5-HT (Saxena and Vcrdouw, 
1982) and 5-carboxamidotrypt;;.minc (Saxena .:md 
Verdouw. 1985} decrease arteriovenous :mnsto-
motic blood now, but increase :J.rtcriolur blood 
flow, particularly to the skin. which becomes red. 
Both the constriction of arteriovenous ~nastomo­
ses and the dilat.:Hion of :trtcriolc..;; arc mediated by 
5-HT1-!ikc receptors (Saxena ct ;d .• 1986). !-low-
ever, these 5-HT1-like receptors seem to he hctao-
geneous (Saxena et al.. 1989) hecausc several other 
5-HT-rclated drugs - mcthyscrgiJr..: (S:1xcna anJ 
Verdouw, 1984), BEA 1654 (Verdouw et al., 1985). 
sumatript:m (GR43175) {Feniuk et al..1987; 1989; 
Den Boer et al.. 1990). 8-0H-DPAT (Bom et al.. 
1989a) and RU 24969 (Born et al.. 1989b) - re-
duce arteriovenous anastomotic blood flow 
without increasing :lrteriolar blood llow or chang-
ing skin colour. The selective artr..:riovenous 
anastomotic response to indorenate further 
strengthens the concept of heterogeneous 5-HT1-
like receptors within the porcine carotid circula-
tion. 
4.2.2. Are the 5-HT,-like receptors mediating ceph-
alic arteriovenous anastomotic constriction related to 
the known 5-HT, binding sites subtypes? 
lt is now well recognized th.:J.t 5-HT1-Iike recep-
tors are heterogeneous and four different subtypes 
of 5-HT1 binding sites (5-HT1", 5-HTm. 5-HTK 
and 5-HT10 ) have been described (for recent re-
views. see Snxena. 1989; Feniuk and Humphrey, 
1990). Although we acknowledge that, except for 
the 5-HT1" binding site. no sdcctive agents are 
available for the other subtypes. we still consid-
ered it important to attempt to c...;tablish the na-
ture or the 5-HT1-like receptors mediating con-
striction of the ceph.:-~lic arteriovenous ;mastomo-
scs. In this connection . .:J. number of drugs with 
high affinity for 5-HT1" binding sites (see Mid-
dlemiss and Fo7 .... 1.rd, 1983; Hoyer et al.. 1985; 
Hoyer, 1988). namely 8~0H-DPAT (Bam et aL. 
1989a). BEA 1654 (Verdouw et al., 1985), methy-
sergide (Saxen.:J. and Verdouw, 1984), RU 24969 
(Born et a!.. 1989b) and indorenate {present re-
sults). decrease porcine arteriovenous anastomotic 
blood Jlow, which suggests that the 5-HT1-Iike 
receptors involved might correspond to 5-HT1A 
binding sites. However, this seems unlikely be-
cause ipsapirone (Oompert et al., 1985; Hoyer et 
al., 1985) \l.nd some other 5·HT1A ligands (unpub-
lished observations) are in.:J.ctivc in the pig carotid 
circub.tion (Born ct al., 1988), and the reduction of 
carotid .:J.nd arteriovenous anastomotic blood flow 
induced hy RU 24<:l69 is not .:J.ffcctcd by a high 
d0se of (±)-pindolol (Born ct oL 1989h): both 
th.:sc comp(>tH\Js disrlay high :lffinity ft\r 5-llT1" 
anJ 5-HT111 binding sites (Hoyer et a!., 1985: 
Hoyer. 1988). The pre$cnt observation th::tt the 
indorenate-induced decrease in both total com-
mon carotid and arteriovenous .:J.nastomotic blood 
now was not markedly affected by mctergoline 
(pK D values: 8.2, 7.6, 9.3 ::lnd 9.1 for 5-HT1", 
5-HT11l, 5-l!T1c anJ 5-HT1D binding sites. n:spcc-
tivdy: Hoyer ct :.:~1.. 1985: Hoyer, l988) further 
revc.:.tls that the 5-HT1-like receptors involved can-
not be related to either 5-HT1A. 5-HT11~. 5~HT1 c 
or 5-HT10 subtypes. It should be realized that 
metergoline h:1s higher .,_ffinity for these subtypes 
than methiothepin (pK!) v.:J.lues: 7.1. 7.3, 7.6 and 
6.3 for 5-HTw 5-HT10, 5-HT1c .:J.nd 5-HT10 bind-
ing sites, rcspectivt::ly: Hoyer et al.. 1985: Hoyer. 
1988). The inactivity vf met.ergoline is prob.:J.b!y 
not rd:1ted to differences in pharmacokinetics 
since, at the 5-HT1-like receptor on the dog 
saphenous vein (Humphrey et al., 1988; 1990). the 
responses to 5-HT. 8-0H-DPAT and/or 
sumatriptan are antagonized by methiothcpin but 
not by metergoline. 
h should be noted th:lt the percentage of caro-
tid blood flow distributed to the arteriovenous 
anastomoses at baseline is less in the metergoline-
trcated group th.:1n in the other groups (dat.:l not 
presented, hut can be deduced from fig. 1 ). It is 
not very likely that this difference in baseline 
value,<; will affect the comparison between the cf. 
fects of indorenate in the sa.line-.treated and 
metergoline-treated animals. The absolute arterio-
venous anastomotic blood now in the different 
groups was similar. and despite higher absolute 
values of total and arteriolar blood flow in the 
metergoline group, indorenate co used more promi-
nent reductions in these variables (fig. 1 ). 
4.3. Possible clinical implications 
Lastly. we would like to consider the possible 
clinical rc\cvance of the constriction of the 
arteriovenous anastomoses induced by indorenate. 
It has been suggested that dilatation of the 
arteriovenous anastomoses probably plays a role 
in the pathophysiology of migraine (Heyck. 1969: 
Saxena. 1987; Saxena and Ferrari. 1989). Indeed. 
a number of effective antimigraine drugs. includ-
ing ergotamine. methysergide and isomethcptene 
(Johnston and Saxena, 1978; Spicrin&" and Saxena, 
1980a.b; Saxena and Vcrdouw. !984; Saxena. 
1987), constrict arteriovenous anastomoses. In ad-
dition. sumatriptan. a newly developed agonist at 
5-HTclike receptors (Humphrey ct aL 1988; 
1990). selectively reduce.<; carotid and arteriovenous 
anastomotic blood now in cats. dogs and pi&<; 
(Feniuk et aL. 1987; 1989: Den Boer ct al.. 1990) 
and has shown considerable potential in the treat-
ment of acute attacks of migraine (Doenicke et aL. 
1988; Perrin et a!.. 1989). it is therefore suggested 
that indorenate may also have an ::mtimigraine 
action. 
In conclusion. the present study demonstrates 
that indorenate. which has high affinity for 5~HT1 A 
binding sites. and to o lesser degree also for the 
5-HT1c and 5-HT10 binding sit.::s. decreases com-
mon carotid arterial blood flow in the pig by 
selectively reducing arteriovenous anastomotic 
blood now. This effect of indorenate. which is 
highly susceptible to methiothepin, but much less 
susceptible to ketanserin or metergolinc. is media-
ted by a subtype of 5¥HT1-like receptors that does 
not seem to correspond to either 5-HT1A' 5-HTw. 
5·HTJC or 5-HTw subtypes. 
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EFFECTS OF S9977 AND DIHYDROERGOTAMINE 
IN AN ANIMAL EXPERIMENTAL MODEL FOR MIGRAINE 
SUMMARY 
The present study concerns the effects of $9977, a nimethylxanthine derivative with 
potential antimigraine characteristics, on the distribution of carotid blood flow in the 
anaesthetized pig. Furthermore, the effects of dihydroergotamine have been analyzed 
for comparison, Dihydroergotamine (3, 10, 30 and 100 p.g/kg, i.v.) elicited 
dose-dependent pressor and bradycardic responses which were probably mediated by its 
partial agonist action on a-adrenoceptors and dopamine, receptors. In contrast, S9977 
(03, 1, 3 and 10 mg/kg, i.v.) caused a moderate hypotension and bradycardia. The 
carotid haemodynamic effects of dihydroergotamine (3, 10, 30 and 100 p.g/kg, i.v.) 
consisted of a dose~dependent reduction of arteriovenous anastomotic blood flow and 
conductance and an increase in nutrient (tissue) blood flow and conductance. As a 
consequence, jugular venous p02 decreased. These findings, demonstrating an active 
constriction of arteriovenous anastomoses, are in agreement with earlier findings in cats. 
Though S9977 (0.3, 1, 3 and 10 mg/kg, i.v.) decreased carotid (two highest doses) and 
arteriovenous anastomotic (highest dose) blood flow, there was no concomitant decrease 
in the vascular conductances. Therefore, the effects of S9977 seem to be related to a 
decrease in arterial blood pressure and not to an active vasoconstriction of arteriovenous 
anastomoses. These results are discussed in terms of the potential therapeutical 
usefulness of S9977 in the treatment of migraine. 
INTRODUCTION 
Migraine is a vascular headache but its pathophysiology is complex and multifactorial. 
Of the many factors that have been implicated in migraine, the changes in cerebral as 
well as non-cerebral cranial circulation and the decrease in blood 5-hydroxytryptamine 
(5-HT) concentrations have been best documented (1). In some migraine patients a 
zone of slowly spreading reduced cerebral blood flow appears during the so-called aura 
phase (2). In the non-cerebral cranial circulation, vasodilatation and increased pulsations 
have been reported on the side affected during the headache phase of migraine (1). The 
idea of simple vasodilatation in the non-cerebral cranial circulation is, however, in direct 
contrast to the facial pallor noticed during headache in the majority of migraine patients. 
Heyck (3) therefore measured the 0 2 content in the arterial and jugular venous blood 
and reponed that the anerio-jugular venous oxygen difference decreased on the side of 
the migraine headache and this difference normalized after spontaneous or drug-induced 
alleviation of the headache. The vascular and biochemical changes in migraine are 
120 
supported by pharmacological experiments showing that 5-Hr ( 4) and a number of 
proven and effective antimigraine drugs (ergotamine, dihydroergotamine, methysergide, 
isometheptene) constrict arteriovenous anastomoses to decrease arteriovenous shunting 
(5-6). More recently, a newly developed agonist at one of the subtypes of 5-Hr,-like 
receptors (GR43175; sumatriptan) contracts large cranial arteries, reduces arteriovenous 
shunting and seems to be highly effective in aborting acute attacks of migraine (7-10). 
Taken together, the above findings suggest that migraine headaches may be, at least 
partly, due to a sudden opening of non-cerebral cranial arteriovenous anastomoses, 
which leads to an increase in arteriovenous shunting and arterial pulsations, and a 
decrease in diastolic arterial pressure and tissue blood flow (3,5,6). The dilatation of 
cranial arteries and arteriovenous anastomoses and the resulting ischaemia and oedema 
may also initiate a nociceptive reflex (7). 
Apart from the use of 5-Hr,-like receptor agonists, a new approach for decreasing 
arteriovenous anastomoses shunting may be via antagonism towards dopamine and/ or 
purinergic mechanisms. In this context, there is evidence that arteriovenous anastomoses 
are innervated by both dopaminergic (11,12) and purinergic (13) neurones which, upon 
stimulation, appear to cause a selective increase in arteriovenous anastomotic blood 
flow. Moreover, it is interesting to remark that hypersensitivity to dopamine-like drugs 
has been reported in migraine patients ( 14, 15). Therefore, it was proposed to investigate 
the effects of a novel trimethylxanthine derivative S9977 (Figure 1), which antagonizes 
the dopaminergic hypersensitivity and increase in adenosine receptors induced by food 
sensitization in the rat (16,17), on the fractionation of carotid arterial blood into 
arteriovenous anastomotic and nutrient parts in the anaesthetized pigs. This animal 
experimental model has shown that a number of proven antimigraine drugs are effective 
in reducing arteriovenous anastomotic flow (4-7, 10) and, therefore, for comparison we 
have also included dihydroergotamine in our investigation. A part of this study has been 
presented recently at the XI International Congress of Pharmacology, Amsterdam (18). 
Figure 1. Chemical structure of S9977. 
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METHODS 
Experimental set-up 
After an overnight fast, young Yorkshire pigs (body weight: 18-25 Kg; n = 24) were 
sedated with 120 mg (i.DL) azaperone and 120-150 mg (i.v.) metomidate, intubated and 
connected to a respirator for intermittent positive pressure ventilation with a mixture 
(1:2) of oxygen and nitrous oxide. A continuous infusion of pentobarbitone sodium (20 
mg/kg.h, i.v.) completed the anaesthesia. Respiratory rate and tidal volume were 
adjusted to keep arterial blood gases and pH within normal limits (pH, 735-7.45; p02, 
90-150 mmHg; pCO,, 35-45 mmHg). The right femoral artery and vein were cannulated 
for the measurement of aortic blood pressure (Statham transducer, model P23 ID) and 
the administration of drugs, respectively. Heart rate was derived from the 
electrocardiogram signals. The common carotid arteries were dissected free and a 
bilateral cervical vagosympathectomy was performed to reduce reflex influences on the 
carotid circulation. Blood flow in one of the common carotid arteries was measured 
with a precalibrated flow probe (2.5 or 3 mm internal diameter) connected to a sine-
wave electromagnetic blood flow meter (Transflow 601 system, Skalar, Delft, The 
Netherlands). After removing its hub, a 0.5 mm (external diameter) needle, connected 
to a snitable polyethylene tubing, was inserted into this common carotid artery for the 
administration of radioactive microspheres (see later). The animals were wrapped in a 
thermo-insulating blanket to maintain body temperature between 37-38"C. 
Distribution of common carotid blood flow 
The distribution of common carotid blood flow was determined with the radioactive 
microsphere method using 15 :t 1 ( s.d.) Jlill diameter spheres labelled with either '"Ce, 
"'Sn, ""Ru, "Nb or "Sc (NEN Company, Dreieich, F.RG.). For each measurement a 
suspension of microspheres, labelled with one of the nuclides, was mechanically agitated 
and injected against the direction of the carotid blood flow to facilitate uniform mixing 
with the blood. At the end of the experiment the animal was killed and the heart, 
kidneys, lungs and the various tissues of the head were dissected out, weighed and 
placed in vials. The radioactivity in these vials was counted for 5-10 min in a gamma-
scintillation counter (Packard Minaxi Autogamma 5000) using snitable windows for 
discriminating the different isotopes. The amount of carotid blood flow distributed to 
the individual tissues (Q,•r=J) was calculated as described earlier (4,19) by: 
Q,.[=J( ml/ min)= (l,/l00,)xQ[=J• 
where I, and !,, are, respectively, the radioactivity (c. p.m.) in a particular tissue and that 
detected in all tissues, and Or=l is carotid blood flow (ml/min). Because there was a 
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complete entrapment of the microspheres passing through the cranial circulation in the 
capillaries of the lungs (no significant amounts of radioactivity were detected in the 
heart or kidneys), the values determined for the lungs provide an index of the 
arteriovenous anastomotic fraction of the conunon carotid blood flow ( 4,20), 
Experimental protocol 
Three series of experiments (n=8 each) were performed. In the first series the effects 
of 4 consecutive intracarotid infusions of physiological saline on carotid blood flow and 
its distribution were determined. In the following series, the effects of i.v. infusions of 
dihydroergotamine (3, 10, 30 and 100 f.lg/kg) or S9977 (03, 1.0, 3.0 and 10.0 mg/kg) in 
cumulative doses at intervals of 15 min were assessed; the drugs were administered at 
a rate of 5 ml/min during a period of 2 min, whereas the physiological saline was 
infused at a rate of 1 ml/min during a period of 10 min. In all experiments the baseline 
values were determined after the preparation had been stable for at least 45 min after 
completion of the surgical procedures. The measurements consisted of the recording of 
the electrocardiogram, arterial blood pressure and common carotid blood flow, while a 
batch of microspheres (100,000 - 150,000) was injected for the determination of tissue 
(arteriolar) and arteriovenous anastomotic blood flows. Subsequently, these measure-
ments were repeated about 15 min after the i. v. infusion of each dose of S9977 or 
dihydroergotamine. 
Statistical analysis 
The significance of the differences between variables was evaluated by Duncan's new 
multiple range test, once an analysis of variance (randomized block desigo) had revealed 
that the samples represented different populations (21). Statistical significance was 
accepted at p<0.05 (two tailed). All data are expressed as means :!: s.e. mean. 
Drugs 
Apart from the anaesthetics, the drugs used in this study were: 1,3,7-trimethyl-8-[3-(4-
diethylarninocarbonylpiperazino )propyl]xanthine hydrochloride (S9977-2; Servier, Paris) 
and dihydroergotamine mesylate (Dihydergot", Sandoz, Basel). The doses of the drugs 
mentioned in the text refer to the respective salts. 
RESULTS 
Arterial and jugular venous blood gases 
Baseline values of arterial and jugular venous blood gases are shown in Table L None 
of these variables showed any significant change during the course of the experiment in 
the saline-treated animals. Except the jugular venous pO,, this was also true for the 
animals treated with dihydroergotamine and S9977. Jugular venous p02 decreased 
significantly with all four doses of dihydroergotamine (from 77 :<: 3 to, respectively, 69 :<: 3, 
58:<:2, 58:<:3 and 54:<:6 nunHg) and with the two highest of the four doses of S9977 
(from 66:<:3 to, respectively, 63:<:3, 62:<:4, 57:<:4 and 53:<:3 nunHg). These changes 
appear to correspond with the decrease in the arteriovenous anastomotic part of the 
carotid blood flow (see below). 
TABLE 1. Baseline values of arterial and jugular venous blood gases in pigs 
subsequently treated with physiological saline, dihydroergotamine (DHE) or S9977 
(n=8 each). 
Saline DHE S9977 
Arterial pH 7.4:<:0.0 7.4:<:0.0 7.4:<:0.0 
Arterial pCO, (nunHg) 38:<:1 38:<:1 35:<:2 
Arterial p02 (nunHg) 171:<:11 188:<:7 178:<:10 
Arterial Hb (g %) 8.5:<:0.2 7.8:<:0.2 7.4:<:03 
Venous pH 7.4:<:0.0 7.4:<:0.0 7.4:<:0.0 
Venous pC02 (nunHg) 39::tl 40:<:3 38::t2 
Venous pO, ( nunHg) 79:<:8 77::t3 66:<:3 
Venous Hb (g %) 7.9:<:0.3 7.8:<:0.2 7.6:<:0.4 
Systemic haemodynamic variables 
As shown in Figure 2, both mean arterial blood pressure and heart rate gradually 
decreased by about 10% from 92:<:9 to 82:<:9 nunHg and 106:<:10 to 95:<:8 beats/min, 
respectively, in the saline-treated group. In the dihydroergotamine-treated group arterial 
blood pressure increased and heart rate decreased (15% and 17%, respectively by the 
highest dose), but during treatment with S9977 both arterial blood pressure and heart 
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rate decreased (36% and 20%, respectively by the highest dose). The changes induced 
by the two drugs were more than those observed in the saline-treated group (Figure 2). 
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Figure 2. Effects of bolus injections of physiological saline, S9977 and 
dihydroergotamine on heart rate and mean arterial blood pressure in anaesthetized 
pigs. BL, Baseline; DHE, dihydroergotamine. •, P<0.05 vs. baseline. 
Carotid haemodynamics 
The effects of four consecutive infusions of either physiological saline, dihydroergotam-
ine or S9977 on the total common carotid blood flow and conductance and their 
fractionation into arteriovenous anastomotic and nutrient pans are shown in Figures 3 
and 4, respectively. In the saline-treated group the carotid haemodynamics remained 
fairly constant, except that there was some tendency for the total carotid and the 
arteriovenous anastomotic vascular conductances to increase slightly. Dihydroergotamin-
e (3, 10, 30 and 100 ,ug/kg) caused a clear dose-dependent decrease in the total carotid 
and arteriovenous anastomotic blood flow and conductance, but the nutrient blood flow 
and conductance increased. Treatment with S9977 also decreased carotid (two highest 
doses) and arteriovenous anastomotic (highest dose) blood flows, but the respective 
conductances did not change. Except for an increase with the highest dose in the 
vascular conductance, S9977 did not affect the nutrient circulation. 
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Figure 3. Effects of bolus injections of physiological saline, $9977 and 
dihydroergotamine on total carotid artery blood flow and its fractionation into 
arteriovenous anastomotic (AVA) and nutrient (tissue) parts in anaesthetized pigs. 
The five columns in each of the three panels represent, sequentially, baseline values, 
and values after the four i.v. bolus injections of saline. $9977 (0.3, 1, 3 and 10 
mg/kg) or dihydroergotamine (DHE, 3, 10. 30 and 100 l'g/kg). •, P<0.05 vs. 
baseline. 
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Figure 4. Effects of bolus injections of physiological saline, S9977 and 
dihydroergotamine on total carotid artery vascular conductance and its fractionation 
into arteriovenous anastomotic (AVA) and nutrient (tissue) parts in anaesthetized 
pigs. The five columns in each of the three panels represent. sequentially, baseline 
values, and values after the four i.v. bolus injections of saline, S9977 (0.3, 1, 3 and 
10 mg/kg) or dihydroergotamine (DHE, 3, 10, 30 and 100 ,ug/kg). •, P<0.05 vs. 
baseline. 
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Analysis of the regional distribution of carotid blood flows (Figure 5) and 
conductances (Figure 6) showed that the infusions of physiological saline were devoid 
of any important effects. Infusions of S9977 caused only modest changes in regional 
blood flows; ocular blood flow was reduced in a dose-dependent manner and, at the 
highest dose, blood flows to the tongue and salivary glands increased (Figure 5). S9977 
increased the conductance to the skin, muscles, tongue, fat and salivary glands 
(Figure 6). In contrast, dihydroergotamine dose-dependently increased both blood flows 
and conductances to w.~e ears, skin, head muscles, tongue, salivary glands and total brain; 
blood flows to the eyes and fat remained essentially unchanged, but vascular conduct-
ance in the eye was slightly reduced (Figures 5 and 6). 
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Figure 5. Effects of bolus injections of physiological saline, S9977 and 
dihydroergotamine on the regional (tissue) distribution of carotid artery blood flow 
in anaesthetized pigs. The five columns in each of the three panels represent, 
sequentially. baseline values. and values after the four i.v. bolus injections of saline, 
S9977 (0.3, 1, 3 and 10 mg/kg) or dihydroergotamine (DHE, 3, 10, 30 and 100 
,ug/kg). •. P<0.05 vs. baseline. 
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Figure 6. Effects of bolus injections of physiological saline, 59977 and 
dihydroergotamine on the regional (tissue) distribution of carotid artery vascular 
conductance in anaesthetized pigs. The five columns in each of the three panels 
represent, sequentially, baseline values, and values after the four i.v. bolus injections 
of saline, 59977 (0.3, 1, 3 and 10 mg/kg) or dihydroergotamine (DHE, 3, 10. 30 and 
100 ,ug/kg). •, P<0.05 vs. baseline. 
DISCUSSION 
Systemic Haemodynamics 
In the saline-treated animals both mean arterial blood pressure and heart rate gradually 
decreased to some extent during the course of the experiment. However. the changes 
in the drug-treated groups were more marked; dihydroergotamine increased arterial 
blood pressure and 59977 decreased it; nevertheless, both drugs caused bradycardia. 
The pressor and bradycardic action of dihydroergotamine may be, at least partly. due 
to its partial agonist action at a-adrenoceptors and/ or dopamine, receptors (22). lt is 
known that dihydroergotamine and ergotamine decrease heart rate in rats by an agonist 
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action at the presynaptic a 2-adrenoceptors located on the cardiac sympathetic nerve 
terminals (23). In the cat. however, the ergotantine-induced bradycardia is mediated by 
presynaptic dopaminergic receptors (24). The mechanism of the hypotensive and 
bradycardic actions of S9977 may involve a muscarinic cholinergic action, since in 
anaesthetized dog atropine antagonizes such effects of S9977 (A Sassine, unpublished). 
Carotid haemodynamics 
The present results confirm the observations that a large fraction of 15 pm nticrospheres, 
injected into the carotid circulation of anaesthetized animals, is not trapped in the 
arteriolar bed of the cephalic tissues; these spheres pass via arteriovenous anastomoses 
and veins to the right side of the heart to be sieved by the pulmonary· capillary bed 
( 4,20,25). The simultaneous use of nticrospheres of four different diameters (10, 15, 25 
and 35 pm) has shown that the large arteriovenous anastomoses in the cephalic 
circulation are mainly present in the skin and ears (26), but such 'shunt' vessels have also 
been located in the nasal mucosa (27), tongue (28), dura mater (29) and rete mirabile 
(30). 
In the saline-treated group there were no important changes in the carotid blood 
flow or its fractionation into nutrient (arteriolar; tissue) and non-nutrient (arteriovenous 
anastomotic) parts. Dihydroergotamine (3, 10, 30 and 100 ,ug/kg) dose-dependently 
decreased carotid blood flow (and conductance) and yet redistributed blood in favour 
of the nutrient compartment at the expense of the arteriovenous shunting. The decrease 
in arteriovenous shunting is also reflected by the decrease in jugular venous p02• Since 
arterial p02 did not change, dihydroergotantine increased arterio-jugular venous 0 2 
difference. These results are in agreement with earlier findings; dihydroergotantine has 
been reported to decrease the arteriovenous anastomotic fraction of the common carotid 
blood flow and the jugular venous 0 2 content in the cat (5) and increase the arterio-ven-
ous 0, difference, with relief of pain in migraine patients (3). 
In contrast to dihydroergotantine, the carotid haemodynantic effects of S9977, used 
in 100 times higher concentrations (0.3, 1, 3 and 10 mg/kg), were less marked. Though 
S9977 did decrease carotid (two highest doses) and arteriovenous anastomotic (highest 
dose) blood flows, there was no concomitant decrease in the vascular conductances. 
Therefore, the above effects of S9977 seem to be related to a decrease io arterial blood 
pressure and not to an active vasoconstriction of the arteriovenous anastomoses. The 
mechanisms underlyiog the vasodilator effects of dihydroergotamine and S9977 on the 
nutrient fraction are difficult to explain from the present experiments. 
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Possible clinical implications 
Over the years we have shown that a number of drugs that are effective in the treatment 
of migraine, for example ergotamine, dihydroergotamine, methysergide and isomethep-
tene (5,6, present results), powerfully reduce cephalic arteriovenous anastomotic 
shunting, though, as suggested for ergotamine (25,31), a reduction in cephalic 
arteriovenous anastomotic blood flow does not necessarily has to be mediated by 
a-adrenoceptors or 5-HT receptors. However, two new highly selective agonists at 
5-HT,-Iike receptors, namely AH25086 and sumatriptan (GR43175), have recently been 
shown to constrict cephalic arteries in several species and to diminish both feline and 
porcine carotid arteriovenous anastomotic blood flow (6,8-10,32). Furthermore, these 
new drugs do not seem to cross the blood brain barrier or have an anti-nociceptive 
effect even after intrathecal administration (9,10), yet they show a remarkable clinical 
effectiveness in acute migraine attacks (33-35). 
On the basis of the above findings one can suggest that drugs which constrict 
cephalic arteries and arteriovenous anastomoses should be effective in the treatment of 
migraine (see 36). A lack of active vasoconstriction in the carotid vascular bed observed 
in this investigation with S9977, therefore, does not allow us to predict positive clinical 
results with this drug in the treatment of migraine. Nevertheless, it is important to 
highlight that, in contrast to the other antimigraine drugs which act as (partial) agonists 
at 5-HT,-Iike and other receptors (6,8-10,32,36), S9977 is active in another potential 
animal model for migraine (16,17) and antagonizes the increased adenosine A, bi11ding, 
electroencephalographic abnormalities (16) and the vascular doparninergic hypersensitiv-
ity (17) during food sensitization in the rat. Despite the evidence that stimulation of 
doparninergic (11,12) and purinergic (13) neurones appear to cause a selective increase 
in arteriovenous anastomotic blood flow, the ineffectiveness of S9977 indicates that, 
under the present experimental circumstances, neither of these neurons is physiologically 
active. In migraine patients, such neurons may become active to open up arteriovenous 
anastomoses; indeed, Burnstock (37) has suggested that the events accompanying the 
headache phase of migraine could be explained by the neurogenic release of A TP during 
vasodilatation following cerebral spasm. 
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CHAPTER 12 
GENERAL DISCUSSION AND CONCLUSIONS 
12.1 EVIDENCE SUPPORTING THE EXTENSION OF THE 
CLASSlFICATION OF 5-HT RECEPTORS 
When Gaddum and Picarelli (1957) described the existence of two types of "tryptamine" 
receptor, called M and D, they certainly did not anticipate how complicated and 
confusing the 5-HT receptor field would be three decades later, when an international 
comntittee (Bradley et al., 1986) subsequently attempted to reconcile the different 
nomenclatures taking into account functional and pharmacological criteria, and proposed 
three main types of 5-HT receptors, namely 5-HT,-like, 5-HT2 and 5-HT3 receptors. In 
this connection, it is important to keep in mind several facts. Firstly, the separation 
between 5~HT1-like and 5-HT2 receptors is not absolute as most antagonists for 
5-HT ,-like receptors (methiothepin, methysergide, mesulergine, metergoline, etc.) display 
similar or higher affinities for 5-HT, receptors (Hoyer, 1988a; Saxena and Villalon, 
1990a). Secondly, amongst the 5-HT,-like and 5-HT, receptor antagonists, methysergide 
and metergoline may act as partial agonists depending on the experimental model 
(Hoyer, 1988a; Schoeffter et al.,1988; Saxena and Villalon, 1990a). Thirdly, 5-HT2c and 
5wHT2 receptors share many features, including second-messenger systems, 
pharmacological profile and structure (see Hoyer, 1988b; I-Iartig, 1989). Lastly, few if 
any 5-HT,-like and 5-HT2 receptor agonists and antagonists display high affinity and/or 
intrinsic activity for 5-HT3 receptors (Fozard, 1990; Hoyer, 1990; Saxena and Villalon, 
1990a). Significantly, in this context, 5-methoxytryptamine is inactive at 5-HT, receptors, 
but a potent agonist at the putative 5-HT, receptor (see Fozard, 1990; Saxena and 
Villalon, 1990a), which makes this compound an interesting tool. 
It should nevertheless be realized that the international comntittee's proposal 
was meant to be a framework, flexible enough to adapt to and to incorporate new 
findings (Bradley eta!., 1986). Thus, Dumnis et al. (1988, 1989) suggested the existence 
of a novel 5-HT receptor type described as the putative 5-HT, receptor, which is 
positively coupled to the adenylate cyclase system in mouse embryo colliculi neurons. 
This novel receptor site is stimulated by 5-methoxytryptamine and some benzamide 
derivatives including renzapride and zacopride, and is sensitive to blockade only by high 
concentrations of the 5-HT3 receptor antagonist ICS 205-930, but not by similar 
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concentrations of other 5-HT receptor antagonists (Dumuis et al., 1988, 1989). These 
findings have been confirmed in peripheral tissues of other species, where the putative 
5-HT, receptor mediates either directly or indirectly, contractions of the guinea-pig 
isolated ileum (Craig and Oarke, 1990) and ascending colon (Elswood eta!, 1991), right 
human atria (Kaumann et a!., 1990a,b) and porcine myocardium (Villalon et a!., 1991c; 
this thesis) as well as relaxation of the rat oesophagus (Baxter and Oarke, 1990) and 
stimulation of the pig sinoatrial pacemaker (Kaumann, 1990c; Villalon et a!., 1990b, 
1991a,b). 
Although the term 5-HT, has not been officially accepted by the nomenclature 
committee of the 5-HT club, the involvement of this novel 5-HT receptor in the above 
functional responses argues in favour of the extension of the 5-HT receptor classification 
to include the 5-HT, receptor. 
12.2 CHARACfERIZATION OF THE 5-HT RECEPTORS MEDIATING 
THEDECREASEINCEPHALICARTERIOVENOUSANASTOMOTIC 
BLOOD FLOW IN THE PIG 
The experimental evidence available up to date suggests that the receptors involved in 
5-HT-induced decrease in porcine cephalic arteriovenous anastomotic blood flow belong 
to the 5-HT,-llke type. In this context, 5-HT (Saxena and Verdouw, 1982, 1984; 
Verdouw et a!., 1984; Saxena et a!., 1986a), 5-CT (Saxena and Verdouw, 1985a), 
methysergide (Saxena and Verdouw, 1984), BEA 1654 (Verdouw et a!., 1985), 
8-0H-DPAT (Born eta!., 1989a), RU 24969 (Born eta!., 1989b), sumatriptan (Den Boer 
et a!., 1991) and indorenate (Villalon et a!., 1990a) decrease porcine arteriovenous 
anastomotic blood flow, but only 5-HT and 5-CT increase arteriolar blood flow 
prominently (see Table 7). These results clearly indicate that the 5-HT,-llke receptors 
involved in constricting arteriovenous anastomoses are different from those mediating 
arteriolar dilatation. 
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Table 7: 5-HT receptors and drug effect on arterioles and arteriovenous anastomoses 
(AV As) in the porcine carotid artery bed. 
Drug Arteri- A VAs Antagonism Resistance Receptor 
oles by to type 
5-HT ++++ Metbiothepin Cyproheptadine 5-HT,-like 
Ketanserin 
WAL 1307 
MDL 12222 
5-CT ++++ Cyproheptadine 5-HT,-Iike 
Methysergide +++ 5-HT,-Iike 
BEA 1654 +++ Ketanserin 5-HT,-Iike 
8-0H-DPAT ++++ Metbiothepin Ketanserin 5-HT,-Iike 
Ipsapirone 0 0 
RU 24969 ++++ Metbiothepin Ketanserin 5-HT,-Iike 
( ± )Pindolol 
Sumatriptan o 1- ++++ Metbiothepin Ketanserin 5-HT,-Iike 
Indorenate ++++ Metbiothepin Ketanserin 5-HT,-Iike 
Metergoline 
-, dilatation~ +, contraction; 0, no effect. The number of- and + indicate the magnitude 
of effect. 
As shown in Table 7. only methiothepin, but not other 5-HT receptor 
antagonists. effectively blocked the effects of the above 5-HT,-Iike receptor agonists. 
However, three implicit drawbacks must be taken into consideration. Firstly, in addition 
to its high potency to block 5-HT,-like and 5-HT, receptors. metbiothepin has other 
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actions, including noradrenaline uptake inhibition and high affinity for a-adrenoceptors, 
histamine, (H,) and dopamine, (D2) receptors (see Leysen, 1985). Secondly, the high 
degree of heterogeneity of the 5-HT, binding site has been revealed from radioligand 
binding studies performed in cerebral tissue membranes. And lastly, all research 
concerning functional studies has been based on the use of these 5-HT receptor ligands, 
but due to the lack of selective antagonists for these putative 5-HT,-Iike receptor 
subtypes it is still impossible to correlate the 5-HT, binding site subtypes demonstrated 
in cerebral tissue with the functional subtypes of 5-HT,-like receptors present in the 
cardiovascular system. 
In this conoection, the 5-HT,-like receptors present in the porcine cranial AV As 
(arteriovenous anastomoses) seem to be unrelated to the 5-HT, binding site subtypes 
(5-HT,_., 5-HT,., 5-HT,0 5-HTm and 5-HTu;) for several reasons, namely: i) the 5-HT,. 
ligand ipsapirone (Dompert et al, 1985; Hoyer, 1988a) had no effect on the porcine 
cranial AVA blood flow (Born et al., 1988b ); ii) pindolo~ which displays high affinities 
for both 5-HT,. and 5-HTm binding sites (Hoyer, 1988a), did not antagonize the effects 
of RU 24969 (Born et al, 1989b ), which also has high affinity for the same binding sites 
(Hoyer, 1988a); and iii) metergoline, which has been shown to display higher affinities 
for 5-HT,., 5-HT,., 5-HT,c and 5-HTm binding sites than methiothepin (Hoyer, 1988a), 
did not antagonize the effects of indorenate (Villalon et al., 1990a), which has high 
affinity for the 5-HT ,_.binding site, and appreciable affinities for the 5-HTm, 5-HT,c and 
5-HTm binding sites (Hoyer et al., 1985; Hoyer, personal communication). These -and 
other- fmdings give support to our view that compounds with high affinity for certain 
5-HT recognition sites in brain tissue membranes and without agonistic action on 
peripheral 5-HT receptors do not necessarily have to behave as 5-HT receptor 
antagonists in pharmacological functional studies (i.e. effect of 5-HT,-like receptor 
agonists and antagonists on porcine cranial AVA blood flow). For this reason, Saxena 
and Villalon (1990a) have coined this receptor 5-HT "'' until more selective antagonists 
be available. 
The implication of the present fmdings is two-fold. One the one hand, it is 
evident that binding data are useful for the screening of new compounds; on the other 
hand, however, by no means is it valid to predict from radioligand binding studies dtug 
effects in functional models; for this purpose, the "classical" pharmacological approach 
should have priority. This is of particular relevance when trying to develop drugs with 
potential therapeutical usefulness in the treatment of some pathologies (e.g. migraine, 
hypertension, etc.) 
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123 THERAPEUTICAL AND PHARMACOLOGICAL APPROACHES FOR 
ANTIMIGRAINE ACTION 
A number of new and established antimigraine drugs interact with 5-Hf receptors 
(Saxena and Villalon, 1990a; Feniuk et aL, 1991; Saxena and Den Boer, 1991). In this 
respect, selective agonists at the 5-Hf,-like receptor subtype mediating contractions of 
cephalic vessels (AH25086, sumatriptan), which do not penetrate into the central nervous 
system, are effective in the treannent of acute migraine attacks (see Pertin eta!, 1989; 
Saxena and Ferrari, 1989; Humphrey et al, 1990; Tfelt-Hanssen and Nielsen, 1990), In 
addition, some antimigraine drugs behave as antagonists at 5-Hf, (methysergide, 
pizotifen, ergotantine, dihydroergotamine) and/ or5-Hf,-like ( methysergide, propranolol) 
receptors, but many 5-Hf2 and/or 5-Hf,-like receptor antagonists (ketanserin, ritanserin, 
cyproheptadine, mianserin, methiothepin, metergoline) have not found much use in 
migraine therapy. It therefore seems likely that additional properties of such 
antimigraine drugs, for example, the vasoconstriction in the extracerebral cephalic 
circulation with methysergide, ergotamine and dihydroergotamine and the antidepressant 
action with pizotifen, may be involved in their therapeutic action (Saxena, 1990). In 
agreement with these findings, dihydroergotantine, which displays high affinities for 
5-HfiA, 5-Hf18, 5-Hf,c, 5-Hf10 and 5-Hf2 binding sites (Hoyer, 1988a) potently 
decreased porcine cranial AVA blood flow (Villalon et a!., 1991d). However, other 
actions of dihydroergotamine such as its ability to interact with a1 and a2 adrenoceptors 
as well as D, and D2 receptors (Peroutka, 1990) cannot be excluded from its 
therapeutical efficacy. 
With respect to the pharmacological approaches to include 5-Hf, receptor 
antagonists in antimigraine therapy, it is of particular interest the finding that 
MDL 72222 (Loisy et al., 1985) and granisetron (Ferrari, 1991) seem to be effective in 
the acute treatment of migraine. In contrast, ICS 205-930 is not at all effective in the 
acute treannent of this pathology (Lataste et al., 1989; Ferrari, 1991). Unfortunately, 
all the 5-HT3 receptor antagonists tested in migraine to date have proved to be 
oncogenic in animals on chronic administration, precluding any follow-up studies 
(Ferrari, 1991). Therefore, within the bounds of serotonergic mechanisms, the 
antimigraine action of the above drugs seems to depend mainly upon agonist action at 
the 5-Hf,-like receptor subtype (5-Hf"'; Table 1) that mediates craniovascular 
contraction (Saxena and Ferrari, 1989; Saxena and Villalon, 1990a; Saxena and Den 
Boer, 1991). 
Notwithstanding, other mechanisms underlying the decrease in cranial AVA 
blood flow cannot be excluded. For instance, it is interesting to note that apart from the 
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use of 5-HT1-like receptor agonists, a new approach for decreasing arteriovenous 
anastomotic shunting may be via antagonism towards dopamine and/ or purinergic 
mechanisms. In this connection, there is evidence that arteriovenous anastomoses are 
innervated by both dopaminergic (Bell et al, 1978; Bell and Lang, 1979) and purinergic 
(Molyneux and Harmon., 1982) neurons which, upon sthnulation, appear to cause a 
selective increase in arteriovenous anastomotic blood flow. Since hypersensitivity to 
dopamine-like drugs has been reported in migraine patients (Sicuteri, 1977; Bes et al., 
1986), it is tempting to suggest that drugs able to antagonize dopaminergic 
hypersensitivity and/or purinergic-mediated effects could have potential therapeutic 
usefulness in the treatment of migraine. Indeed, the novel trimethylxanthine derivative 
S9977 displays such properties (Della Zuana et al., 1991; Duhault et al, 1991). In our 
hands, however, S9977 did not induce an active vasoconstriction of the porcine cranial 
A VAs (Villalon et al, 1991d), which might reflect the fact that under the experimental 
circumstances of our model dopaminergic and/ or purinergic neurons are not 
physiologically active. Nevertheless, it should be emphasized that there seems to be 
other potential animal models to predict antiroigraine action, such as the blockade of 
vascular dopaminergic hypersensitivity and electroencephalographic abnormalities during 
food sensitization in the rat (Della Zuana et al, 1991; Duhault et a!., 1991); in this 
model, S9977 is effective. 
Likewise, several antimigraine drugs shown to decrease crarrial AVA blood flow 
(including ergotamine, dihydroergotamine, methysergide and sumatriptan) are also able 
to antagonize neurogenic inflammation in rat dura mater (which occurs via the release 
of neuropeptide pro-inflammatory mediators such as substance P and neurokinin A from 
perivascular sensory axons) induced either by electrical sthnulation of trigeminal ganglla 
or by capsaicin (Moskowitz and Buzzi, 1991). Interestingly, all these drugs elicit also a 
potent vasoconstriction of the dura mater blood vessels (Feniuk et al., 1991), 
emphasizing the possibility that neurogenic inflanunation and vasodilatation of blood 
vessels (including AV As) in the dura mater may be interrelated in the pathophysiology 
of migraine. In this context, some attention should be drawn to the fact that dura mater 
has an extensive network of arteriovenous anastomoses (see, for example, Rowbotham 
and Little, 1965; Kerber and Newton., 1973). Therefore, studies to determine the effect 
of antimigraine drugs on the fractionation of blood flow within the dura mater would 
give additional weight to the role of A VAs in the pathogenesis of migraine. 
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SUMMARY 
The biogenic amine 5-hydroxytryptamine (5-HT; serotonin) seems to play a role in 
several (patho)physiological processes (Chapter 1). The present thesis describes the 
effects of 5-HT-related drugs on heart rate, cardiac contractility and carotid blood flow 
distribution in anaesthetiaed pigs. Using "selective" agonists and antagonists the 5-HT 
receptor (sub)types involved in the 5-HT-induced changes in the above haemodynamic 
variables were characterized, taking into account the most recent advances in the 
classification of 5-HT receptors (Chapter 2). 
After delving into the literature about the general cardiovascular effects of 5-HT and 
related drugs (Chapter 3) and their effects on heart rate and cardiac contractility in 
several species (Chapter 4 ), the receptors involved in 5-HT -induced positive chronotropic 
(Chapters 7 and 8) and positive inotropic effects (Chapter 9) were delineated in the 
anaesthetized pig. Intravenous (i.v.) bolus injections of 5-HT induced dose-dependent 
increases in heart rate, which were mimicked (in order of potency) by the tryptamine 
derivatives 5-methoxytryptamine and a-methyl-5-HT, and by the substituted benzamide 
derivatives renzapride, zacopride, cisapride, metoclopramide and dazopride. These 
benzamide derivatives behaved as partial agonists, antagonizing the increases in heart 
rate by 5-HT and 5-methoxytryptamine. Likewise, the selective 5-HT, receptor 
antagonists MDL 72222 and granisetron as well as the selective D, receptor antagonist 
domperidone (3 mg/kg each) all failed to antagonize the tachycardiac responses induced 
by 5-HT and 5-methoxytryptamine. 1n marked contrast, the increases in heart rate 
induced by either 5-HT, tryptamine- or benzamide derivatives were clearly antagonized 
by high doses (1-3 mg/kg, i.v.) of lCS 205-930, without affecting the tachycardiac 
responses to isoprenaline. These findings suggest that 5-HT and the tryptamine- and 
benzamide derivatives increase porcine heart rate by a direct action on the cardiac 
pacemaker, via the activation of a putative 5-HT, receptor. Similarly, 5-HT (i.v.) 
induced also an increase in the maximum rate of rise in left ventricular pressure 
(LV dP I dt_) and cardiac output (CO) either at the animal's own sinus rhythm or during 
atrial pacing (150 beats/min), suggesting a positive inotropic effect, which was mimicked 
by 5-methoxytryptamine and, to a lesser extent, by renzapride. As previously described, 
renzapride behaved as a partial agonist, antagonizing the increases in LV dP I dt_ and 
CO induced by 5-HT and 5-methoxytryptamine, but not those by isoprenaline, suggesting 
the involvement of the putative 5-HT, receptor. The pharmacological profile of this 
porcine myocardial receptor is similar to that of the putative 5-HT, receptor present in 
neurons from mouse embryo collicuii, guinea-pig cholinergic neurons and human heart. 
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Chapter 5 deals with the effects of 5-Hr and related drugs in the carotid circulation 
and its distribution into nutrient (arteriolar) and non-nutrient (arteriovenous 
anastomotic; A VA) fractions. On the basis of these findings, an attempt was made to 
further delineate the putative subtype of 5-Hr,-like receptor in the porcine carotid 
circulation, analyzing the effects of the 5-HT '-' receptor agonist indorenate (Chapter 10). 
Intracarotid infusions of indorenate resulted in dose-related decreases in total common 
carotid artery blood flow, which were almost exclusively due to a reduction in the 
cephalic AVA blood flow. These effects of indorenate were not appreciably modified 
after treatment with the 5-HT2 receptor antagonist ketanserin, but were markedly 
reduced after treatment with methiothepin, which antagonizes not only 5-HT2 receptors, 
but also the putative 5-Hr'-', 5-Hr,6, 5-Hr,c and 5-Hrm subtypes of 5-Hr,-like 
receptors. Nevertheless, metergoline, a drug with higher affinities than metlriothepin for 
the foregoing 5-Hr1 receptor subtypes, failed to significantly modify the responses to 
indorenate. Therefore, the above effects of indorenate are mediated by 5-Hr,-like 
receptors unrelated to either 5-Hr'-', 5-Hr,6 , 5-Hr,c or 5-Hrm binding site subtypes. 
Based on the proposal that dilatation of cephalic arteries and arteriovenous 
anastomoses (AVA's) probably plays a role in the pathophysiology of ntigraine, and that 
a number of effective antirnigraine: drugs, including ergotamine, methysergide, 
isometheptene and sumatriptan, have a selective carotid vasoconstrictor action which is 
mainly confined to cephalic AVA's, one ntight propose the porcine fractionation of 
carotid arterial blood flow into A VA and arteriolar parts as an experimental model for 
the screening and development of drugs with potential antintigraine action. With this 
suggestion in mind, in Chapter 11 we set out to study the effects of a novel 
trimethylxanthine derivative, $9977, which antagonizes the dopaminergic hypersensitivity 
and the increase in adenosine receptors induced by food sensitization in the rat (another 
animal experimental model for ntigraine ), on the fractionation of total common carotid 
blood flow in anaesthetized pigs. Furthermore, the effects of dihydroergotamine, a 
clinically established antintigraine drug, were analyzed for comparison. 
Dihydroergotamine elicited a dose-dependent reduction in AVA blood flow and 
conductance, and an increase in the arteriolar blood flow and conductance. In marked 
contrast, $9977 decreased carotid (two highest doses) and AVA (highest dose) blood 
flow, but there was no concomitant decrease in the vascular conductances. These 
findings indicate that the effects of $9977 seem to be related to a decrease in arterial 
blood pressure and not to an active vasoconstriction of AVA's. Therefore, in line with 
the "shunt theory" of ntigraine, these results do not predict an antintigraine action of 
$9977. However, on the basis of other pharmacological effects of the drug, it still 
remains a pnssibility. 
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SAMENV ATIING 
De biogene amine 5-hydroxytryptamine (5-Hf; serotonine) lijkt een rol te spelen in 
verscheidene (patho)fysiologische processen (Hoofdstuk 1). Dit proefschrift beschrijft 
de effecten van aan 5-Hf gerelateerde stoffen op de hartfrequentie, cardiale 
contractiliteit en de bloedstroomverdeling over het carotide vaatbed in genarcotiseerde 
varkens. De 5-Hf-receptor (sub)typen betrokken bij 5-Hf-geinduceerde verandetingen 
in bovenstaande haemodynamische variabelen werden, met behulp van relatief selectieve 
agonisten en antagonisten gekarakteriseerd. Hierbij werd met de meest recente 
ontwikkelingen op het gebied van 5-HT -receptor classificatie rekening gehouden 
(Hoofdstuk 2). 
Na een diepgaand literamur onderzoek naar de algemene cardiovasculaire effecten 
van 5-Hf en gerelateerde stoffen (Hoofdstuk 3) en hun effecten op hartfrequentie en 
cardiale contractiliteit in verschillende species (Hoofdstuk 4 ), werden de receptoren 
welke betrokken zijn bij de door 5-Hf-geinduceerde positief chronotrope (Hoofdstuk 
7 en 8) en positief inotrope effecten (Hoofdstuk 9) beschreven in het genarcotiseerde 
varken. intraveneuze bolus injecties met 5-Hf induceerde een dosis afhankelijke 
toename van de hartfrequentie. Overeenkomstige responsen werden waargenomen (in 
volgorde van potentie) met de tryptamine derivaten 5-methoxytryptamine en 
a-methyi-5-Hf, en met de gesubstitueerde benzamide derivaten renzapride, zacopride, 
cisapride, metoclopramide en dazopride. Deze benzamide derivaten gedroegen zich als 
partH~le agonisten, omdat ze de toename in hartfrequentie gelnduceerd door 5-HT en 
5-methoxytryptamine antagoneerden. Daarentegen werden de tachycarde responsen 
geinduceerd door 5-lff en 5-methoxytryptamine noch door de selectieve 5-HT3-receptor 
antagonisten !viDL 72222 en granisetro~ noch door de selectieve D2-receptor antagonist 
domperidon (elk 3 mg/kg) geantagoneerd. Echter, de toename in hartfrequenrie 
geinduceerd door 5-Hf, tryptamine- of benzamide-derivaten werd duidelijk 
geantagoneerd door hoge doses (1-3 mg/kg) ICS 205-930, zonder dat het de tachycarde 
responsen van isoprenaline beinvloed werden. Deze bevindingen zijn in 
overeeenstemrning met het concept dat 5-HT en de tryptamine- en benzamide-derivaten 
de hartfrequentie van varkens verhogen door een directe werking op de cardiale 
pacemakercellen, via activering van een mogelijke 5-HT4-receptor. 
Intraveneuze bolus injecties met 5-HT induceerden eveneens een toename in 
LV dP I dt_ en CO, zowel gedurende een spontaan sinus ritrne als ook gedurende 
stimulatie van het atrium (150 slagen/ min), hetgeen een posirief inotroop effect doet 
vermoeden. Een overeenkomstig effect werd gezien met 5-methoxytryptam.ine en in 
mindere mate met renzapride. Zoals hierboven beschreven, gedroeg renzapride zich 
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opnieuw als een panieel agonist, doordat het de toename in LVdP/dt.., en CO 
gei"nduceerd door 5-HT en 5-methoxytryptamine, maar niet door isoprenaline 
antagoneerde. Dit suggereert de betrokkenheid van een gepostuleerde 5~HT4-receptor. 
Het farmacologisch profiel van deze nieuwe receptor in bet myocard van het varken 
komt overeen met dat van de gepostuleerde 5-ffi4-receptor aanwezig in neuronen van 
mnis embryo colliculi, cavia cholinerge neuronen en bet humane han. 
In hoofdstuk 5 worden de effecten van 5-HT en verwante stoffen op de carotide 
circulatie en de verdeling in nutrient (arteriolar) en non-nutrient (arterioveneuze 
anastomosen) beschreven. Op basis Vail deze resultaten, is een paging ondernomen het 
gepostuleerde subtype van de 5-HT,-achtige receptor te beschrijven door de effecten van 
de 5-HT lA-agonist indorenate te analyseren (Hoofdstuk 10). Infusies met indorenate in 
de a carotis communis van genarcotiseerde varkens na vagosympathectornie, resulteerde 
in een dosis afhankelijke afname van de bloed flow door de a. carotis communis, welke 
bijna uitsluitend het gevolg was van een reducti.e van de flow door arterioveneuze 
anastomosen. Deze effecten van indorenate werden nauwelijks beinvloed door 
voorbehandeli.ng met de 5-HT2-receptor antagonist ketanserine, maar werden duidelijk 
gereduceerd door behandeling met methiothepine, hetgeen Diet aileen 5-HT2-receptoren 
antagoneert, maar ook de gepostuleerde5-HT w 5-HT,B, 5-HT1c of 5-HT10 subtypen van 
5-HT1-achtige receptoren. Echter, metergoline, een stof met een hogere affiniteit voor 
5-HT ,-achtige receptor-subtypen dan methiothepine, bleek niet instaat de responsen van 
indorenate te beinvloeden. Er kan dan ook geconcludeerd worden dat indorenate, 
overeenkomstig 8-0H-DPAT en RU 24969, zowel de flow door het carotus vaatbed als 
ook de cephale arterioveneuze anastomosen vermindert in het varken via stimulatie van 
5-HT1-achtige receptoren. Hoewel deze receptoren niet overeen lijken te komen met 
5-HTlA, 5-HTrn, 5-HT1c of 5-HT10 bindingsplaatsen. 
Uitgaande van het concept dat dilatatie van cephale anerien en A VAs waarschijnlijk 
een rol speelt in de pathofysiologie van migraine en dat een aantal effectieve 
antimigraine farmaca,. waaronder ergotamine, methysergide, isomethepteen en 
sumatriptan, een selectieve constrictoire werking op het carotis vaatbed vertonen welke 
voornamelijk bet gevolg is van een constrictie van cephale arterioveneuze anastomose~ 
lijkt een onderverdeling van de arteriele carotis bloeddoorstroming in een arterioveneus 
anastomotisch en een anerieel gedeelte, in varkens, als experimenteel model voor 
screening en ontwikkeling van farmaca met potentieel antimigraine werking mogelijk. 
Vanuit deze achtergrond, is in hoofdstuk 11 de studie naar de effecten van een nieuw 
trimethylxanthine-derivaat, 59977, op de verdeling van de totale carotide doorbloeding 
in arterioveneuze-en aneriolaire-bloeddoorstroming in genarcotiseerde varkens 
beschreven. S9977 antagoneert de dopaminerge overgevoeligheid en de toename in 
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adenosine receptoren geinduceerd door voedingsgevoeligheid ( dierexperimenteel model 
voor migraine). 
Ter vergelijking werden de effecten van dihydroergotamine, een klinisch toegepast 
antimigraine geneesmiddel, geanalyseerd. Dihydroergotamine vertoonde een dosis 
afhankelijke reductie van de artrioveneuze doorbloeding en geleiding, en een toename 
in nutrient (arteriolair) fractie en conductance. ln duidelijk contrast biermee is de 
bevinding dat S9977 de car otis ( twee boogste doses) en de arterioveneuze doorbloeding 
(hoogste dosis) verminderde, zonder gelifktijdige afname in vasculaire conductance. Dus 
lijken de effecten van S9977 gerelateerd aan een afname in arteriole bloeddruk en niet 
aan een actieve vasoconstrictie van arterioveneuze anastomosen. Deze resultaten 
voorspellen danook geen antimigraine werking voor S9977, indien wordt nitgegaan van 
de "shunt tl1eorie". Ecbter op basis van andere farmacologische effecten van deze stof 
blijft het wei mogelijk. 

LIST OF PUBLICATIONS 
AND 
CURRICULUM VITAE 

179 
UST OF PUBUCATIONS 
ABSTRACTS 
1. Hong, E. and Villalon, C.M., External carotid vasodilatation induced by serotonin 
and indorenate. Proc. West. Pharmacal. Soc., 31, 99-101, 1988. 
2. Hong, E. and Villalon, C.M., Potential therapeutic use for 5-HT,. and £-blockers 
in migraine. Proceedings of the International Congress on Cardiovascular 
Pharmacology of 5-HT. Amsterdam, October 4-7, 1988. Abstract No. 64. 
3. Villalon, C.M. and Hong, E., Inhibitory effect of pelanserin and ketanserin on the 
external carotid bed vasodilatation induced by serotonin. Proceedings of the 
International Congress on Cardiovascular Pharmacology of 5-HT. Amsterdam, 
October 4-7, 1988. Abstract No. 65. 
4. Hong, E., Villalon, C.M. and de Leon, H., Pharmacological evidences indicating that 
indorenate is a S,A agonist. The Pharmacologist, 31, 3, 1989. 
5. Saxena, P.R. and Villalon, C.M., Cardiovascular effects of serotonin agonists and 
antagonists. Proceedings of the International Symposium on 5-HT,. Receptors in the 
Brain: A subtype of serotonin receptors involved in blood pressure reduction. Bonn, 
Federal Republic of Germany. November 18, 1989. Abstract No.3. 
6. Villalon, C.M., Born, A.H., Heiligers, J., den Boer, M. and Saxena, P.R, Reduction 
of porcine carotid arteriovenous shunting by indorenate is unrelated to 5-HT lA' 
5-HT,., 5-HT,0 or 5-HTm receptor subtype. Br. J. Pharmacol., 99, 36P, 1990. 
7. Den Boer, M., Villalon, C.M., Heiligers, J., Saxena, P.R. and Humphrey, P.P.A., 
The craniovascular effects of sumatriptan in the pig. Br. J. Pharmacol., 99, 37P, 
1990. 
8. Villalon, C.M., Heiligers, J., den Boer, M.O. and Saxena, P.R., Putative 5-HT, 
receptor mediates 5-HT -induced tachycardia in the anaesthetized pig. Eur. J. 
Pharmacol., 183, 1160, 1990. 
180 
9. Heiligers, J.P.C., Villalon, C.M., Born, A.H. and Saxena, P.R., Effects of S9977, a 
potential antimigraine drug, on arteriovenous anastomoses in the carotid vascular 
bed of the anaesthetized pig. Eur. J. Pharmacol., 183, 1279-1280, 1990. 
10. Den Boer, M.O., Villalon, C.M., Heiligers, J.P.C., Saxena, P.R. and 
Humphrey, P.P .A, The effects of surnatriptan on the carotid circulation of the pig. 
Eur. J. PhannacoL, 183, 1275-1276, 1990. 
11. Saxena, P.R., Villalon, C.M. and van Heuven, D., 5-HT,-like receptors unrelated to 
the known binding sites ? Proceedings of the 2nd IUPHAR satellite meeting on 
serotonin. Basel, Switzerland. July 11-13, 1990. Abstract No. 17. 
12. Villalon, C.M., den Boer, M., Heiligers, J.P.C. and Saxena, P.R., 5-HT, receptors 
mediate tachycardia in the pig. Proceedings of the 2nd IUPHAR satellite meeting 
on serotonin. Basel, Switzerland. July 11-13, 1990. Abstract No. 67. 
13. Den Boer, M., Villalon, C.M., Heiligers, J.P.C., Saxena, P.R. and Humphrey, P.P.A, 
The effects of surnatriptan on the carotid circulation of the pig. Proceedings of the 
2nd IUPHAR satellite meeting on serotonin. Basel, Switzerland. July 11-13, 1990. 
Abstract No. P147. 
14. Villalon, C.M.,DenBoer, M.O.,Heiligers, J.P.C.,Verdouw, P .D.,Duncker, DJ.GM. 
and Saxena, P.R., Role of the putative 5-HT, receptor in the positive inotropic 
effect of 5-HT in the pig. Fundament. Clin. Pharmacol., !991. In Press. 
FULL PAPERS 
!. Born, A.H., Villalon, C.M., Verdouw, P. and Saxena, P.R., The 5-HT,-like receptor 
mediating reduction of porcine carotid arteriovenous shunting by RU 24969 is 
unrelated to either 5-HT"' or 5-HT,8 subtype. Eur. J. Phannacol., 171, 87-96, 1989. 
2. Saxena, P.R. and Villalon, C.M., Cardiovascular effects of serotonin agonists and 
antagonists. J. Cardiovasc. Pharmacol., 15 (Suppl. 7), S17-S34, 1990. 
181 
3. Villalon, C.M., Den Boer, M.O., Heiligers, J.P.C. and Saxena, P .R, Mediation of 
5-hydroxytryptamine-induced tachycardia in the pig by the putative 5-Hf, receptor. 
Special Report. Br. J. PharmacoL, 100, 665-667, 1990. 
4. Saxena, P.R. and Villalon, C.M., Brain 5-HftA receptor agonism: A novel 
mechanism for antihypertensive action. Trends Pharmacol. Sci., 11, 95-96, 1990. 
5. Villalon, C.M., Born, A.H., Heiligers, J.P.C., den Boer, M.O. and Saxena, P.R., 
Porcine arteriovenous anastomotic constriction by indorenate is unrelated to 5-HT lA• 
5-Hf,., 5-Hf1c or 5-Hrm receptor subtype. Eur. J. Pharmacol., 190, 167-176, 1990. 
6. Villalon, C.M., Den Boer, M.O., Heiligers, J.P.C. and Saxena, P.R., Further 
characterization, using tryptamine and benzamide derivatives, of the putative 5-HT4 
receptor mediating tachycardia in the pig. Br. J. Pharmacol., 102, 107-112, 1991. 
7. Den Boer, M.O., Villalon, C.M., Heiligers, J.P.C., Humphrey, P.P .A. and 
Saxena, P.R., Reduction of porcine cranial &.-teriovenous anastomotic shunting by 
the antimigraine drug sumatriptan is mediated by a 5-Hf1-like receptor. Br. J. 
Pharmacol., 102, 323-330, 1991. 
8. Saxena, P.R. and Villalon, C.M., 5-Hydroxytryptamine, a chameleon in the heart. 
Trends Pharmacol. Sci., 12, 223-227, 1991. 
9. Van Heuven, D., Villalon, C.M., den Boer, M.O. and Saxena, P.R., 5-Hf,-like 
receptors unrelated to the known binding sites ? In: Serotonin: Molecular Biology, 
Receptors and Function. Ed. Fozard, J.R. and Saxena, P.R., 1991, Basel. Birkhauser, 
(in press). 
10. Villalon, C.M., Den Boer, M.O., Heiligers, J.P.C. and Saxena, P.R., The 5-Hf, 
receptor mediating tachycardia in the pig. ln: Serotonin: Molecular Biology, 
Receptors and Function. Ed. Fozard, J.R. and Saxena, P.R., 1991. Basel. Birkhauser, 
pp. 253-263. 
11. Villalon, C.M., Born, A.H .. Den Boer, M.O. Heiligers, J.P.C. and Saxena, P.R., 
Effects of S9977, a potential antimigraine drug, and dihydroergotamine on carotid 
blood flow fractionation in the pig. Pharmacol. Res, 1991 (in press). 
182 
12. Villalon, C.M.. Heiligers, J.P.C.. Verdouw, P .D, Duocker, DJ.G.M. and 
Saxena, P.R., Role of the putative 5-HT, receptor in the positive inotropic effect 
of 5-HT in the pig. To be submitted. 
13. Dhasmana, K.M., Villalon, CM., Zhu, Y .N. and Saxena, P.R, Role of 
5-hydroxytryptantine,-like receptors in the 5-HT-induced increases in rat intragastric 
pressure. To be submitted. 
183 
CURRICULUM VITAE 
Carlos M. Villalon was born on November 2, 1959 in Mexico City, Mexico. After 
secondary school education (concluded in 1978), he studied pharmacy from 1978 to 1983 
at the National School of Biological Sciences (E.N.C.B, Mexico City). Two years later, 
he obtained the degree of Pharmacist. From 1983 to 1986 he was enrolled in the Master 
Sciences Programme in Pharmacology at the Centre for Research and Advanced Studies 
(CINVESTA V, Mexico City), obtaining the M.Sc. degree in Pharmacology on Apri11986. 
Subsequently, he was accepted to continue his studies in the Doctor Sciences Programme 
in Pharmacology at the same Research Centre from 1986 to 1988, obtaining the D.Sc. 
degree in Pharmacology on September 1988, under the supervision of 
Prof. Dr. Enrique Hong. Im.1nediatly afterwards, he continued his postdoctoral training 
at the Institute of Pharmacology of the Erasmus University of Rotterdam, under the 
supervision of Prof. Dr. Pramod R. Saxena, for which he has been awarded postdoctoral 
grants from CONACyT (Mexico), the Ministry of Education and Science (the 
Netherlands), the European Economic Community and the Department of 
Pharmacology, Erasmus University Rotterdam. 
He has also worked as a teacher of Chentistry and Biology at secondary school from 
1981 to 1984, and as a lecturer of Physiology and Pharmacology at the Department of 
Physiology of the E.N.C.B. (head: Prof. Dr. Mauricio Russek) from 1985 to 1986. 

ACKNOWLEDGEMENTS 

187 
ACKNOWLEDGEMENTS 
My gratitude to all the people who have contributed to the completion of this thesis 
cannot be adequately expressed here. Nevertheless, may I show clearly that two people 
have been particularly influential in my scientific development, namely: 
- Prof. Dr. Pramod R Saxena (Department of Pharmacology, Erasmns University, 
Rotterdam). Thank you for giving me the opportunity to interact in an international 
atmosphere, for providing me with the essential enthusiasm to do scientific research in 
spite of the inherent limitations when abroad, and for doing your best to improve many 
skills, including my understanding of pharmacology of 5-Hf and my ability to write 
scientific papers in the English langnage. 
- Prof. Dr. Enrique Hong (Secci6n de Terapeutica Experimental, CINVESTA V, 
Mexico City). I am equally indebted to you for your wise teaching, not only in the 
personal context, but also scientifically. You were my first inspitation to do research in 
cardiovascular pharmacology. 
I also wish to thank several people from the Department of Pharmacology, Erasmns 
University Rotterdam, who made my stay pleasant. To Mr. Jan P.C. Heiligers, for his 
honesty, excellent technical assistance and contribution to a friendly atmosphere. To 
Drs. Marien den Boer, for his help with the computer drawings. To Drs. Marcel van 
Gelderen, for making the Dutch translation of the summary of this thesis. To 
Drs. Shreekanth Tadipatri, for his patience, comradeship and lively talks. To Dr. Anton 
H. Born, for his in depth discnssions on scientific subjects and comradeship while in this 
department. The secretarial assistance of Mrs. Magda Bnsscher-Lauw is also 
acknowledged. 
Dr. K. Mohan Dhasmana (Department of Anesthesiology, Erasmns University 
Rotterdam). I am grateful to you for your personal support and confidence in my 
scientific abilities. 
I mnst also thank the members of the ''Promotiecommissie": Prof. Dr. P.R Saxena, 
Prof. Dr. AJ. Man in't Veld. Prof. Dr. P.D. Verdouw and Prof. Dr. P.A van Zwieten 
for their constructive criticisms. 
Para finalizar, pero no por eso menos importante, deseo hacer patente mi sincere 
agradecimiento al Dr. Carlos Hoyo-Vadillo por su constante apoyo moral y su autentica 
amistad. 

ADP 
AVA's 
cAMP 
5-CT 
5-CH,O-T 
mCPP 
D 
DOl 
EDRF 
!lg 
mg 
cGMP 
GTP 
5-HJAA 
HR 
5-HT 
5-HTP 
J.IIL 
i.v. 
Kg 
LSD 
LVdP/dt_ 
M 
mM 
~tM 
fM 
MAO 
8-MeO-CJEPAT 
a-methyl-5-HT 
2-methyl-5-HT 
min 
8-0H-DPAT 
PI 
SNC 
TFMPP 
LIST OF ABBREVIATIONS 
adenosine diphosphate 
arteriovenous anastomoses 
cyclyc adenosine monophosphate 
5-carboxamidotryptamine 
5-methoxytryptamine 
1-(3-chlorophenyl)piperazine 
dopamine 
1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane 
endothelium-derived relaxing factor 
microgram 
milligram 
cyclic guanosine monophosphate 
guanosine t..riphosphate 
5-hydroxyindole acetic acid 
heart rate 
5-hydroxytryptamine; serotonin 
5-hydroxytryptophan 
intramuscular administration 
intravenous administration 
kilogram 
lysergic acid diethylamide 
maximum rate of rise in left ventricular pressure 
molar 
millimolar 
micromolar 
fentomolar 
monoamine oxidase 
8-methoxy-2-(N-2-chloroethyl-N-n-propylamino )tetralin 
alpha-methyl-5-hydroxytryptamine 
2-methyl-5-hydroxytryptamine 
minute 
8-hydroxy-2-( di-N-propylamino )tetralin 
phosphoinositide 
central nervous system 
1-(3-trifluoromethyl)piperazine 
189 



